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P1-001: EXPRESSION AND CLINICAL SIGNIFICANCE OF CN- II IN 
NON-SMALL CELL LUNG CANCER TISSUES
Li L. Qu, Qing X. Liu, Jun H. Gao, Feng H. Qin, Jie J. Li, Feng W. Guo, Xia W. Wang, Hao 
C. Tang, Yan X. Li  
Department Of Pulmonary Oncology, 307 Hospital Of Pla, Bei Jing/CHINA
Background: Abnormal expression of the kinase, Cytosolic 5’-nucleotidase(CN-II) may 
be associated with a variety of nucleoside drug resistance behavior in human tissue. The 
proof of this hypothesis needs to be further explored. Methods: Design: This study was 
designed to investigate the expression level of CN-II in human non-small cell lung cancer 
(NSCLC) tissues and its relationship with clinical pathological factors. Evaluation of the 
correlation between expression levels and gemcitabine efficacy and survival period of 
patients was also performed. Methods: Immunohistochemistry was employed to detect 
CN-II protein expression in 116 patients with NSCLC primary tumor and metastatic 
lesions. Results:  The positive expression rate of CN-II in 116 cases of NSCLC specimens 
is 53.4%. Expression levels have no correlation with age, sex, KPS score, clinical staging, 
histological type of tumor or the degree of differentiation. Significant difference of CN-II 
expression level between non-small cell lung cancer (NSCLC) primary lesions and lymph 
node metastasis was not found. It was found that CN-II expression positive in tumor 
tissue specimens from 67 patients with NSCLC treated with gemcitabine chemotherapy. 
The results demonstrated that the positive expression rate of CN-II from Gemcitabine 
chemotherapy group (CR+PR), disease control group (CR+PR+SD) and the inactive 
group (PD) is 30.4%, 36.7% and 57.6%, respectively. CN-II expression rate difference 
between the first two groups and the third group are statistically significant (CR+PR vs 
PD group, p=0.008; CR+PR+SD vs PD group, p=0.013). 49 patients were followed up to 
the end of survival period. Among these 49 patients, 21 patients who were found CN-II 
expression positive had a median survival of 12.5 months (95% CI 9.76~14.24), while 29 
patients with negative CN-II expression had a median survival of 9.0 months (95% CI 
6.89~9.11). The survival difference is also statistically significant (p=0.004). Conclusion: 
Abnormal expression of CN-II may be associated with gemcitabine resistance. It’s likely 
to be a potential predictive factor of gemcitabine efficacy and prognosis of patients.
Keywords: Resistance, Non- small cell lung cancer, Cytosolic 5’-nucleotidase II, 
Gemcitabine
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P1-002: CLINICOPATHOLOGAL CHARACTERISTICS OF PULMO-
NARY PLEOMORPHIC CARCINOMA
So Miyahara1, Makoto Hamasaki1, Daisuke Hamatake2, Shinichi Yamashita2, Takeshi 
Shiraishi2, Akinori Iwasaki2, Kazuki Nabeshima1  
1Department Of Pathology, Fukuoka University Hospital And School Of Medicine, 
Fukuoka City/JAPAN, 2Department Of Thoracic Surgery, Fukuokara University Hospital 
And School Of Medicine/JAPAN
Background: Pulmonary pleomorphic carcinoma (PPC) is defined as a group of poorly 
differentiated non-small cell carcinomas containing spindle cells and/or giant cells, or a 
carcinoma consisting only of spindle and giant cells. Its clinicopathological characteristics 
and prognostic factors are still controversial, although there have been several 
clinicopathological studies. Moreover, the information about epithelial mensenchymal 
transition (EMT) markers, such as E-cadherin, Snail, ZEB and Twist lacks in PPC. To 
address these questions, analysis in more cases of PPC is needed. Methods: We reviewed 
2328 lung cancers resected between 1988 and 2011 and found 62 patients with PPC, in 42 
of which follow up data were available to analyze clinicopathlogical variables correlated to 
overall survival (OS). Immunohistochemical study with EMT markers was also performed. 
Results: The patients with PPC included 51 (82.2%) men and 11 (17.8%) women, with the 
mean age of 65.5 years (range, 31-81 years). According to the TNM classification, patients 
with pathological stage IA, IB, IIA, IIB, IIIA IIIB and IV were 7 (11.2%), 15 (24.1%), 3 
(4.8%), 20 (32.2%), 10 (16.1%), 4 (6.4%) and 3 (4.8%), respectively. The overall survival rate 
in 42 patients was 68.3% at 5 years. Fifteen (24.1%) tumors consisted entirely of spindle 
and giant cells, whereas the other 47 (75.8%) contained additional carcinoma components, 
such as adenocarcinoma (34/62, 54.8%), squamous cell carcinoma (7/62, 11.3%), 
adenosquamous carcinoma (4/62, 6.5%) and large cell carcinoma (2/62, 3.2%). Four of 7 
(57%) stage IA (<20 mm) tumors consisted only of spindle and giant cells, suggesting that 
the additional carcinoma component may develop as the tumor enlarges. By univariate 
analysis, lymph node metastasis and pleural invasion predicted poorer OS (P=0.042 and 
0.014, respectively), although presence of any additional carcinoma components did 
not cause significant differences. Among patients with stage II/III tumors, there were 7 
long survivors with no recurrence. Immunohistochemically, E-cadherin was positive 
in additional carcinoma components and negative in spindle/giant cell components, 
while Snail stained positive in the latter and negative in the former. Correlation between 
expressions of EMT-related molecules and OS was now under investigation. Conclusion: 
This study suggested lymph node metastasis and pleural invasion as indicators of poorer 
prognosis in PPC. Furthermore, we will report more in detail about clinicopatholgical 
characteristics of smaller pT1a tumors and longer survivors with p-stage II/III tumors, 
which help in more understanding of PPC.
Keywords: LUNG CANCER, pleomorphic
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P1-003: CHROMOSOMAL INSTABILITY AND DNA DAMAGE RE-
SPONSE PATHWAY IN LUNG ADENOCARCINOMA
Tatsuro Okamoto1, Hiroyuki Kitao2, Hirokazu Kitahara1, Shinichiro Shimamatsu1, 
Mikihiro Kohno1, Tsukihisa Yoshida1, Kenichi Suda1, Hiroshi Saeki1, Eriko Tokunaga1, Eiji 
Oki1, Yoshihiko Maehara1  
1Department Of Surgery And Science, Kyushu University, Graduate School Of Medical 
Sciences, Fukuoka/JAPAN, 2Department Of Molecular Oncology, Kyushu University, 
Graduate School Of Medical Sciences/JAPAN
Background: Chromosomal instability is considered to be important for cancer 
development and intratumoral heterogeneity. A model was proposed that DNA 
double-strand breaks (DSBs) as a result of oncogene-induced stalling and collapse of 
replication folks and impairment of DNA damage response (DDR) lead to chromosomal 
instability, which eventually causes cancer development (Science, 2008:319;1352-55). We 
investigated the relationship among driver mutations of oncogenes, DDR pathway status 
and chromosomal instability in clinical lung cancer specimens to better understand the 
lung cancer development. Methods: Genome DNA and total RNA were prepared from 
20 surgically resected lung adenocarcinoma. Mutation status of EGFR gene (deletion at 
exon 19 and point mutation at exon 21) was examined by peptide nucleic acid-locked 
nucleic acid polymerase chain reaction (PNA-LNA PCR) clamp method. The expression 
level of BRCA1 and Chk2 mRNA was evaluated by qPCR. Chromosomal aberration (CA) 
was assessed by single–nucleotide polymorphism–Comparative genome hybridization 
(SNP–CGH) (Illumina). To evaluate the CA level, we calculated %Defect, which represents 
the percent of genome region that contains CA, by KaryoStudio v1.4. The Chromosomal 
aberration (CA) level was determined to be high when %Defect was 20% or more and to 
be low when it was less than 20%. Results: Seven samples were determined to be high CA, 
while 13 samples to be low CA according to our criteria. Chk2 mRNA level was higher in 
high CA samples than in low CA samples (Ave. 0.326 vs. 0.185; p=0.0129). No statistical 
difference was found in BRCA1 mRNA level according to CA status. Six out of 12 samples 
(50%) with EGFR mutation had high CA, while only 1 out of 8 samples (12.5%) without 
EGFR mutations had high CA (statistically not significant). Conclusion: Chk2 mRNA 
expression level was increased in lung adenocarcinoma that showed high chromosomal 
aberration. DDR pathway might be important for tumor survival in lung adenocarcinoma 
with chromosomal instability.
Keywords: Chromosomal instability, DNA damage response, driver mutation
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P1-004: TARSH GENE EXPRESSION IN LUNG ADENOCARCINOMA 
WITH GGO APPEARANCE ON A CT IMAGE
Kunihiko Terauchi1, Junichi Shimada2, Mitsuo Maruyama3  
1Nara City Hospital, Nara/JAPAN, 2Division Of Chest Surgery, Department Of Surgery, 
Kyoto Prefectural University Of Medicine, Kyoto/JAPAN, 3National Center For Geriatrics 
And Gerontology, Obu/JAPAN
Background: A cellular senescent related gene, TARSH (Target of NESH-SH3) is a 
presumptive signal transduction molecule interacting with NESH which is implicated to 
have some roles in lung cancer metastasis. We have previously demonstrated that TARSH 
mRNA expression was downregulated in lung cancer cell lines and clinical non-small cell 
lung cancers. In this study, we analyzed TARSH mRNA expression in adenocarcinoma 
with GGO appearance on a CT image. Methods: Forty-eight clinical lung cancers which 
showed GGO appearance on a CT image were enrolled in this study. They were 31 of 
bronchiolioalveolar carcinoma (pure BAC) and 17 of mixed adenocarcinoma with BAC 
(mixed BAC). Their tumor specimens and the corresponding non-neoplastic tissue samples 
were analyzed. Total RNA was extracted from each sample, followed by quantitative 
real-time reverse transcription PCR. The expression level of TARSH mRNA in each 
sample was normalized with respect to that of GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase). We then defined T/N ratio as the ratio of the average mRNA expression 
levels for each clinical cancer specimen to that of corresponding non-neoplastic lung 
tissue. Results: TARSH mRNA expression level was significantly low in 46 of 48 tumor 
specimens compared to that in the corresponding non-neoplastic lung tissue specimens (p 
< 0.001). The average of the T/N ratio in pure BAC and mixed BAC was 0.395 (ranged from 
0.041 to 1.868) and 0.170 (ranged from 0.006 to 0.602), respectively. The T/N ratios in pure 
BAC were higher than those in mixed BAC (p = 0.004). This correlated with the presence 
of a BAC component. There was some correlation between TARSH mRNA expression and 
clinicopathological characteristics. Conclusion: TARSH mRNA was downregulated in 
adenocarcinoma with BAC features. These results suggest that TARSH might be associated 
with carcinogenesis of lung adenocarcinoma in early stage.
Keywords: TARSH, bronchiolioalveolar carcinoma, mRNA
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P1-005: THE EXPRESSION OF THE GAMMAH2AX, A SENSITIVE 
MOLECULAR MARKER OF DNA DAMAGE AND REPAIR IN THE 
ADENOCARCINOMA OF THE LUNG.
Chika Takai1, Kazuya Kondo1, Yuki Kawahara1, Yui Fujita1, Hiromitsu Takizawa2, 
Yasushi Nakagawa2, Hiromitsu Takizawa2, Gyokei Kawakami2, Mitsuteru Yoshida2, Shoji 
Sakiyama2, Akira Tangoku2  
1Dept. Of Oncological Medical Srevices, Tokushima University, Tokushima/JAPAN, 
2Thoracic, Endocrine And Oncological Surgery, Tokushima University, Tokushima/JAPAN
Background: Phosphorylation of the Ser-139 residue of the histone variant H2AX, forming 
gammaH2AX, is an early cellular response to the induction of DNA double-strand breaks. 
Detection of this phosphorylation event has emerged as a highly specific and sensitive 
molecular marker for monitoring DNA damage initiation and resolution. Methods: We 
examined the expression of the gammaH2AX (phosphorylation of the Ser-139 residue 
of the histone variant H2AX) and H2AX (normal form) in 39 lung adenocarcinomas 
(Noguchi’s type A 11, type B 8, type C 8, type D 9, others 3 cases). Immunohistochemical 
staining for gammaH2AX((#9718, Cell signaling Technology, x400) and 
H2AX(IHC-00008, bethyl laboralories.Inc, x400) in formalin-fixed, paraffin-embedded 
tissue sections was performed using the Catalyzed Signal Amplification system II (DAKO 
Co., Carpinteria, CA) method. Under microscopy, we evaluated at least 200 tumor cells per 
high power field, which were more stained in all fields. The frequency of nuclear staining 
was scored as percentage. We defined gammaH2AX index as “gammaH2AX positive 
cells/ H2AX positive cells”. Results: The normal staining pattern for anti-gammaH2AX 
antibody and anti-H2AX antibody was nuclear. The immunoreactivity rate of H2AX was 
similar among various adenocarcinomas (93% in type A (n=8), 86% in type B (n=4), 87% in 
type C (n=6) and 86% in type D (n=8)). On the other hand, The immunoreactivity rate of 
gammaH2AX was 71% in type A (n=11), 86% in type B (n=8), 59% in type C (n=8) and 28% 
in type D (n=9). The immunoreactivity rate of gammaH2AX in Type D was significantly 
lower than that in other types (vs type A, type B; p<0.0001, vs type C; p=0.008). 
gammaH2AX index was 0.74 in type A, 0.99 in type B, 0.62 in type C and 0.39 in type D. 
The gammaH2AX index in Type D was significantly lower than that in other types (vs type 
A; p=0.022, type B; p<0.0001, vs type C; p=0.037). Conclusion: The immunoreactivity 
rate of gammaH2AX in non-invasive adenocarcinoma was high (71-86%), it in type C 
adenocarcinoma as moderate (59%), and it in poorly differentiated adenocarcinoma was 
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low (28%). It is possible that there is the differences of the repair function of double-strand 
break between non-invasive and invasive adenocarcinoma of the lung.
Keywords: gammaH2AX, DNA damage and repair, adenocarcinoma of the lung
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P1-007: PREVALENCE OF EGFR IN QATAR POPULATION AND USE 
OF TKI S
Kakil I. Rasul  
Haem/Oncology, Ncccr, Doha/QATAR
Background: Aim of the study, to find out the prevalence of epidermal growth factor 
receptor (EFGR) mutation in Qatar popultaion and the efficacy of Erlotinib in EGFR 
mutated patients. We studied the prevalence EGFR in Qatar population and the efficacy of 
erlotinib in patients with mutated EGFR. Methods: Methods and material: in the period 
between Nov 2009- Feb 2012, all patients with Non –sauamous cell NSCLC were diagnosed 
at Hamad Medical Corporation were included in our study and were tested for EGFR at 
Lab -21 in UK. Results: Twenty five patients with non squamous cell NSCLC had been 
tested for EGFR, 17 (68%) were male and 8(32%) were female. Mean age was 51(34-69y).
Twenty four (96%) patients have adenocarcinoma and 1 (4%) was large cell carcinoma. 
TTF1 were positive in16 (64%) patients and negative in 2 (8%) patients and unknown in7 
(28%) patients’. CK7 were positive n 16 (64%) patients, negative in 2 (8%) and unknown in 
7(28%). CK 20 was negative in 15 (60%) positive in 2(8%) patients and unknown in 8(32%). 
Eight (32%) patients were mutant for EGFR, 15 (60%) were no mutation and 2 (8%) samples 
were inadequate to be tested for EGFR. Of the mutated cases 6(75%) were exon19 and 
2(25%) were exon 21. All the patients with EGFR mutation received TKI, either erlotinib 
or gefitinib. Conclusion: Discussion: Qatar population is heterogeneous multinationals of 
1.5 million. The prevalence of EGFR mutation was 32% which is the prevalence in between 
the South East Asia and Western population. Most of the cases were TTF1 positive as well 
as CK7 but not CK20.survival outcome was better in female, nonsmokers and mutant 
EGFR patients. P values were not significant due to small sample size. Conclusion: EGFR 
mutation prevalence is 32% in Qatar population, Exon 19 mutation is the most common 
type. Survival outcome were better females, non-smokers and EGFR mutatnt patients P 
value 0.760 not significant due to small sample size.
Keywords: Erlotinib, gefitinib, EGFR, NSCLC
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P1-008: ANTI-PROLIFERATIVE MICRORNA EXPRESSION IN 
SQUAMOUS CELL CARCINOMA OF THE LUNG
Yasumitsu Moriya1, Endi Xia1, Toshihiko Iizasa2, Hajime Tamura2, Yukiko Matsui2, 
Hideki Kimura2, Sana Yokoi3, Ichiro Yoshino1  
1General Thoracic Surgery, Graduate School Of Medicine, Chiba University, Chiba/
JAPAN, 2General Thoracic Surgery, Chiba Cancer Center, Chiba/JAPAN, 3Cancer 
Genome Center, Research Institute, Chiba Cancer Center, Chiba/JAPAN
Background: Recently molecular-targeted strategy for alteration of genes that act as main 
driver of proliferation has been established in lung adenocarcinoma, however, no target 
is yet to be identified in other histological types of lung cancer. To elucidate a therapeutic 
target in squamous cell carcinoma of the lung, microRNA (miRNA) specially reduced 
in cancer tissues was tried to be identified through investigation of expression profile of 
miRNAs. Methods: Surgical specimen obtained from 25 patients with lung squamous 
cell carcinoma and human lung squamous cell carcinoma cell lines were subjected to 
the study. Patients included 23 men and two women, and all of them were smoker with 
smoking index of 19 to 137. A mean age of them was 70 years. 1) Expression profiles of a 
total of 665 miRNAs of the resected lung cancer and corresponding normal lung tissues 
were investigated using a microarray. 2) The expression profiles of lung squamous cell 
carcinomas were compared with those of other tobacco-related cancers derived from 
the urinary bladder and esophagus. Then, commonly down-regulated miRNAs in the 
tumor tissues were tried to be identified. 3) To investigate the function of the referred 
miRNA, behaviors of the cell lines introduced with the miRNA were examined. Results: 1) 
Expression of 21 miRNAs was recognized to be down-regulated in cancer tissues compared 
to non-cancerous tissues in clinical specimens of lung squamous cell carcinoma. 2) One 
of the miRNAs was commonly down-regulated in the other tobacco-related cancers. 3) 
Introduction of the referred miRNA substantially suppressed proliferative activity of lung 
squamous cell carcinoma cell lines. Conclusion: In tobacco-related cancers including 
lung squamous cell carcinoma, disorder of anti-proliferative miRNA expression may 
be involved in the pathogenesis, and one of the miRNAs is likely to be a candidate of 
molecular targets. Now the referred miRNA is further analyzed for the expression status in 
a large series of clinical lung cancers.
Keywords: lung squamous cell carcinoma, microRNA
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P1-009: DESMOPLAKIN ACTS AS A TUMOUR SUPPRESSOR BY 
INHIBITION OF THE WNT/β-CATENIN SIGNALLING PATHWAY 
IN HUMAN LUNG CANCER
Yuan Chen1, Linlin Yang1, Tiantian Cui1, Thomas Knosel1, Qing Zhang1, Kai Albring2, 
Otmar Huber2, Iver Petersen1  
1Institute Of Pathology, University Hospital Jena, Jena/GERMANY, 2Jena University 
Hospital/GERMANY
Background: Desmosomes are intercellular junctions that confer strong cell-cell adhesion 
thus providing resistance against mechanical stress on epithelial tissues. A body of 
evidence indicates that decreased expression of desmosomal proteins is associated with 
poor prognosis in various cancers. As a key component of desmosomal plaque proteins, 
the functional role of desmoplakin (DSP) in cancer is not yet elucidated. Here, we reported 
the anti-tumourigenic activity of DSP in non-small cell lung cancer (NSCLC). Methods: 
Real time RT-PCR immunofluorescence, and western blotting were applied to analyse 
the expression/localization of DSP. Demethylation test, bisulfite sequencing, as well 
as methylation-specifc PCR were carried out to analyse the methylation status of DSP. 
For the functional analysis, stable transfection and siRNA knockdown were performed 
followed by proliferation assay, colony formation assay, migration/invasion assay, and 
apoptotic assay. Additionally, reporter gene assays were carried out to detect the β-catenin 
signalling activity. In primary lung tumours, the expression of DSP protein was evaluated 
by immunohistochemistry on tissue microarray. Results: We found that DSP expression 
was downregulated in 8 out of 11 lung cancer cell lines and in 34 out of 56 primary lung 
tumours, and DSP DNA methylation was responsible for the downregulation. Ectopic 
expression of DSP in the NSCLC cell line H157 significantly inhibited cell proliferation, 
anchorage-independent growth, migration, as well as invasion, and also increased the 
sensitivity of NSCLC cells to apoptosis induced by an anticancer drug, gemcitabine. 
Furthermore, overexpression of DSP enhanced expression of plakoglobin (γ-catenin), 
resulting in decreased TCF/LEF-dependent transcriptional activity and reduced expression 
of the Wnt/β-catenin target genes Axin2 and MMP14. In accordance, DSP suppression 
by siRNA resulted in downregulation of plakoglobin and upregulation of β-catenin and 
MMP14. Conclusion: Taken together, these data suggest that DSP is inactivated in lung 
cancer by epigenetic mechanism, DSP increases the sensitivity to anticancer drug-induced 
apoptosis, and DSP has tumour suppressive function possibly through inhibition of the 
Wnt/β-catenin signalling pathway in NSCLC cells. The epigenetic regulation of DSP and 
its ability to increase the sensitivity to anticancer drug-induced apoptosis has potential 
implications for clinical application.
Keywords: desmoplakin, non-small cell lung cancer, Wnt/β-catenin signalling, tumour 
suppressive function
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P1-010: IGBP1 IS AN INDICATOR OF THE MALIGNANT PROGRES-
SION OF LUNG ADENOCARCINOMA
Taiki Sato1, Shingo Sakashita2, Dongping Li2, Yuko Minami2, Masayuki Noguchi2  
1Graduate School Of Comprehensive Human Sciences, University Of Tsukuba, Tsukuba-
shi, Ibaraki/JAPAN, 2Department Of Pathology, Faculty Of Medicine, University Of 
Tsukuba, Tsukuba-shi, Ibaraki/JAPAN
Background: IGBP1 [immunoglobulin (CD79a) binding protein 1] was initially identified 
as a signal transduction molecule coprecipitating with Igα of the B cell antigen receptor 
complex and was later found to be broadly expressed in many organs, including the 
liver, spleen, and brain. It is also known that binding of PP2Ac to IGBP1 confers an anti-
apoptotic effect. We have already reported that the expression of IGBP1 is associated 
with progression of lung adenocarcinoma (Sakashita S. et al. Pathol Int, 2011), and that 
apoptosis is initiated in the lung adenocarcinoma cell line PC-14 after treatment with an 
anti-IGBP1 molecule (lactoferrin)(Li D. et al. Anticancer Res, 2011). However, details of 
genetic or epigenetic abnormalities of IGBP1 itself have not been reported except for one 
study indicating suppression of IGBP1 expression in a human hepatic tumor cell line. In 
the present work, we confirmed the localization of IGBP1 in cancer cells and focused on 
the molecular mechanism of IGBP1 overexpression in the course of development of lung 
adenocarcinoma. Methods: 1. Immunocytochemistry of IGBP1 protein using washing 
cytology specimens from patients with minimally invasive adenocarcinoma (MIA) and early 
invasive adenocarcinoma (Noguchi type C). 2. MicroRNA array analysis using total RNA 
extracted from fresh cytological specimens of resected early lung adenocarcinoma(Figure 1). 
Results: First, we devised a system for taking fresh samples of very early-stage 
adenocarcinoma, as shown in Figure 1. Total RNAs were extracted from tumor cells and 
examined for expression of microRNAs. Tumor cells were also examined cytologically. 
IGBP1 was expressed in the nucleus of MIA tumor cells but in the cytoplasm of early 
invasive adenocarcinoma (Figure 2, next page). 
APLCC/ITMIG 2012 Abstracts  Volume 7, Number 11, Supplement 5, November 2012
S461  Copyright © 2012 BY THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER
MicroRNA array analysis comparing one MIA with two early invasive adenocarcinomas 
showed that miR-4301 was commonly expressed to a greater degree in early invasive 
adenocarcinomas than in MIA. On the other hand, the expression of miR-30b, miR-30d, 
miR-659, and miR-675 was greater in MIA than in early invasive adenocarcinomas. 
Conclusion: 1. Differences in the cytological localization of IGBP1 between MIA and 
invasive adenocarcinoma were confirmed by immunocytochemistry. 2. The expression of 
several microRNAs differed between MIA and early but invasive adenocarcinomas.
Keywords: adenocarcinoma, IGBP1, microRNA
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P1-011: DNA COPY NUMBER ALTERATIONS IN PRENEOPLASTIC 
ENDOBRONCHIAL LESIONS PREDICT PROGRESSION TO LUNG 
CANCER
Johannes M.A. Daniels1, Robert A. Van Boerdonk2, Thomas G. Sutedja1, Peter J. Snijders3, 
Eric F. Thunnissen4, Sylvia Duin3, Katrien Grunberg5, Pieter E. Postmus6, Egbert F. Smit6, 
Danielle A.M. Heideman3  
1Pulmonary Diseases, Vu University Medical Center, Amsterdam/NETHERLANDS, 
2Molecular Pathology, Vu University Medical Center, Amsterdam/NETHERLANDS, 
3Molecular Pathology, Vu University Medical Center/NETHERLANDS, 4Pathology, VU 
University Medical Center/NETHERLANDS, 5Pathology, Vu University Medical Center, 
Amsterdam/NETHERLANDS, 6Pulmonary Diseases, Vu University Medical Center/
NETHERLANDS
Background: Autofluorescence bronchoscopy (AFB) can be used to detect premalignant 
endobronchial lesions. However, only a minority of these lesions progress to lung cancer, 
which leads to unnecessary follow-up examinations and overtreatment. Our goal was to 
identify preneoplastic lesions with malignant potential by DNA copy number profiling. 
Methods: From a large cohort we identified six patients from with squamous metaplastic 
(SqM) lesions that had progressed to lung cancer during follow-up with regular AFB 
examinations. These progressive SqM lesions were compared by array comparative 
genomic hybridization with 23 SqM lesions of subjects who remained cancer-free. 
Specific DNA copy number alterations (CNAs) linked to cancer risk were identified 
and accuracy of CNAs to predict endobronchial cancer in this series was determined. 
In order to validate the findings from the first set in an independent set we identified 
14 more individuals with AFB visualized lesions that progressed to lung cancer and 21 
controls and applied the same array techniques. Results: The mean number of CNAs 
in baseline SqM of cases was significantly higher compared with control subjects (P < 
0.01). Chromosomal regions significantly more frequently altered in SqM of cases were 
3p26.3-p11.1, 3q26.2-q29, 9p13.3-p13.2, and 17p13.3-p11.2 (family-wise error rate <0.10). 
CNAs were specifically detected at the site of future cancer. In cases, baseline-detected 
CNAs persisted in subsequent biopsies taken from the initial site, and levels increased 
toward cancer progression. In this series, a model based on CNAs at 3p26.3-p11.1, 
3q26.2-29, and 6p25.3-24.3 predicted cancer with 97% accuracy. In the validation set 
findings were similar with multiple CNAs in most of the cases and hardly in controls 
(i.e. flat profiles) with an accuracy of 85% for predicting cancer. Conclusion: The data 
indicate that specific CNAs in endobronchial squamous lesions predict lung cancer.
Keywords: Bronchoscopy, LUNG CANCER, Molecular pathology, Genetics
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P1-012: ASSOCIATION OF PACLITAXEL RESISTANCE WITH DRUG 
ACCUMULATION IN INTRACELLULAR COMPARTMENTS IN HU-
MAN LUNG CANCER CELL LINES
Masanori Shimomura1, Takeshi Yaoi2, Kunihiko Terauchi1, Daishiro Katoh1, Junichi 
Shimada1, Shinji Fushiki2  
1Division Of Chest Surgery, Department Of Surgery, Kyoto Prefectural University Of 
Medicine, Kyoto/JAPAN, 2Department Of Pathology And Applied Neurobiology, Kyoto 
Prefectural University Of Medicine, Kyoto/JAPAN
Background: Several mechanisms have been proposed to explain resistance to 
chemotherapeutic agents in cancer cells; however, many of these mechanisms have not 
yet been completely elucidated. A combination of paclitaxel and carboplatin is one of 
the most frequently used regimens for the treatment of lung cancer, but the response 
rate associated with this therapy is 30–40%. In a previous study using 7 cancer cell 
lines, we found that the inhibitory concentration (IC50) values of carboplatin for the 
different cell lines fell within a narrow range of −4.46 to −3.42 logM, whereas the IC50 
values of paclitaxel were widely distributed between −10.80 and −4.48 logM. Here, 
we examined the mechanisms underlying this remarkable variation in resistance to 
paclitaxel. Methods: We used 3 human lung cancer cell lines, II18, A549, and RERF-
LC-KJ with IC50 values of paclitaxel of −8.33, −7.69, and −4.51 logM, respectively. 
These cell lines did not have β-tubulin mutations. We evaluated the level of ABCB1 
expression, intracellular accumulation of paclitaxel, paclitaxel-induced microtubule 
stabilization, and intracellular localization of Oregon Green® 488-conjugated paclitaxel. 
Results: Resistance to paclitaxel was not correlated with the level of ABCB1 expression, 
but was strongly correlated with the accumulation of intracellular [3H]-paclitaxel (r2 
= −0.804). Paclitaxel-induced changes in the amount of polymerized and acetylated 
tubulin were not correlated with resistance to paclitaxel. Intracellular localization of 
paclitaxel differed between RERF-LC-KJ, the most resistant cell line, and the other 
cell lines. Oregon Green® 488-conjugated paclitaxel made it possible to visualize not 
only the normal microtubule formation on the partial cells, but also the aggregated 
vesicle formation in some of the RERF-LC-KJ cells, whereas in the other cell lines this 
phenomenon was not remarkable. Conclusion: Paclitaxel accumulation in intracellular 
compartments may play an important role in producing resistance to paclitaxel, in 
addition to the mechanisms already proven to be involved in drug resistance. 
Keywords: paclitaxel, drug resistance, intracellular compartment, LUNG CANCER
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P1-013: MET INCREASES THE SENSITIVITY OF GEFITINIB-RESIS-
TANT CELLS TO SN-38, AN ACTIVE METABOLITE OF IRINOTE-
CAN, BY UP-REGULATING THE TOPOISOMERASE I ACTIVITY.
Asao Sakai  
Respiratory Medicine, National Hospital Organization Kanazawa Medical Center, 
Kanazawa/JAPAN
Background: Most non-small cell lung cancer (NSCLC) tumors with EGFR mutations 
are responsive to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and 
erlotinib, but almost all such tumors ultimately acquire resistance. We previously found 
that a gefitinib-resistant cell line, PC-9/Met, in which MET is amplified, was more 
sensitive than its parent cell line (PC-9) to SN-38 (7-ethyl-10-hydroxy-camptothecin), 
an active metabolite of irinotecan. The purpose of this study was to investigate the 
mechanisms responsible for the increased sensitivity of the gefitinib-resistant cell line 
to SN-38. Methods: The sensitivity of PC-9 and PC-9/Met to SN-38 was assessed by 
performing WST assays. Topoisomerase I (topo I) activities were determined for the cell 
lines cultured in the presence of hepatocyte growth factor (HGF) and for those of which 
MET expression was knocked-down by introducing a MET-specific siRNA. Results: 
PC-9/Met exhibited higher topo I activities, as well as higher topo I gene and protein 
expression levels than PC-9. Suppression of MET expression by a METspecific siRNA led 
to a decrease in the topo I protein expression in the PC-9/Met cells. The stimulation of 
PC-9 with HGF caused an increase in the topo I protein level via the activation of MET.  
Conclusion: The increased sensitivity of PC-9/Met cells to SN-38 compared to PC-9 cells 
was partially due to topo I activities resulting from increased topo I mRNA and protein 
expression due to MET signaling.
Keywords: Met, topoisomerase I, SN-38, gefitinib-resistance
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P1-014: GENOME-WIDE CDNA MICROARRAY SCREENING OF 
GENES RELATED TO PEMETREXED RESISTANCE IN MESOTHE-
LIOMA CELL LINES
Ikuo Sekine1, Miyako Kitazono-Saitoh1, Ryota Kurimoto1, Emiko Sakaida1, Yuji Tada2, 
Katsushi Kurosu2, Koichiro Tatsumi2, Yuichi Takiguchi1  
1Department Of Medical Oncology, Chiba University Graduate School Of Medicine, 
Chiba/JAPAN, 2Department Of Respirology, Chiba University Graduate School Of 
Medicine, Chiba/JAPAN
Background: Gene alterations responsible to acquired pemetrexed resistance in 
mesothelioma cells remained unknown. We previously established 4 pemetrexed-
resistant mesothelioma cell lines by the stepwise dose-escalation method (Kitazono-
Saitoh M. Oncology Rep 28: 33-40, 2012). Of these, two lines showed no increase in 
thymidylate synthase expression, suggesting other mechanisms might be involved in 
pemetrexed resistance. Methods:  Total RNA was prepared from 4 mesothelioma cell 
lines (H28-parent, H28-resist, H226-parent, and H226-resist) with the RiboPure™ 
Kit (Ambion Inc., Austin, TX, USA). Following RNA amplification and labeling, 
cRNA was hybridized to Whole human Genome Array (44K x 4) version 2.0 (Agilent 
Technologies Inc., Santa Clara, CA, USA). Then, the arrays were scanned and signal 
values were manipulated using the DNA Microarray Scanner and Feature Extraction 
software version 10.7.1.1 (Agilent Technologies Inc., Santa Clara, CA, USA). Following 
background correction and normalization, data with low signal intensities were excluded 
from the following investigation. A hierarchical clustering analysis was performed to 
compare gene expression signatures between the resistant and parental cell lines. Fold 
change analyses were performed to identify up-regulated genes in resistant cell lines 
with the corresponding parental cell line as a control. Results:  The clustering analysis 
failed to show the similarity of gene expression profiles between the resistant cell lines. A 
gene expression ratio of the resistant to parental cell lines was 5 or higher for 28 genes in 
H28 and for 393 genes in H226, and the ratio was 50 or higher for 2 genes in H28 and for 
19 genes in H226. For 6 genes, the ratio was 5 or higher in both H28 and H226 cell lines 
(Table). 
N of genes 
Resistant/parental ratio ≥3 ≥5 ≥10 ≥50 
H28 89 28 5 2 
H226 918 393 155 19 
H28 and H226 27 6 0 0 
 
Conclusion: This study suggested that several genes might be involved in the 
mechanisms of 
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P1-015: ANALYSIS OF C-MET GENE AMPLIFICATION IN JAPA-
NESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)
Takashi Sone1, Tomohiro Matsui1, Kouji Kurokawa1, Asao Sakai2, Kazuo Kasahara1  
1Respiratory Medicine, Cellular Transplantation Biology, Division Of Cancer Medicine, 
Kanazawa University Graduate School Of Medical Science, Kanazawa City, Ishikawa/
JAPAN, 2Respiratory Medicine, National Hospital Organization Kanazawa Medical 
Center, Kanazawa/JAPAN
Background: Several studies have reported that increased gene copy number (GCN) of 
c-Met is associated with poor prognosis and resistance to EGFR tyrosine kinase inhibitors 
(EGFR-TKI). A recent phase II study of mostly Caucasians showed that addition of c-Met 
receptor TKI inhibitor to EGFR-TKI prolonged progression free survival in NSCLC. It 
is unclear whether c-Met gene status differ between Caucasians and Asians. Thus, c-Met 
GCN was evaluated in Japanese patients with advanced NSCLC to determine whether 
confirm c-Met could be a relevant therapeutic target in Asian patients. EGFR mutation and 
GCNs of EGFR and Her2 were also analyzed. Methods: Tumor samples suitable for gene 
amplification and mutation analysis were collected from 43 patients with institutional 
review board approval and the patient’s written informed consent. Fluorescence in 
situ hybridization (FISH) was used to assess c-Met, EGFR, and Her2 GCNs. DNA was 
extracted from tumor tissue after micro dissection. PCR and direct sequencing of exons 
18, 19, and 21 of the EGFR gene were also performed. Results: Of the 43 patients, 11 
(25.6%) were female, 13 (30.2%) were light or never-smokers, and 37 patients (86.0%) had 
adenocarcinoma. The median age was 63 (range 41-81) years, and 38 patients (88.4%) had 
a good PS (0-1). EGFR mutation was deteted in 13 patients (30.2%).c-Met, EGFR, and Her2 
GCNs could be assessed by FISH in 42 of all patients. The median GCNs of c-Met, EGFR, 
and Her2 were 3.1 (range 1.8-5.9), and 3.2 (range 1.9-21.0), and 3.2 (range 1.8-5.9). GCNs of 
c-Met, EGFR, and Her2 were not associated with any patients’ characteristics. The c-Met 
GCN was significantly correlated with EGFR GCN (r=0.41) and Her2 GCN (r=0.50). The 
GCN of c-Met was not different between patients with EGFR mutation and those without 
mutation. Eighteen patients were treated with EGFR-TKI, the response rate was higher in 
patients with EGFR mutations (6/12 vs. 0/6). The mean c-Met GCN was not correlated with 
EGFR-TKI response in either patients with EGFR mutation or those without mutattion.  
Conclusion: In our study, the c-Met GCN was correlated with EGFR and Her2 GCNs.The 
GCN of c-Met did not any correlation with response to EGFR-TKI. The predictive and 
prognostic impact of EGFR-TKI treatment should be examined in the prospective study.
Keywords: c-Met, gene amplification, non-small cell lung cancer, Japanese
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P1-016: EGFR, K-RAS AND EML4-ALK MUTATIONAL PROFILE  
OF LUNG ADENOCARCINOMAS WITH MICROPAPILLARY  
COMPONENT
Masashi Furukawa1, Shinichi Toyooka1, Koucihi Ichimura2, Junichi Soh1, Kazuhiko Shien3, 
Hiromasa Yamamoto3, Hiroaki Asano1, Kazunori Tsukuda3, Shinichirou Miyoshi1  
1Thoracic Surgery, Okayama University Hospital, Okayama/JAPAN, 2Pathology, Okayama 
University Hospital, Okayama/JAPAN, 3Department Of Thoracic Surgery, Okayama 
University Graduate School Of Medicine, Dentistry And Pharmaceutical Sciences, 
Okayama/JAPAN
Background: Lung adenocarcinoma with micropapillary component has been associated 
with an aggressive clinical course compared with traditional papillary adenocarcinoma 
and bronchioalveolar carcinoma. Lung adenocarcinoma with micropapillary component 
often manifests at a high stage in nonsmokers, with intralobar satellites, and frequently 
metastasizes to the contralateral lung, mediastinal lymph nodes, bone, and adrenal 
glands, with high mortality. Because lung adenocarcinoma with micropapillary 
component represents a unique form of lung adenocarcinoma, we analyzed 28 cases 
of primary lung adenocarcinoma with micropapillary component for the common 
genetic mutations in lung adenocarcinoma to determine whether a distinct genetic 
profile was associated with this histopathologic growth pattern. Lung adenocarcinoma 
with micropapillary component has been associated with an aggressive clinical course 
compared with traditional papillary adenocarcinoma and bronchioalveolar carcinoma. 
Lung adenocarcinoma with micropapillary component often manifests at a high stage in 
nonsmokers, with intralobar satellites, and frequently metastasizes to the contralateral 
lung, mediastinal lymph nodes, bone, and adrenal glands, with high mortality. Methods: 
A total of 28 patients with lung adenocarcinoma with micropapillary component were 
randomly selected between April 2004 and May 2012. We analyzed their clinical and 
molecular profile for EGFR, K-ras mutations and EML4-ALK fusion. EGFR and K-ras 
mutations were examined using PCR-based assay and direct sequencing, respectively. 
EML4-ALK fusion was screened by ALK IHC and confirmed using reverse transcriptional 
PCR assay. Results: In all, patients underwent a lobectomy or segmentectomy or partial 
resection with or without regional lymph nodes dissection at the time of the operation. 
Nine patients showed metastasis to the regional lymph nodes. The duration of follow-up 
ranged from 11 to 79 months (median 37 months). Forteen patients are alive without 
disease, whereas 12 patients are alive with disease and one patient died of disease. In 
our study, 15 (55.5%) of 28 micropapillary lung adenocarcinomas harbored mutually 
exclusive mutations: 11 (40.7%) EGFR mutation, 1 (3.7%) K-ras mutation and 3 (11.1%) 
EML4-ALK fusion. Conclusion: These results suggest that the lung adenocarcinomas 
with micropapillary component are a manifestation of aggressive behavior, as shown 
by the frequent lymph node metastases. Although the size of our study was small, we 
conclude that EGFR, K-ras mutations and EML4-ALK fusions are disproportionately seen 
in lung adenocarcinoma with micropapillary component compared with conventional 
adenocarcinoma in previous reports.
Keywords: micropapillary adenocarcinoma, LUNG CANCER, EGFR, EML4-ALK
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P1-017: A RATIONAL DIAGNOSTIC ALGORITHM FOR THE IDEN-
TIFICATION OF EML4-ALK TRANSLOCATION IN LUNG CANCER
Kazuya Takamochi, Shiaki Oh, Kenji Suzuki  
General Thoracic Surgery, Juntendo University School Of Medicine, Tokyo/JAPAN
Background: EML4-ALK translocation occurs in only a small subset of non-small cell 
lung cancer (2-5%) and lung adenocarcinoma (4-5%) cases. A dramatic response to the 
ALK inhibitor (crizotinib) is observed in a majority of lung cancers with EML4-ALK 
translocation. As a result, there is an urgent need to establish a rational, cost-effective 
diagnostic algorithm to identify this rare, but, important EML4-ALK translocation in 
lung cancer in regular clinical practice.  Methods: This study performed a comprehensive 
analysis of the EGFR/KRAS mutation and EML4-ALK translocation in 226 surgically 
resected lung cancers (167 adenocarcinomas and 59 non-adenocarcinomas). EML4-
ALK translocation was simultaneously examined by three different methods, namely 
multiplex RT-PCR, ALK break-apart fluorescent in situ hybridization (FISH) and anti-ALK 
immunohistochemistry (IHC), using the intercalating antibody-enhanced polymer (iAEP) 
method. Results: EML4-ALK translocations were identified in 2 (0.9%) of 226 lung cancers 
and both of cases were adenocarcinoma (2/167 [1.2%]). EML4-ALK translocations could be 
confirmed by all three methods in both cases. Although RT-PCR and FISH showed 100% 
of sensitivity, specificity and accuracy, 3 (1.3%) false positive results were observed by IHC. 
EGFR and KRAS mutations were detected in 74 (33%) and 29 (13%) of the 226 lung cancers, 
respectively. EML4-ALK translocations, EGFR and KRAS mutations were observed in a 
mutually exclusive manner. Two (2.9%) of the 69 EGFR/KRAS mutation-negative lung 
adenocarcinomas were positive for EML4-ALK translocations. Therefore, screening of the 
EML4-ALK translocations should be performed for EGFR/KRAS mutation-negative lung 
adenocarcinomas by IHC. If EML4-ALK translocation is identified, it should be confirmed 
by FISH or RT-PCR. Conclusion: This study established a rational diagnostic algorithm for 
the identification of the EML4-ALK translocation, and a validation study of this diagnostic 
algorithm is now on goingusing 200 prospectively collected surgically resected lung 
adenocarcinomas. The results of the validation will be presented at this APLCC meeting.
Keywords: EML4-ALK, LUNG CANCER, adenocarcinoma
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P1-018: NICOTINE INDUCES EPIDERMAL GROWTH FACTOR 
RECEPTOR TYROSINE KINASE INHIBITOR RESISTANCE IN PC9 
CELLS VIA α1 NICOTINIC ACETYLCHOLINE RECEPTOR MEDI-
ATED SIGNALING PATHWAYS
Shuo Wang, Koichi Takayama, Taishi Harada, Kazuto Furuyama, Heyan Li, Yoichi 
Nakanishi  
Graduate School Of Medical Sciences,Kyushu University, Research Institute For Diseases 
Of The Chest, Fukuoka/JAPAN
Background: Cigarette smoking and second-hand smoke account for nearly 90% of lung 
cancer deaths.Studies in recent years raise the possibility that exposure to nicotine might 
lead to the worsening of lung cancer; however, the detailed molecular mechanisms remain 
largely unknown. In patients diagnosed with smoking-related lung cancer and who 
continue smoking, nicotine exposure as a negative factor in the efficiency of epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) had been shown. However, 
the mechanisms that contribute to the drug resistance remain unclear. Here, we examined 
the muscle-type α1 nAChR subunit involved in these actions. Methods: We detected 
mRNA for α1 nAChR in three NSCLC cell lines. Expression of α1 nAChR subunit in 
resected primary NSCLC tissues was analyzed with Immunohistochemistry.Functions 
of α1 nAChR in nicotine-induced resistance to EGFR-TKI were determined by RNA 
interference (siRNA) methodology, Western blot and MTS assay . Results: Phosphorylation 
of ERK1/2, Akt (Ser-473) and EGFR were up-regulated by nicotine treatment. Blocking 
experiments (siRNA) and western blot analysis showed that α1-nAChR subunit was 
responsible for EGFR release and down-regulating phosphorylation of EGFR by activating 
ERK and Akt (Ser-473) pathways. The resistance to EGFR-TKI was significantly abridged 
by knocking down α1-nAChR subunit in PC9 cells.  Conclusion: Our findings might 
provide a mechanistic basis for the resistance to EGFR- TKI therapy and suggest that 
nicotine and α1 nAChR may modulate the response of lung cancer patients to EGFR 
inhibitors. Thus, α1 nAChR may as a personalizing target molecule for smoking-related 
lung cancer patients. 
Keywords: nAChR, NSCLC, nicotine, EGFR-TKI
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P1-019: ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBI-
NATION WITH ERLOTINIB IN HUMAN NON-SMALL CELL LUNG 
CANCER XENOGRAFT MODEL
Heyan Li, Koichi Takayama, Yoshimasa Shiraishi, Shuo Wang, Kazuto Furuyama, Taishi 
Harada, Yoichi Nakanishi  
Research Institute For Diseases Of The Chest, Graduate School Of Medical Sciences, 
Kyushu University, Fukuoka/JAPAN
Background: Bevacizumab (Avastin), a vascular endothelial growth factor (VEGF) 
targeted recombinant humanized monoclonal antibody, and Erlotinib (Tarceva), a human 
epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, act on two 
different pathways to tumor growth and dissemination as target therapies. However, drug 
resistance of target treatment has shown in many clinical trials. In this study, we examined 
the antitumor activity and tolerability of bevacizumab and/or erlotinib in non-small cell lung 
cancer (NSCLC) xenograft model and investigated the mechanism of combination therapy in 
vivo. Methods: BALA /cAJc1-nu/nu mice bearing NCI-H157 (human NSCLC cell line) were 
treated with vehicle, bevacizumab (5mg/kg) and /or erlotinib (100mg/kg). Determination 
of erlotinib concentration was made by extraction of serum and tumor samples followed by 
High Performance Liquid Chromatography (HPLC). Results: Drug monotherapy inhibited 
tumor growth in the model. The tumor growth inhibition (TGI) of bevacizumab /erlotinib 
is > 60% (P<0.05), >30% (P<0.05), respectively. Combination treatment produced greater 
antitumor activity (TGI>80%, P<0.01) more than either agent alone without toxicity increase. 
Bevacizumab may affect erlotinib concentration in serum and tumor tissue. Conclusion: 
The combination of bevacizumab and erlotinib can enhance antitumor activity, probably 
as a result of the interaction between these targeted agents in NSCLC xenograft model. This 
provides a theoretical basis for the combination therapy in NSCLC.
Keywords: antitumor activity, human xenograft model, Bevacizumab, Erlotinib
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P1-020: DIRECT THERAPEUTIC EFFECT OF REIC/DKK-3-EN-
CODING ADENOVIRAL VECTOR FOR NON-SMALL CELL LUNG 
CANCER
Hiromasa Yamamoto, Norimitsu Tanaka, Shinichi Toyooka, Masami Watanabe, Masakiyo 
Sakaguchi, Junichi Soh, Kazuhiko Shien, Masashi Furukawa, Hiroaki Asano, Kazunori 
Tsukuda, Yasutomo Nasu, Nam-ho Huh, Hiromi Kumon, Shinichirou Miyoshi  
Department Of Thoracic Surgery, Okayama University Graduate School Of Medicine, 
Dentistry And Pharmaceutical Sciences, Okayama/JAPAN
Background: REIC/Dkk-3 is down-regulated in immortalized cells and considered to be 
a tumor suppressor gene. REIC/Dkk-3 is known to induce endoplasmic reticulum (ER) 
stress, resulting in apoptosis in several human malignant tumors. We previously reported 
the therapeutic potential of REIC/Dkk-3 for human malignancies using an adenovirus 
vector (Ad-REIC). Based on preclinical data, a clinical trial using Ad-REIC for human 
prostate cancer has been ongoing in Japan and U.S.A. (NCT01197209). In this study, we 
examined the therapeutic effect of Ad-REIC in non-small cell lung cancers (NSCLC).  
Methods: The effect of Ad-REIC transfer on cell viability was examined by MTS assay in 17 
NSCLC cell lines, the somatic alterations of which were characterized. Among them, there 
were 2 cell lines that were artificially established as EGFR-TKI-resistant sublines. We also 
examined GRP78 and CAR expressions and correlated them to the sensitivity to Ad-REIC 
to develop the customized Ad-REIC therapy for NSCLC. Furthermore, the effect of Ad-
REIC for tumor growth in vivo was examined using A549 cells.  Results: Ad-REIC transfer 
inhibited the cell viability by 40% or more in 9 (53 %) of 17 cell lines at 20 multiplicity of 
infection (MOI). These cell lines were regarded to be sensitive cells. The effect of Ad-REIC 
seemed to be independent of the type of known molecular alterations. Non-malignant 
immortalized cell line OUMS-24 was not inhibited at 200 MOI of Ad-REIC. The effects of 
Ad-REIC on EGFR-TKI-resistant sublines were equivalent to their parental cell lines. As 
the predictive factors of Ad-REIC in NSCLC, we examined the expression status of CAR 
and GRP78 and classified NSCLC into three categories based on the expression status of 
them; cells with Low GRP78 / High CAR expression as Category A, Low GRP78 / Low 
CAR or High GRP78 / High CAR expression as Category B, and High CRP78 / Low CAR 
expression as Category C. Eight Ad-REIC-sensitive cells consisted of 2 Category A cells 
and 6 Category B cells, whereas 6 Ad-REIC-insensitive cells consisted of 4 Category B cells 
and 2 Category C cells. Ad-REIC transfer activated c-Jun terminal kinase (JNK), indicating 
induction of ER stress, which resulted in apoptosis. A single intratumoral injection of 
Ad-REIC markedly inhibited the tumorigenic growth of A549 cells in vivo.  Conclusion: 
Ad-REIC induced ER stress and subsequent apoptosis in NSCLC cells irrespective of the 
type of known molecular alterations or sensitivity to EGFR-TKI. Our study suggests Ad-
REIC has a therapeutic potential for NSCLC and expression status of GRP78 and CAR can 
be a predictor of Ad-REIC therapy. 
Keywords: REIC, gene therapy, non-small cell lung cancer
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P1-021: HYALURONIC ACID BASED CISPLATIN NANOGEL SELEC-
TIVELY INHIBITS CD44 EXPRESSED NON-SMALL CELL LUNG 
CANCER GROWTH AND METASTASIS.
Yuhua Quan1, Yeonho Choi2, Jiho Park3, Hyunkoo Kim1, Choi Y. Ho1  
1Thoracic And Cardiovascular Surgery, Korea University, Seoul/KOREA, 2Biomedical 
Engineering, Korea University, Seoul/KOREA, 3Bio And Brain Engineering, Kaist 
Institute For The Nanocentury/KOREA
Background: Hyaluronan (HA) is a ligand for the transmembrane receptor CD44, which 
acts through multiple signaling pathways to influence the cellular behavior. The interaction 
between HA and CD44s may influences the in vitro chemosensitivity of CD44 that is 
expressed in non-small cell lung cancer (NSCLC). The aim of this study is to investigate 
whether the HA-cisplatin selectively inhibits NSCLC growth and metastasis, which 
overexpresses CD44v. Methods: A CD44 expressing cell-targeted pro-drug was developed 
for the anti-cancer drug cisplatin, using hyaluronic acid (HA) as the drug carrier. The 
conjugated HA-cisplatin nanogel was treated to human non-small cell lung cancer cell line 
(H1299, A549) and human normal lung cell line (HFL-1), and measured the effects in cell 
proliferation, migration, and invasiveness. We also investigated the effects of HA-cisplatin 
nanogel in the HA-CD44v signaling pathway. Results: HA-cisplatin conjugates showed 
a selective toxicity toward the human non-small cell lung cancer cell lines H1299 that 
are known to overexpress the HA receptor CD44, while no toxicity was observed toward 
human non-small cell lung cancer cell line A549 and human fibroblast lung cell line (HFL-
1) at the same concentrations used with the H1299 cells. HA-cisplatin nanogel also inhibits 
the H1299 cell motility and invasiveness, but not to A549 and HFL-1. HA-cisplatin nanogel 
inhibits the H1299 cell, due to the inhibition of CD44v6 expression and the blocking of the 
CD44 signaling pathway. HA-cisplatin significantly inhibits PI3-MAPK signaling pathway 
and induces cell apoptosis in the H1299. Conclusion:  With this insight, we demonstrate 
that HA-CD44 interaction contributes to anti-cancer effects of HA-cisplatin nanogel in 
CD44 expressed non-small cell lung cancer (NSCLC). HA-CD44 interaction may play a 
crucial role in the tumor targeted anti-cancer delivery system.
Keyword: nanogel, cisplatin
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P1-022: MICROSATELLITE INSTABILITY AT SELECTED TETRA-
NUCLEOTIDE REPEAT SEQUENCE IN NON-SMALL CELL LUNG 
CANCER.
Hiromasa Arai1, Koji Okudela2, Hisashi Oshio3, Noriko Komitsu4, Teppei Nishii1, Masahiro 
Tsuboi1, Akinori Nozawa5, Yasuharu Noishiki4, Kenji Inui1, Munetaka Masuda6  
1Respiratory Disease Center, Yokohama City University Medical Center, Yokohama/
JAPAN, 2Department of Pathology, Yokohama City University Graduate School Of 
Medicine, Yokohama/JAPAN, 3Department Of Pathology, Tokyo Medical University, 
Tokyo/JAPAN, 4Department Of Artificial Organ Science/JAPAN, 5, Department Of 
Pathology, Yokohama City University Medical Center, Yokohama/JAPAN, 6Department of 
Surgery, Yokohama City University Graduate School Of Medicine, Yokohama/JAPAN
Background: Microsatellite instability (MSI) can be analyzed by microsatellite markers 
consisting of mono-, di- and trinucleotide repeat sequences (Bethesda panel markers: 
D17S250, D2S123, D5S346, BAT25 and BAT26). In primary lung cancer, chromosomal 
instability including loss of heterozygosity (LOH) has been thought to play an important 
role in carcinogenesis. However, MSI was thought to be unrelated to lung carcinogenesis. 
Recently, the role of tetranucleotide repeat sequence instability in prostate, skin, bladder 
and lung cancers has been reported. However, unlike Bethesda panel markers, these 
tetranucleotide markers are not unified. Recent studies show that elevated microsatellite 
alterations at selected tetranucleotides (EMAST: D8S321, D20S82, UT5037, D8S348, 
D2S443, D21S1436, D9S747, D9S303, D9S304 and MYCL1) which are distinct from 
traditional MSI are frequent in several tumor types. EMAST in lung cancer has not 
been reported to date. We investigated allelic imbalance including EMAST and LOH 
in non-small cell lung cancers (NSCLCs) using selected tetranucleotide repeat markers 
based on previous reports and analyzed their correlation to clinicopathological factors. 
Methods: We investigated 65 NSCLC tissue samples (19 squamous cell carcinomas, 39 
adenocarcinomas, 1 adenosquamous cell carcinoma and 6 large cell carcinomas) without 
lymph node metastasis and preoperative chemotherapy or radiation therapy obtained after 
resection from Yokohama City University Medical Center. Tumorous DNA was extracted 
by laser captured microdissection, and paired normal DNA was extracted from non-
tumorous tissue or normal lymph nodes. Genotyping for EMAST and LOH determination 
was carried out using 10 tetranucleotide repeat markers and 5 Bethesda panel markers. 
Results:  Using the 10 tetranucleotide repeat markers, MSI was detected in 42 of 65 
(64.9%) of the tissue samples. There was a higher rate of MSI at selected tetranucleotide 
markers than at Bethesda panel markers in the tissue samples (12.3%). The high EMAST 
group (MSI found at two or more markers) was significantly correlated to the presence of 
multiple malignant neoplasms (p=0.014) and poor prognosis in overall survival (p=0.0018) 
compared to the low EMAST group (MSI at none or one marker). Conclusion:  Our results 
suggest that EMAST could participate in carcinogenesis of NSCLCs and lead to other 
malignant neoplasms.
Keywords: Microsatellite instability, tetranucleotide repeat sequence, non-small cell 
lung cancer
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P1-023: EPIGENETIC ALTERNATION OF LUNG ADENOCARCI-
NOMA INDUCED SMOKING
Koichiro Kajiura1, Kazuya Kondo2, Issei Imoto3, Hiromitsu Takizawa1, Yasushi 
Nakagawa1, Mitsuteru Yoshida1, Gyokei Kawakami1, Shoji Sakiyama1  
1Department Of Thoraci,Endocrine Surgery And Oncology, Institute Of Health 
Biosciences The University Graduate School, Tokushima/JAPAN, 2Oncological Medical 
Services Institute Of Health Biosciences, The University Of Tokushima Graduate School, 
Tokushima/JAPAN, 3Institute Of Health Biosciences The University Graduate School, 
Department Of Human Genetics, Tokushima/JAPAN
Background: Cigarette smoking is one of the most common cause of lung cancer. Small 
cell carcinoma and squamous cell carcinoma are related to smoking, but adenocarcinoma 
is occurred in smokers and non-smokers. Mechanism of genesis and progression of cancer 
contains of both genetic aberrance and epigenetic aberrance. Epigenetic aberrance is 
aberrant histone modification or methylation for DNA. It is said that hypermethylation 
of CpG islands is associated with exposure to tabacco smoking. We studied aberrant 
methylation of lung adenocarcinoma induced smoking. We worked out 470 thousands 
CpG sites in adenocarcinoma of smoker and non-smoker by methylation specific 
microarray and searched new cancer related gene for detecting DNA methylation site 
specific to smoking. Methods: DNA was extracted from 12 cancer tissues and normal lung 
tissues, resected in Tokushima university Hospital as lung adenocarcinoma. All cases were 
men and contained of 6 smokers and 6 non-smokers. Bisulfited DNA was analysed 470 
thousands CpG sites by infinium methylation assay ( illumine, America). We examined 
the DNA methylation of 470 thousands CpG sites and compared DNA methylation of 
cancer tissue with normal part and DNA methylation of cancer with smoker with that 
with non-smoker. We checked up methylated pattern, methylated level, and methylated 
part of the gene, and picked up hypermethylated CpG sites effected smoking differentially. 
Results: Clinical characteristics of smokers (n=6) was 69.3±8.5 years old, 1370±554 in B.I., 
5 in stage I a, 1 in I b, and 14.0±4.2mm in tumor size. Non-smokers (n=6) was 66.6±10.4 
years old, 1.6±4.1 in B.I., 5 in stage I a, 1 in I b, and 14.0±4.2mm in tumor size. There was 
no significant difference of clinical factors except B.I.. Candidate gene of hypermetyalation 
were TRIM58 (16, 0.454, 0.108, 1q44), ADAMTS16 (53, 0.436, 0.033, 5p15), POU4F2 (11, 
0.441, 0.214, 4q31.2), TCERG1L (94, 0.443, -0.225, 10q26.3), BARHL1 (16, 0.376, 0.180, 
1p22.2), SIX3 (22, 0.426, 0.128, 2p21), PTPRN (17, 0.419, 0.054, 2q35-q36.1), CXCL12 (21, 
0.419, 0.055, 10q11.1), ONECUT2 (32, 0.416, 0.104, 18q21.31), and GBX2 (17, 0.411, 0.191, 
2q37.2). *inside of ( ) are number of CpG sites, max β difference, averageβ difference, and 
location of the chromosome. β difference indicates that methylation level of cancer tissue 
minus that of normal part of resected lung. Some genes were reported as hypermethylated 
genes in the other kind of cancer. Conclusion: We could pick up novel candidate genes 
with epigenetic alternation of smoking related adenocarcinoma, and are checking up the 
situation of DNA methylation and RNA expression of candidate genes now.
Keyword: methylation
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P1-024: ABERRANT STRATIFIN OVEREXPRESSION ENHANCES 
TUMOR PROGRESSION OF EARLY INVASIVE LUNG  
ADENOCARCINOMA
Aya Shiba-Ishii, Yukio Morishita, Masayuki Noguchi  
Department Of Pathology, Faculty Of Medicine, University Of Tsukuba, Tsukuba-shi, 
Ibaraki/JAPAN
Background: Adenocarcinoma in situ (AIS) of the lung has a very favorable prognosis, 
with a 5-year survival rate of 100%. However, early but invasive adenocarcinoma (eIA) 
sometimes has a fatal outcome. We previously compared the expression profiles of AIS 
with those of eIA showing lymph node metastasis or a fatal outcome, and found that 
stratifin (SFN, 14-3-3 sigma) was a differentially expressed gene related to tumor 
progression (Aya Shiba-Ishii, IJC. 2011): IHC revealed immunopositivity for SFN in more 
than 95% of eIAs, in comparison with only 13% of AISs. We also found that promoter 
demethylation triggered aberrant SFN overexpression in eIAs in a p53-independent 
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manner (Aya Shiba-Ishii, AJP. 2012). Here, we performed functional analysis to clarify 
how SFN affects the progression of lung adenocarcinoma. Methods: For in vitro 
functional analysis, we performed siRNA or expression vector transfection and 
subsequent cell proliferation assays with a lung adenocarcinoma cell line (A549). An in 
vivo animal study was also performed. Tumor kinetics were measured by s.c.-injecting 
7-week-old nude mice with 1 x 106 siSFN-transfected A549 cells in 0.2 ml of DMEM. The 
dimensions of developing tumors were measured using calipers on alternate days, and 
tumors were evaluated by HE staining and IHC after sacrifice. Results: Suppression of 
SFN expression by siSFN significantly reduced cell proliferation activity and BrdU 
uptake. However, transfection of the SFN expression vector led to a significant increase 
in cell proliferation. Also, cell cycle analysis revealed that the S-phase subpopulation was 
decreased after siSFN treatment. In vivo, cells that had been treated with siSFN showed 
reduced tumor development in comparison with untreated controls (figure), but there 
was no inter-group difference in the histological features and SFN expression levels of 
the developed tumors. 
Conclusion: Although SFN was originally identified as a negative regulator of the 
cell cycle, especially in response to p53-sensitive DNA damage, subsequent reports 
indicated that it is a positive mediator of cell proliferation. In breast cancer, SFN 
induces G1/S progression by increasing cyclin D1 expression. Here, we demonstrated 
that SFN enhanced the proliferative capacity of lung adenocarcinoma cells both in 
vitro and in vivo. Since the BrdU uptake and S-phase subpopulation of the cells also 
decreased after siSFN transfection, SFN might regulate DNA replication in S phase. The 
results of our in vivo study suggest that suppression of SFN expression may block lung 
adenocarcinogenesis at a very early stage. In conclusion, aberrant expression of SFN in 
lung adenocarcinoma induces progression of AIS to eIA by facilitating cell proliferation.
Keywords: early invasive adenocarcinoma, stratifin
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P1-025: STAT3-INDUCED MIR-92A PROMOTES INVASIVENESS BY 
TARGETING THE TUMOR SUPPRESSOR RECK IN LUNG CANCER 
CELLS
Wen-chun Hung  
National Institute Of Cancer Research, National Health Research Institutes, Tainan/
TAIWAN
Background: STAT3 (signal transducer and activator of transcription 3) has been 
reported to be an oncogenic transcription factor and high expression of STAT3 is 
associated with lung cancer progression. Recent studies demonstrate that STAT3 may 
control micrRNAs to promote cancer progression. RECK (reversion-inducing cysteine-
rich protein with Kazal motifs) is a tumor suppressor gene and a membrane-anchored 
glycoprotein that reduces the matrix metalloproteinases (MMPs)-induced destruction 
of extra-cellular matrix (ECM) and tumor metastasis. RECK also inhibits tumor 
angiogenesis. In this study, we try to elucidate whether ovexpression of STAT3 can affect 
microRNA expression to regulate RECK via post-transcriptional modulation. Methods: 
Regulation of miR-92a by STAT3 was studied by overexpression of constitutively active 
STAT3 or STAT3 inhibitors. 3’UTR reporter assay was performed to verify RECK is a 
miR-92a target. Pre-miR-92a and anti-miR-92a were used to study their roles in STAT3-
mediated down-regulation of RECK. Transwell assays were carried out to show the effect 
of miR-92a on cell migration and invasion. Results: We found that miR-92a, a member of 
miR-17-92a cluster could target RECK 3’UTR. In addition, our data showed that STAT3 
regulated the expression of miR-92a and inhibition of STAT3 significantly decreased 
miR-92a expression. Furthermore, miR-92a reduced RECK protein but not mRNA level. 
Knockdown of miR-92a expression in STAT3-overexpressing cell lines restored RECK 
protein level, and attenuated cell invasion and migration. Conclusion: Collectively, 
our results suggest that STAT3 up-regulates miR-92a to inhibit RECK expression and 
promote lung cancer metastasis.
Keywords: STAT3, microRNA, tumor suppressor
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P1-026: TIMELESS IS OVEREXPRESSED IN LUNG CANCER AND 
ITS KNOCKDOWN INDUCES APOPTOSIS AND CHEMOSENSITI-
ZATION IN LUNG CANCER CELLS
Kenya Yoshida1, Mitsuo Sato1, Tetsunari Hase1, Momen Elshazley1, Ryo Yamashita1, 
Noriyasu Usami2, Tetsuo Taniguchi2, Kohei Yokoi2, Masashi Kondo1, Luc Girard3, John 
D. Minna3, Yoshinori Hasegawa1  
1Department Of Respiratory Medicine, Nagoya University Graduate School Of Medicine, 
Nagoya/JAPAN, 2Department Of Thoracic Surgery, Nagoya University Graduate School 
Of Medicine, Nagoya/JAPAN, 3Hamon Center For Therapeutic Oncology Research, 
University Of Texas Southwestern Medical Center At Dallas/USA
Background: TIMELESS (TIM) was initially cloned as a mammalian homolog of 
Drosophila timeless, which functions as a main clock gene. Its role in the circadian 
clock system in mammals has yet to be determined, although previous studies have 
shown that TIM functions in replication protection and genomic stability. Recently, 
mutations in the TIM gene in breast cancer and an association between breast cancer 
risk and SNPs in TIM were reported, suggesting the involvement of TIM in human 
cancer.TIMELESS (TIM) was initially cloned as a mammalian homolog of Drosophila 
timeless, which functions as a main clock gene. Its role in the circadian clock system in 
mammals has yet to be determined, although previous studies have shown that TIM 
functions in replication protection and genomic stability. Recently, mutations in the 
TIM gene in breast cancer and an association between breast cancer risk and SNPs in 
TIM were reported, suggesting the involvement of TIM in human cancer. Methods: We 
evaluated TIM expression in lung cancer cell lines and tumor specimens by microarray 
expression, western blotting and/or immunohistochemistry analyses. We performed 
mutation analysis for TIM in 21 human lung cancer cell lines, and evaluated the effects 
of TIM knockdown on proliferation, clonogenic growth and sensitivity to cisplatin in 
H157 lung cancer cells . Results: Microarray expression analysis of lung cancer cell lines 
showed that TIM expression was elevated by 3.7-fold (P < 0.001) in non-small cell lung 
cancer (NSCLC, n=116) cell lines compared to normal lung controls (n=59). In addition, 
small cell lung cancer (SCLC, n=29) cell lines expressed TIM at levels 2.2-fold (P < 
0.001) higher than NSCLCs. Western blot analysis of 21 lung cancer cell lines revealed 
that all cell lines studied expressed TIM protein and that 19 cell lines (90%) expressed 
TIM protein at higher levels than a normal control line. Immunohistochemistry of 30 
surgically resected lung cancer specimens showed that all lung cancer specimens but no 
matched normal lung tissues were positive for TIM expression. Analyses of TIM in 21 
lung cancer cell lines revealed no mutation. TIM knockdown in H157 cells suppressed 
proliferation and clonogenic growth, induced apoptosis, and increased sensitivity to 
doxorubicin and cisplatin. Conclusion: These results suggest that TIM inhibition has 
potential utility in the treatment of lung cancer.
Keywords: cisplatin, Overexpression, Apoptosis, TIMELESS
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P1-027: THE NONCODING RNA EXPRESSION PROFILE AND THE 
EFFECT OF LNCRNA AK126698 ON CISPLATIN RESISTANCE IN 
CISPLATIN RESISTANT NON-SMALL-CELL LUNG CANCER CELLS
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Yong Yang1, Hui Li2, Shengcai Hou2, Bin Hu1, Jie Liu3, Jun Wang3  
1Thoracic Surgery, Beijing Chao-Yang Hospital, Captial Medical Uuniversity, Beijing/
CHINA, 2Thoracic Surgery, Beijing Chao-Yang Hospital, Captal Medical University, 
Beijing/CHINA, 3Beijing Key Laboratory Of Respiratory And Pulmonary Circulation, 
Capital Medical University, Beijing/CHINA
Background: Cisplatin-based chemotherapy is the standard therapy used to treat 
non-small-cell lung cancer. However, its efficacy is largely limited by the acquired drug 
resistance. So far, little is known about the RNA expression changes in the cisplatin 
resistant lung cancer. Identification the RNAs related to the cisplatin resistance may 
provide precise clues for lung cancer therapy. Methods:  mRNAs, lncRNA, miRNA 
expression profiling was analyzed and compared between A549 cells and cisplatin 
resistant A549/CDDP cells by microarray. Some differentially expressed mRNAs, 
lncRNAs and miRNAs, as verified by realtime RT-PCR, were subject to pathway analysis 
by using Fisher exact test and test. The expression of NKD2 and β-catenin was assessed 
by realtime RT-PCR and western blot, respectively. The effect of AK126698 on cisplatin 
induced apoptosis was investigated by annexin-V/PI flow cytometry.  Results:  There 
were 1471 mRNAs, 1380 lncRNAs and 25 miRNAs differentially expressed RNA in 
A549/CDDP cells compared with A549 cells. Among them, 8 mRNAs, 8 lncRNAs and 
5 miRNAs that differentially expressed in gene chip were validated. High-enrichment 
pathways analysis and gene co-expression network indicated many pathways that 
participate in proliferation, differentiation, evading apoptosis, and drug metabolism 
were differently expressed. Among these, canonical Wnt pathway may play an important 
role in cisplatin resistance, which was targeted by both lncRNAs and miRNAs including 
lncRNA AK126698. Knockdown of lncRNA AK126698 greatly decreased NKD2, 
increased expression of the accumulation and nuclear translocation of β-catenin, and 
significantly depressed apoptosis rate induced by cisplatin in A549 cells. Conclusion:  
The cisplatin resistance of non-small-cell lung cancer cells may relate to numerous 
changes of noncoding RNAs. Among these, AK126698 may be essential for cisplatin 
resistance by targeting Wnt pathway.
Keywords: lncRNA, A549 cells, Wnt pathway, cisplatin
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P1-028: PROGNOSTIC IMPACT OF C-MET/PHOSPHO-MET AND 
TOPOISOMERASE I IN SMALL CELL LUNG CANCER
Hideko Ikeda1, Kazuo Kasahara1, Shinji Nakao2  
1Respiratory Medicine, Cellular Transplantation Biology, Division Of Cancer Medicine, 
Kanazawa University Graduate School Of Medical Science, Kanazawa City, Ishikawa/
JAPAN, 2Cellular Transplantation Biology, Division Of Cancer Medicine, Kanazawa 
University Graduate School Of Medical Science, Kanazawa City, Ishikawa/JAPAN
Background: The hepatocyte growth factor/Met pathway has been shown to cause 
tumor progression in several types of carcinomas. We reported that c-Met up-regulated 
topoisomease I (Topo I) in non-small cell lung cancer cell lines (submitted for 
publication). In this study we examined the prognostic influence of c-Met/phospho-
Met (p-Met), or Topo I expression and elucidated correlation between c-Met/p-Met 
expression and Topo I expression in small cell lung cancer (SCLC). Methods: This 
retrospective study included 72 SCLC patients with available tumor tissue from primary 
lung tumor or metastatic lesions and clinical data including survival. We performed 
immunohistochemistry to detect c-Met/p-Met and Topo I expression, and fluorescence 
in situ hybridization (FISH) to evaluate Met gene copy number. Results: Tumor tissues 
were obtained from 72 SCLC patients. Sixty-six patients, (51 male, 15 female, median age 
67.5 range 43-91, LD/ED 38/28, PS 0,1/2,3,4 57/9) were evaluated. c-Met overexpression 
was seen in 40.9%, p-Met in 74.2%, and Topo I expression in 59.1%, respectively. High 
expression of Topo I associated with lower response rate (RR) (96.7% in low group vs 
78.4% in high group, p=0.029) and shorter progression-free survival (PFS) (65W vs 
39W, p=0.040) but did not correlate with overall survival (OS). Phosphorylation of Met 
protein and Met-FISH did not correlate with RR, PFS or OS. Interestingly, intensity of 
p-Met significantly correlated with Topo I expression (p=0.048). High expression of 
c-Met protein did not associated with RR or PFS but significantly associated with shorter 
OS (high 53W, low 95W, p=0.018). Multivariate analysis which included c-Met, stage, 
Performance Status, and age resulted that c-Met was an independent prognostic factor 
for OS of patients with SCLC (HR; 2.144, 95% confidence interval 1.162-3.956, p=0.015). 
Conclusion: This study suggested c-Met high expression was an independent prognostic 
factor, and Topo I was up-regulated by Met in SCLC.
Keywords: HGF/Met pathway, Topo I, small cell lung cancer
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P1-029: DETECTION AND TISSUE DISTRIBUTION OF HOMEODO-
MAIN INTERACTING PROTEIN KINASE 2 (HIPK2)  IN LUNG LYM-
PHOMA: PRELIMINARY DATA OF AN IMMUNOHISTOCHEMICAL 
STUDY
Mirella Marino1, Enzo Gallo1, Massimo Filippetti2, Daniela Assisi3, Robert Martucci1, 
Gabriele Alessandrini2, Edordo Pescarmona1, Silvia Soddu4, Francesco Facciolo2, Cinzia 
Rinaldo5  
1Pathology, Italian National Cancer Institute “Regina Elena”, Rome/ITALY, 2Thoracic 
Surgery, Italian National Cancer Institute “Regina Elena”, Rome/ITALY, 3U. 
Gastroenterology And Endoscopy, Italian National Cancer Institute “Regina Elena”, 
Rome/ITALY, 4Experimental Oncology, Italian National Cancer Institute “Regina 
Elena”, Rome/ITALY, 5Ibpm, Cnr At University “La Sapienza”, Rome/ITALY
Background: Among lung tumors, the rare lymphoma require fine differential 
diagnostics and subtyping. The new minimally invasive diagnostic surgical techniques 
add difficulties to a biologically complex lymphatic scenario. In our series, atypical 
lung resections as well as Trans Bronchial Needle Aspiration (TBNA) and echo-
guided endoscopic ultrasound-fine needle aspiration (EUS-FNA), according to 
the lesion localization, provide diagnostic specimens of epithelial and lymphoid 
tumors. Prognostic and predictive factor evaluation in the hera of translational and 
personalized medicine constitute for pathologists the new frontiers. We recently started 
to characterize the detectability and cellular localization of HIPK2 (Homeodomain-
Interacting Protein Kinase 2), a p53 activator and regulator, in lymphatic tissue and 
lymphoma arising in extranodal sites. Our recent studies indicate the existence of 
different mechanisms of HIPK2 inactivation in human breast and thyroid cancers (e.g., 
allele-specific LOH, forced cytoplasmic re-localization). The p53 apoptosis regulator is 
usually unmutated in lymphomas, therefore increasing the interest in characterizing 
alternative p53 inactivation pathways. Methods: Histopathological diagnosis in different 
diagnostic specimens was established by morphological and immunohistochemical 
criteria by applying principles and antibody (Ab) panels according to the World Health 
Organization of Lymphoid malignancies (WHO 2008). Immunohistochemistry for 
HIPK2 was performed with a monoclonal (mc) mouse IgM Ab to HIPK2 developed in 
our Institute by S.Soddu and C. Rinaldo and suitable for immunostaining in formalin 
fixed, paraffin embedded samples (unpublished results). Results: In our series of lung 
lymphomas, B cell non Hodgkin lymphomas constitute the main diagnostic category, 
with the extranodal marginal zone lymphoma (Bronchus-associated lymphoid tissue 
lymphoma, BALT-lymphoma), representing the prevalent histotype and Diffuse Large 
B Cell Lymphomas(DLBCL) representing the second. However, a case of Hodgkin 
lymphoma and a therapy-linked, T cell lymphoma occurring metachronously to a 
primary B cell lymphoma were also diagnosed. The detectability and subcellular 
distribution of HIPK2 was investigated until now in four cases, three cases of BALT 
lymphomas and in one case of DLBCL. The 3 BALT-lymphomas were diagnosed on 
atypical lung resections, the DLBCL was characterized on a pneumectomy. specimen. 
In the 3 BALT lymphoma, HIPK2 was seen at high magnification (1000x) as fine (1 case) 
or coarse globular nuclear granules. In the one DLBCL a reverse, cytoplasmic strong 
positivity for HIPK2 was seen. In the 3 BALT lymphoma cases, no p53 nuclear staining 
was detected.  Conclusion: Our preliminary data shows that in the lung well as in 
other extranodal sites HIPK2 could be detected by immunohistochemistry. In normal 
lymphoid tissue, we observed the nuclear distribution of HIPK2 as small or coarse 
globular granules, similarly to the pattern detected in the “indolent” BALT lymphomas. 
The strong cytoplasmic HIPK2 in the DLBCL suggests a HIPK2 inactivation. Until now 
we detected a cytoplasmic HIPK2 delocalization in very few DLBCL cases with different 
extranodal origin among the 23 cases studied ( unpublished results). The data suggest 
that HIPK2 is functionally heterogeneous in extranodal lymphoma with different 
subtype and localization, and require further correlation with other apoptosis regulatory 
proteins involved in the p53 pathway. 
Keyword: lung lymphoma/HIPK2/p53 regulation
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P1-030: MECHANISMS OF ACQUIRED RESISTANCE TO MTOR 
INHIBITOR IN SMALL CELL LUNG CANCER.
Masaru Toyokawa, Rintaro Noro, Masahiro Seike, Nobuhiko Nishijima, Kazuhiro 
Kitamura, Yuji Minegishi, Chie Soeno, Kuniko Matsuda, Kaoru Kubota, Akihiko 
Gemma  
Department Of Pulmonary Medicine/Infection And Oncology, Nippon Medical School 
Hospital, Bunkyo, Tokyo/JAPAN
Background: Molecular-targeted therapies have been recently developed for non-
small cell lung cancer (NSCLC) treatment. NSCLC patients with EGFR mutations have 
shown a dramatic response to epidermal growth factor receptor (EGFR) inhibitors. 
However, it is recognized that, clinically, drug resistance eventually emerges and 
this limits the mean duration of response. Recently, mammalian target of rapamycin 
(mTOR) inhibitor showed promising efficacy in patients with renal cell carcinoma and 
pancreatic neuroendocrine tumor (pNET). It has also been evaluated as second-line 
therapy for small cell lung cancer (SCLC) in a phase II study. In this study, we analyzed 
the antitumor effects of mTOR inhibitors in SCLC cell lines and tried to clarify the 
mechanism of resistance for mTOR inhibitors and overcome the resistance. Methods: 
We analyzed the antitumor effects of mTOR inhibitors (everolimus, temsirolimus and 
rapamycin) in eight SCLC cell lines by MTS assay. To identify genes associated with 
sensitivity to mTOR inhibitors, we conducted gene expression profiling on the same set 
of cell lines. Protein expressions of PI3K-mTOR signal pathways were also evaluated 
by Western blot analysis. Results: SBC-5 cells were sensitive to mTOR inhibitors. We 
established an everolimus-resistant SBC-5 cells by continuous exposure to everolimus. 
Several downstream molecules of PI3K-mTOR signal pathways were elevated in the 
resistant cells than in parent cells. Conclusion: We identified the several candidates 
correlated with the acquired resistance to mTOR inhibitor. Overcoming the acquired 
resistance may lead to important advances for mTOR inhibitor treatment for SCLC.
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P1-031: CRKL GENE AMPLIFICATION IN ACQUIRED RESISTANT LUNG 
CANCERS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION TO 
TYROSINE KINASE INHIBITORS – ANALYSIS OF IN VITRO MODELS AND 
CLINICAL SPECIMENS
Kenichi Suda1, Hiroshi Mizuuchi1, Isao Murakami2, Kenji Tomizawa3, Mikihiro Kohno1, 
Tsukihisa Yoshida1, Tatsuro Okamoto1, Yoshihiko Maehara1, Tetsuya Mitsudomi4  
1Department Of Surgery And Science, Graduate School Of Medical Sciences, Kyushu 
University, Fukuoka/JAPAN, 2Department Of Respiratory Medicine, Higashihiroshima 
Medical Center, Higashihiroshima/JAPAN, 3Department Of Thoracic Surgery, Aichi 
Cancer Center Hospital, Aichi/JAPAN, 4Department Of Thoracic Surgery, Kinki 
University Faculty Of Medicine, Osaka-sayama/JAPAN
Background: Lung adenocarcinomas with the epidermal growth factor receptor (EGFR) 
gene mutation often dramatically respond to orally available EGFR tyrosine kinase 
inhibitors (TKIs). However, acquired resistance develops almost inevitably within one 
year, and this limits the improvement in patient outcomes. Several secondary molecular 
aberrations have been reported as the causes or as the candidates of acquired resistance. 
Lung cancers that harbor CRKL gene amplification have been identified in 3% of primary 
lung cancers and were reported to be very sensitive to CRKL suppression by Cheung, et 
al. in 2011. In addition, the authors showed that the artificial overexpression of CRKL by 
gene transfection conferred resistance to EGFR-TKI in HCC827 lung cancer cell line 
with the EGFR gene mutation. However, clinical significance of the CRKL gene 
amplification in acquiring resistance to EGFR-TKIs is unclear. Methods: Previously 
established EGFR-TKI acquired resistant cell lines (HCC827ER, HCC827EPR, and 
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HCC4006ER cells) and their parents were analyzed as in vitro acquired resistance 
models. In addition, thirty-two autopsy samples from six lung adenocarcinoma patients, 
whose T790M status and the MET gene copy numbers have been previously determined, 
were analyzed. These six patients all responded well to gefitinib monotherapy and 
experienced disease progression while on continuous treatment with gefitinib. Genomic 
DNAs were extracted from these samples and the gene copy numbers of CRKL were 
analyzed by Real-time PCR method. Gene copy numbers of Line-1 repetitive element 
were used as internal controls. Results: 
In the analysis of in vitro acquired resistance models, CRKL gene copy numbers were 
identical between parent cells and acquired resistance descendants, and no CRKL gene 
amplification was observed (0.52~0.60 times compared with normal genomic DNA). In 
addition, CRKL gene amplification was not identified in all clinical specimens (0.78~2.19 
times compared with normal genomic DNA, Figure 1). Conclusion: These results 
indicate that CRKL gene amplification may not be a frequent acquired resistance 
mechanism to EGFR-TKIs in lung cancer with the EGFR gene mutations. Future analysis 
using additional samples with acquired resistance is desired.
Keywords: acquired resistance, EGFR mutation, molecular target therapy
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P1-032: GENETICALLY ENGINEERED ONCOLYTIC MEASLES 
VIRUS LYSES NON-SMALL CELL LUNG CANCER STEM CELLS IN 
VITRO AND IN VIVO
Hiroyuki Inoue, Keisuke Yasunari, Yumiko Matsumura, Shohei Miyamoto, Kaname 
Nosaki, Akira Sakamoto, Koichi Takayama, Yoichi Nakanishi, Kenzaburo Tani  
Kyushu University, Fukuoka/JAPAN
Background: Accumulating evidences suggest that cancer stem cells (CSCs) play 
a critical role in cancer development, chemo- and radio-resistance, and seemingly 
initiation of metastasis. Thus, novel strategies to target CSCs derived from NSCLC 
(NSCLC-CSCs) offer great possibilities to open new avenues in cancer therapy. Oncolytic 
viruses are now considered to be an emerging therapeutic platform for the treatment of 
human cancer with distinctive properties in comparison with conventional therapeutic 
modalities. Recently, we recently developed a novel oncolytic MV-Edm tag strain (a 
V-defective vaccine-lineage strain, MV-Etag) genetically engineered by replacing the N, 
P, and L genes with those of the wild-type MV strain (MV-NPL). This virus was shown 
to possess more potent oncolytic effects with rapid replication on human renal cell 
carcinoma cells than the parental MV-Etag, and to retain a capacity of forming virus–
cell membrane fusion after binding to MV receptor CD46 preferentially up-regulated in 
cancer cells. In current study, we hypothesized that this newly developed MV-NPL would 
elicit an effective oncolytic activity against human NSCLC-CSCs. Methods: We isolated 
side population (SP) cells of human lung adenocarcinoma A549 cells using FACS Aria 
and utilized them as NSCLC-CSCs with several stem cell properties. We comparatively 
investigated expression level of CD46and MV-Etag- or MV-NPL-mediated oncolytic 
cytotoxicity between A549-SP cells and their counterpart A549-NSP cells by Crystal 
Violet and MTS assay. Subsequently we examined whether induced apoptosis or PI3K/
Akt survival signaling pathways contributed to MV-NPL mediated cytotoxicity. Finally, 
the oncolytic activity and tolerability of intratumoral MV-NPL administration were 
investigated in A549-SP xenograft mouse model. Results: Nine human NSCLC cell lines 
expressed more than 94% human CD46 expression levels, whereas 2 normal lung cell 
lines expressed less than 10 % CD46 expression levels. All 4 NSCLC cell lines examined 
contained a rare subpopulation of SP cells, ranging from 0.8 % to 2.2% of gated cells in 
the presence of reserpine. Each SP fraction in 3 NSCLC cell lines exhibited equivalent 
or slightly higher level of surface CD46 expression compared with its respective 
counterpart. Results of in vitro cytotoxicity assay showed that MV-NPL infection 
revealed more enhanced oncolytic activity against A549-SP cells while sparing human 
normal lung cells, compared with the parental MV. Both A549-SP and A549-NSP 
cells at 16 hours after MV-NPL infection elicited more robust apoptosis as evidenced 
by an increased early apoptotic cells (annexin V+ /PI− ) compared with those infected 
with MV-Etag. Caspase-dependent apoptosis activity substantially contributed to the 
cytotoxicity of in A549-SP cells induced by MV-NPL infection, despite their higher 
expression levels of anti-apoptotic protein of both XIAP and Mcl-1 in A549-SP cells. 
In addition, combination use of MV-NPL with PI3K inhibitor augmented the oncolytic 
effects by MV-NPL in a dose-dependent manner. Furthermore, consecutive intratumoral 
MV-NPL administrations into subcutaneous A549-SP xenografts significantly inhibited 
the outgrowth without severe side effects. Conclusion: Altogether, this study opens the 
perspective that MV-NPL may have value as a novel oncolytic virotherapy for NSCLC 
patients resistant to conventional therapies.
Keywords: Oncolytic Virotherapy, Cancer stem cells
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P1-033: EFFECTS OF LOW-DOSE HUMAN ATRIAL NATRIURETIC 
PEPTIDE FOR PREVENTING CANCER RECURRENCE OR  
METASTASIS IN LUNG CANCER
Takashi Nojiri1, Hiroshi Hosoda2, Takeshi Tokudome2, Toru Kimura1, Yasushi Shintani1, 
Masayoshi Inoue1, Hajime Maeda3, Yukiyasu Takeuchi3, Masato Minami1, Noriyoshi 
Sawabata1, Tomoyuki Nakagiri1, Soichiro Funaki1, Mikiya Miyazato2, Kenji Kangawa2, 
Meinoshin Okumura1  
1General Thoracic Surgery, Osaka University Graduate School Of Medicine, Suita/
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Background: Cancer metastasis is the most common cause of death in cancer patients. 
Although surgical resection remains the only potentially curative treatment for 
lung cancer, lung cancer patients after curative surgery still have high risk of cancer 
recurrence. If we can perform any prophylactic strategy during the perioperative period 
for cancer recurrence, surgical outcome for lung cancer could be improved significantly. 
Atrial natriuretic peptide (ANP) has been used clinically for the treatment with heart 
failure in Japan, and exhibits a wide range of biological activities including beneficial 
effects on cardiovascular system through binding the guanylate cyclase-A (GC-A) 
receptor. We previously reported that ANP had a prophylactic effect on postoperative 
cardiopulmonary complications in lung cancer patients, and performed the follow-
up survey in this study. The objective of the present study was to evaluate the clinical 
effects of ANP on cancer recurrence in lung cancer patients following curative surgery. 
Furthermore, we investigated the mechanism of ANP in the prevention of cancer 
metastasis in the basic research. Methods: Among 753 patients who underwent lung 
cancer surgery in two specialized thoracic centers between 2007 and 2011, the cases with 
carcinoma in situ or limited surgery were excluded. Finally 552 consecutive patients 
who underwent curative surgery were included in this study. The results of patients were 
compared with surgery alone (control group; 462 patients) and receiving ANP infusion 
during the perioperative period (ANP group; 90 patients). In the basic research, we 
used B16 mice melanoma cell line (F10), which don’t have the GC-A receptor, in the 
experimental hematogenous metastasis model. Results: Results (Clinical): There were 
no significant differences in surgical factors and pathological stage in both groups. The 
incidence of cancer recurrence in two years after surgery was significantly lower in the 
ANP group (total, 5%; IA-0%, IB-4%, II-17%, III-20%) than in the control group (total, 
20%; IA-5%, IB-15%, II-24%, III-48%). Results (Basic): When B16 cells (5 x 105 cells) were 
intravenously injected into B6 mice, 100-150 of visible lung macrometastasis occurred 
in two weeks. In this hematogenous metastasis model, administration of ANP via 
osmotic mini-pump notably inhibited metastasis in the lung of the control mice (13±2 vs. 
119±13, P<0.001). Furthermore, lung metastasis significantly increased in the vascular 
endothelial cell GC-A-specific knock-out mice, and decreased in the vascular endothelial 
cell GC-A-specific overexpression mice compared to the control mice. These studies 
indicate that ANP/GC-A signaling in the vascular endothelial cells mediates crucial roles 
in the inhibition of the cancer metastasis. Conclusion: The treatment of ANP during 
the perioperative period had a prophylactic effect on cancer recurrence in lung cancer 
patients after curative surgery. We found that ANP inhibits cancer metastasis through 
GC-A receptor in the vascular endothelial cells. Our data provide novel insights into the 
prophylactic therapy for various type of cancers.
Keywords: cancer metastasis, lung cancer surgery, cardiovascular peptide
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P1-034: PHARMACOLOGIC DISRUPTION OF POLYCOMB 
GROUP PROTEIN EZH2 VIA 3-DEAZANEPLANOCIN A INHIBITS 
GROWTH OF NON-SMALL CELL LUNG CANCER CELLS
Ichiro Kinoshita1, Taichi Takashina2, Kikuchi Junko2, Yasushi Shimizu1, Jun Sakakibara-
Konishi2, Satoshi Oizumi2, Masaharu Nishimura2, Hirotoshi Dosaka-Akita1  
1Department Of Medical Oncology, Hokkaido University Graduate School Of Medicine, 
Sapporo/JAPAN, 2First Department Of Medicine, Hokkaido Univershity School Of 
Medicine/JAPAN
Background: EZH2 (enhancer of zeste homolog 2) is the catalytic subunit of 
PRC2 (polycomb repressive complex 2), which transfers a methyl group from the 
cofactor S-adenosyl methionine to histione H3 on lysine 27, resulting in epigenetic 
transcriptional silencing of target genes. EZH2 is involved in maintenance of embryonic 
and adult stem cells and in malignant transformation and biological aggressiveness 
of several human malignancies. Recently, an S-adenosyl-L homocysteine hydrolase 
inhibitor, 3-Deazaneplanocin A (DZNep), has been shown to deplete and inhibit 
EZH2. Methods: We conducted an immunohistochemical assessment of 157 surgically 
resected NSCLCs. Then, we evaluated the effect of knockdown of EZH2 by siRNA 
and pharmacologic disruption of EZH2 by DZNep in four NSCLC cell lines.  Results: 
Most NSCLCs overexpressed EZH2, while normal bronchial epithelia revealed only 
sporadic expression of EZH2. Patients with high EZH2 expression in tumor cells had a 
poorer prognosis than patients with low EZH2 expression in all pStages (p =.001) and 
in pStage I (p =.006). Multivariate analysis revealed that high EZH2 expression was an 
independent, unfavorable prognostic factor in patients with pStage I disease (p=.048). 
High EZH2 expression was correlated significantly with nonadenocarcinoma histology, 
moderate and poor differentiation, advanced pT Stage, and high Ki-67 and cyclin E 
labeling indices. Knockdown of EZH2 by siRNA resulted in decreased growth of all 
four NSCLC cell lines. MTT assays demonstrated that DZNep treatment resulted in 
dose-dependent inhibition of proliferation in the NSCLC cell lines with a half maximal 
inhibitory concentration (IC50) ranging from 0.08 to 0.24 μM. Immortalized but non-
cancerous bronchial epithelial and fibroblast cell lines were less sensitive to DZNep than 
the NSCLC cell lines. Soft agarose assays demonstrated that anchorage-independent 
clonogenicity was also reduced in all three NSCLC cell lines that were evaluated using 
this assay. Flow cytometry analysis demonstrated that DZNep induced apoptosis and G1 
cell cycle arrest in NSCLC cells, which was partially associated with cyclin A decrease 
and p27Kip1 accumulation. DZNep depleted cellular levels of EZH2 and inhibited the 
associated histone H3 lysine 27 trimethylation. Conclusion: These results suggest that 
EZH2 is overexpressed and correlated with tumor aggressiveness in NSCLCs, and that 
an epigenetic therapy that pharmacologically targets EZH2 via DZNep may constitute a 
novel approach to treatment of NSCLCs.
Keywords: EZH2, DZNep, polycomb-group protein, NSCLC
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P1-035: POSITRON-EMISSION TOMOGRAPHY-COMPUTED 
TOMOGRAPHY WITH THE GLUCOSE ANALOGUE [18F] FLUORO-
DEOXYGLUCOSE IN ORTHOTOPIC IMPLANTATION SCID MICE 
MODEL OF LUNG CANCER
Hiromitsu Takizawa1, Kazuya Kondo2, Tamaki Ohtani3, Hitoshi Kubo4, Koichiro 
Kajiura1, Yukikiyo Kawakami1, Mitsuteru Yoshida1, Shoji Sakiyama1, Akira Tangoku1 
1Thoracic Endocrine Surgery And Oncology, Tokushima University School Of Medicine, 
Tokushima/JAPAN, 2Oncological Medical Services Institute Of Health Biosciences, The 
University Of Tokushima Graduate School, Tokushima/JAPAN, 3Program In Biomedical 
Information Science, University Of Tokushima Graduate School/JAPAN, 4Department 
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Background: Positron-emission tomography-computed tomography (PET-CT) with 
the glucose analogue [18F] fluorodeoxyglucose (FDG) has been recently applied for 
evaluating tumor response to anticancer therapy. We have evaluated the utility of 
FDG PET-CT in orthotopic implantation SCID mice model of lung cancer. Methods: 
Human lung cancer cell line Ma44-3 was injected into left lungs of 6 severe combined 
immunodeficiency disease (SCID) mice. Nine or 10 days after implantation (3 mice on 
day 9 and other 3 mice on day 10), the SCID mice were examined with FDG PET-CT. 
Tumor volume and maximal standardized uptake value (SUV max) of the lung tumor 
were calculated for all mice. All SCID mice were sacrificed at 10 days after implantation 
for histopathologic analysis.  Results: Fusion of CT and PET images showed FDG 
uptake in the lung tumors. Tumor volume calculated by CT images was 24.3 ± 9.3 
mm3, and SUV max of the lung tumor was 1.2 ± 0.3. Pearson’s product-moment 
correlation coefficient between tumor volume and SUV max was r=0.7. Lung tumors 
were histopathologically proved in left lungs of all mice. Conclusion: Lung tumors 
orthotopically implanted in the SCID mice showed FDG uptake relative to tumor size. 
FDG PET-CT in orthotopic implantation SCID mice model of lung cancer is useful in 
evaluating tumor response to anticancer therapy.
Keywords: PETCT, animal model, LUNG CANCER
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P1-036: THE DISPLACEMENT OF PRIMARY LUNG CANCER AND 
NORMAL TISSUES DURING RESPIRATION BY 4D-CT.
Ying Jie Zhang  
Radiotherapy, Shandong Cancer Hospital, Jinan/CHINA
Background: This study is to investigate the correlation of position movement of 
primary tumor with interested organs and skin markers, and to investigate the 
correlation of volume variation of primary tumors and lungs during different 
respiration phases for patients with lung cancer at free breath condition scanned by 
4D-CT simulation. Methods: 16 patients with lung cancer were scanned at free breath 
condition by simulation 4D-CT which connected to a respiration-position-monitoring 
system (RPM). A coordinate system was created based on image of T5 phase, GTVs and 
normal tissue structures of 10 phases were contoured. The three dimensional position 
variation of them were measured and their correlation were analyzed, and the same for 
the volume variation of GTVs and lungs of 10 respiratory phases. Results: Movement 
range of lung cancer in different lobe differed significantly: 0.8mm–5.0mm in upper lobe, 
5.7mm–5.9mm in middle lobe and 10.2mm–13.7mm in lower lobe. Movement range of 
lung cancer in three dimensional direction was different: Z-axis 4.31±4.34mm>Y-axis 
2.19±1.04mm>X-axis 1.73±1.5mm. There was no statistical significant correlation for 
movement vector of GTV and interested structures, nor for volume variation of tumor 
and lung. Conclusion: Based on 4D-CT, statistically significant differences of GTVs 
centroid movement were observed at different pulmonary lobes and in three dimensional 
directions. So individual 4D-CT measurement is necessary for definition of ITV margin 
for lung cancer.
Keywords: Non-small-cell lung cancer, Four-dimensional CT, Three-dimensional 
motion vector, Radiotherapy
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P1-037: THE INFERENCE OF RESPIRATORY AND HEART-BEAT TO 
THE DISPLACEMENT OF MEDIASTINAL LYMPH NODES. 
Ying Jie Zhang  
Radiotherapy, Shandong Cancer Hospital, Jinan/CHINA
Background: Before this paper, there was no study compare the infection of respiratory 
and heart-beat on the displacement of mediastinal lymph nodes based on 4D-CT. 
Methods: 18patients with thorax cancer, 15 patients with non-small-cell lung cancer and 
3 patients with esophageal cancer were included, were scanned by 4D-CT simulation 
at free breathing condition, and each respiratory cycle of CT images were divided into 
10 phases of 0% ~ 90%. Based on CT images of 0% phase, upper (1,2group) and middle 
(4,5group) and under (7,9 group) sections of the mediastinal lymph nodes metastasis and 
heart, bilateral lungs on CT images of 10 phases were contoured separately . On the basis 
of the phase marked by the maximum and minimum volume data of hearts or lungs, the 
displacement data related to respiratory or heart-beat were gotten. And comparison and 
correlation analysis were performed between the maximum displacement and these two 
sorts of displacement. Results: For all mediastinal lymph nodes, the displacement in CC 
direction was significantly greater than that in LR and AP directions (z=6.609, p=0.037), 
the maximum displacement were greater than the displacements related to respiratory 
or heart-beat. The displacement of 7, 9 groups mediastinal lymph nodes in CC direction 
were significantly greater than that of 1, 2 groups. there was no significant difference for 
all the mediastinal lymph nodes between the displacement related to respiratory and that 
related to heart-beat (z=-1.261– -0.108, p=0.207– 0.914), but there was significant or close 
to the significant difference between the two kinds of displacement and the maximum 
displacement of mediastinal lymph nodes (z=-2.673– -1.826, p=0.008– 0.068). Only for 
7,9 group mediastinal lymph nodes in CC direction were there significant correlation 
of the maximum displacement and the displacement related to heart-beat (r=0.980, 
p=0.000). Conclusion: The effection of the heart-beat for 7,9 group mediastinal lymph 
nodes in CC direction was more evident. The ITV expansion of mediastinal lymph nodes 
in different directions or at different positions should be distinguished.
Keywords: four dimensional CT, displacement of mediastinal lymph nodes, respiratory, 
heart-beat
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P1-038: POTE MRNA EXPRESSION LEVEL AND CLINICAL 
OUTCOME OF ADVANCED-NSCLC PATIENTS TREATED WITH 
PLATINUM-BASED CHEMOTHERAPY
Xuefei Li1, Xiu Chen2, Shengxiang Ren3, Jiayu Li2, Ruixin Ren2, Liang Tang2, Caicun 
Zhou3  
1Department Of Lung Cancer And Immunology, Shanghai Pulmonary Hospital, 
Shanghai/CHINA, 2Department Of Lung Cancer And Immunology, Shanghai 
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Background: POTE was an apoptosis-related protein, and expressed in most tumor 
tissues, including breast cancer, lung cancer, colon cancer, etc, not in most normal 
tissues. In our previous study, we found that POTE was low expression in cisplatin-
resistant A549/cDDP cells, compared with cisplatin-sensitive A549 cells by 2-DE 
combined with MALDI-TOF-MS/MS. Abnormal apoptosis is one of the major 
mechanisms of platinum-resistance, so we hypothesized that POTE may be implicated 
in platinum-resistance of NSCLC patients. To define the hypothesis, we investigated 
the association between the expression level of POTE mRNA and clinical outcome of 
advanced-NSCLC patients treated with platinum-based chemotherapy in first-line. 
Methods: 81 patients with IIIB/IV NSCLC were enrolled into the study. Total RNA 
was extracted, and cDNA was synthesized. The expression level of POTE and ERCC1 
mRNA in tumor tissue samples was determined by real-time qRT-PCR. The association 
between POTE mRNA expression level and clinical information were evaluated by using 
Chi-square test or one-way ANOVA. The effection of POTE mRNA expression level 
and the combination of ERCC1 mRNA on time to progress and overall survival were 
estimated by Kaplan-Meier test and assessed using the log-rank test. Hazard ratios were 
determined using Cox proportional hazard model. Results: The median age of patients 
was 58.5 years. Forty patients had high expression of POTE mRNA, and 41 patients with 
low expression of POTE mRNA (cutoff value: median value=0.002). There was boardline 
significance between the expression level of POTE mRNA and disease control rate 
(high level vs low level, 78.0% vs 65.9%, p=0.048). However, objective response rate was 
higher in patients with high level of POTE mRNA than those of low expression (47.5% 
vs 25.0%, p=0.036). The significant relationship was observed between the expression 
levels of POTE mRNA and time to progress and overall survival (median, high level vs 
low level, 5.5 months vs 4.5 months, p=0.013; 13.1 months vs 10.8 months, p=0.012). It 
was noteworthy that POTE seems to play a leading role in clinical efficacy of platinum-
based chemotherapy in first-line when the combination of POTE and ERCC1 mRNA 
expression was analyzed. The patients with low POTE combined with high ERCC1 
demonstrated a significant association with poor overall survival (p=0.026). High level of 
POTE mRNA was an independent prognostic factor for good overall survival (p=0.034). 
Conclusion: High expression level of POTE mRNA may serve as a useful prognostic 
factor for good outcome in advanced NSCLC patients treated with platinum-based 
doublet chemotherapy and may provide important information to guide personalized 
therapy of NSCLC patients. In addition, the combination of POTE and ERCC1 may have 
an synergistic effect on prognosis of advanced-NSCLC patients. Further, large sample 
study should be performed in future.
Keywords: Apoptosis, POTE, NSCLC, cisplatin resistance
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P1-039: RELATIONSHIP BETWEEN STEM CELL-RELATED MARK-
ERS AND CHEMOTHERAPY IN HUMAN LUNG CANCER
Chunxia Su1, Xuefei Li2, Ying Xu3, Lixia Lv4, Guotong Xu4, Caicun Zhou1  
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Background: The expression of several cancer stem cell (CSC)-related markers has been 
confirmed in non-small cell lung cancer (NSCLC). Chemotherapy plays an important 
role in the treatment of lung cancer. Therefore, a detailed understanding of relationship 
between these markers and chemotherapy is essential. This study was to investigate the 
potential prognostic value of cancer stem cell (CSC)-related markers expression in lung 
cancer and their relationship with chemotherapy. Methods: One hundred and nine 
patients with clinically diagnosed NSCLC who underwent surgery (48 males and 61 
females) were immunohistochemically examined for the expressions of stem cell markers 
(CD133,ABCG2 and ALDH).The associations with disease free survival and overall 
survival were analyzed. The stem cell markers’ expression were evaluated by IHC on 
tissue microarrays and scored according to the >=50% of cells with moderate or strong 
staining as positive. The significances of the expressions of cancer stem cell (CSC)-related 
markers and chemotherapy in clinical and pathological characteristic were evaluated. 
Results: Stages of the tumors were IA (n = 8), IB (n = 48), IIA (n=1), IIB (n = 11), IIIA (n = 
25), IIIB (n = 6) and IV (n = 10). Histology revealed adenocarcinoma (n = 74), squamous 
carcinoma (n = 21), other type (n = 14). Of the 109 tumors, 51(49.0%) were positively 
stained for CD133, and 33 (64.7%) of the CD133 positive tumors were adenocarcinoma. 
The disease free survival of the patients with CD133-positive or ALDH1-positive 
specimens were significantly worse than that of the patients with both CD133-negative 
and ALDH1-negative expressions (77.6 months vs. 46.7 months, respectively; P = 0.014).
The overall survival of the patients with CD133-positive or ALDH1-positive specimens 
were significantly worse than that of the patients with both CD133-negative and ALDH1-
negative expressions (82.6 months vs. 56.7 months, respectively; P = 0.033). Subgroup 
analysis showed that stage Ib to IIIB patients with CD133-positive or ALDH1-positive 
APLCC/ITMIG 2012 Abstracts  Volume 7, Number 11, Supplement 5, November 2012
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can benefit from chemotherapy.( disease free survival 50.6 months versus 31.2 months, 
respectively). Cox-regression analysis showed that stage and tumor classification were 
the independent prognostic factors. Conclusion: CD133 and ALDH1 expression may 
be independent prognostic marker and the combination of CD133 with ALDH1 may 
provide better prognostic value in predicting the overall survival of the patients with 
lung cancer. The development of therapeutic strategies including adjuvant chemotherapy 
that take CSC-related marker positivity into consideration is likely to be a key factor in 
further improvements of the prognosis of patients with stage IB to IIIB lung cancer.
Keywords: cancer stem cell (CSC)-related markers, chemotherapy, LUNG CANCER, 
immunohistochemistry
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P1-040: IN SILICO METHOD TO PREDICT DRUG SENSITIVITY IN 
NOVEL EGFR MUTATIONS
Vachiranee Limviphuvadh1, Jackie Tan2, Sebastian Maurer-Stroh1, Wei Peng Yong3, Ross 
Soo3  
1Bioinformatics Institute, Agency For Science, Technology And Research (A*Star), 
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Background: Somatic mutations of the epidermal growth factor receptor (EGFR) have been 
identified in selected patients with non-small cell lung cancer (NSCLC). While most 
mutations have been characterized and are associated with clinical response or sensitivity to 
the EGFR inhibitors such as erlotinib and gefitinib, rare and uncharacterized EGFR 
mutations appear and provide uncertainty in the clinical outcomes of EGFR inhibitor 
treatment. Thus, there is a need to be able to predict for the effects of these mutations. We 
report the development of a novel in silico methodology to predict the effects of EGFR 
mutations that are relevant to drug binding through the calculation of protein stability.  
Methods: We used a structural modeling program, YASARA, with a FoldX plugin to 
calculate the protein stability changes after undergoing mutation. We validated this model 
through two approaches. Firstly, a literature search was conducted to build a database of 
EGFR missense mutations and their known associated clinical and biochemical outcomes of 
gefitinib or erlotinib. These effects of these mutations on protein stability are then calculated 
and tabulated. Secondly, we used the method to predict the effects of three novel EGFR 
missense mutations identified in NSCLC patients from the National University Hospital and 
conducted corresponding in vitro studies using stably transfected BaF3 cell lines. The in 
silico prediction and in vitro data are then compared with in vivo clinical data. Results: We 
found 43 papers describing 154 EGFR missense mutations. 113 mutations were calculated 
for gefitinib response while 50 were calculated for erlotinib response. The results were then 
tabulated in a contingency table (Table 1). There is significant association between mutations 
which cause protein instability and drug sensitivity. Similarly, there is a significant 
association between mutations which cause protein stability and drug resistance. 
 
The prediction was that the three novel EGFR mutations cause gefitinib and erlotinib 
sensitivity. This prediction was supported by cell proliferation assays of stably transfected 
BaF3 cell lines. It was found that the cells with the mutant EGFR were more sensitive to the 
drugs. The patients harboring these three mutations also had favourable outcomes after 
gefitinib treatment, matching our predictions. In vitro and in vivo data are in concordance 
with the in silico predictions. Conclusion: We have demonstrated that using in silico 
methods to characterize novel EGFR mutations is possible. This method has clinical 
implications in the treatment management of the lung cancer, especially for novel EGFR 
mutations.
Keywords: In silico prediction, Predictive oncology, Novel EGFR mutations
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P1-041: PHENOTYPE PROFILING OF CANCER CELL INVASION 
IDENTIFIED UNIQUE SIGNATURE THAT CAN PREDICT CHEMO-
THERAPEUTIC RESPONSE IN LUNG CANCER
Yi-chiung Hsu1, Hsuan Yu Chen1, P-c Yang2, Ker-chau Li1  
1Academia Sinica, Taipei/TAIWAN, 2, National Taiwan University Hospital, Taipei/
TAIWAN
Background: The anticancer drug screen of NCI-60 has generated a rich database for 
exploring the genomic mechanism of tumor growth inhibition. However, direct genomic 
chemosensitivity analysis does not connect well with clinical outcome. Because metastasis 
is essential in cancer mortality, we asked if enriching the NCI-60 database with the 
additional phenotype data about the cancer cell invasion ability may help bridge the gap. 
Methods: In this study, we first performed an invasion assay on NCI-60 cell lines. The data 
indicated a great variation, with the heterogeneity within the same tissue group being no 
less than between-tissue groups. We characterized gene expression patterns associated 
with both invasion heterogeneity and compound-sensitivity. Results: A set of eight 
invasion-associated genes was selected for predicting drug-sensitivity and was validated by 
107 drug-tests on 78 tumor cell lines outside of the NCI-60 panel. Applying to two recent 
adjuvant chemotherapy cohorts, our signature predicted distant relapse-free survival for 
the lung cancer patients (log-rank P = 0.0263). Multivariate Cox regression showed that 
the adjusted hazard ratio of our signature (adjusted for tumor staging and other important 
clinical variables) is 5.33 (CI=1.76 to 16.1). Conclusion: We concluded that augmenting 
the NCI-60 model with in-vitro characterization of important phenotypes like invasion 
potential is a cost-effective approach to power the genomic chemosensitivity analysis. An 
eight-gene signature derived from characterizing genes associated with both compound 
sensitivity and tumor-invasiveness predicted survival from standard chemotherapy for 
newly diagnosed lung cancer patients with the adjuvant chemotherapy. This is the first 
time this important cancer driver gene was identified from an unbiased full genome search 
for predictive gene signature. We concluded that augmenting the NCI-60 model with 
in-vitro characterization of important phenotypes like invasion potential is a cost-effective 
approach to power the genomic chemosensitivity analysis.
Keywords: invasion, chemotherapy, microarray
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P1-042: MET FISH POSITIVE PREDICTS THE RESISTANCE TO 
EGFR-TKI IN NON-SMALL LUNG CANCER PATIENTS. 
Rintaro Noro, Masahiro Seike, Chie Soeno, Kuniko Matsuda, Teppei Sugano, Kazuhiro 
Kitamura, Nobuhiko Nishijima, Seiji Kosaihira, Yuji Minegishi, Kaoru Kubota, Akihiko 
Gemma  
Department Of Internal Medicine, Division Of Pulmonary Medicine, Infectious Diseases 
And Oncology, Nippon Medical School, Tokyo/JAPAN
Background: Non-small cell cancer (NSCLC) patients with EGFR gene mutations have 
shown a dramatic response to EGFR tyrosine kinase inhibitor (EGFR-TKI). However, 
it is recognized that, clinically, drug resistance eventually emerges and this limits the 
mean duration of response. Although mechanisms of acquired resistance to EGFR-TKI, 
such as T790M secondary mutation and MET amplification, have recently been found, 
other mechanisms of resistant to EGFR-TKI should be identified to widen the therapeutic 
strategy for NSCLC with EGFR gene mutations at pretreatment. Methods: We evaluated 
30 lung tumor samples from NSCLC patients who had received EGFR-TKI treatment from 
2007 to 2011 at Nippon Medical School Hospital. Status of copy numbers and amplification 
of MET gene were examined by fluorescence in situ hybridization (FISH). High copy 
numbers (≧4 copies/cell) and amplification (MET/CEP7 ≧2.0) were defined as MET FISH 
positive. Results: High copy numbers was observed in 9 patients (31%) and amplification 
was in 1 patient (3%) of 30 NSCLC patients. MET FISH status was not correlated with 
EGFR gene mutation, gender, histology, serum CEA and smoking history. Among 3 of 10 
cases with MET FISH positive, high copy numbers and amplification were found at both of 
pre-and post-treatment stage. Nine patients achieved partial response (PR) and one patient 
showed stable disease (SD) by EGFR-TKI therapy among 10 patients with MET FISH 
positive. However, the 10 patients with MET FISH positive had statistically significantly 
shorter progression free survival (PFS) than the 20 patients with low copy numbers. 
(p==0.0008, log-rank test). Median PFS of patients with MET FISH positive and MET 
FISH negative copy numbers were 7.6 months and 13.6 months, respectively. Conclusion: 
Detection of high copy numbers and amplification of MET gene by FISH may be useful for 
predicting the response to EGFR-TKI. Correlation between MET gene status and response 
to EGFR-TKI should be further evaluated using large scale samples.
Keyword: MET FISH positive
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P1-043: CLINICAL CHARACTERISTICS OF PATIENTS WITH NON-
SMALL-CELL LUNG CANCER HARBORING EGFR MUTATION OR 
EML4-ALK IN CHINESE HAN ETHNICITY POPULATION 
Aiwu Li, Shengxiang Ren, Xiaoxia Chen, Jian Ni, Caicun Zhou  
Oncology Department, Shanghai Pulmonary Hospital, Shanghai/CHINA
Background: EGFR (epidermal growth factor receptor) mutation and EML4-
ALK(echinoderm microtubule-associated protein-like 4- anaplastic lymphoma kinase ) 
rearrangement are the most frequent and important oncogenic drivers and enriched in 
some subgroups of patients with non–small-cell lung cancer (NSCLC). This study was 
to investigate the clinical characteristics of NSCLC patients harboring EGFR mutation 
or EML4-ALK in Chinese Han ethicany population. Methods: NSCLC patients with 
known EGFR mutation and EML4-ALK rearrangement were included in this study. 
ARMs and RT-PCT were used to detect EGFR mutation and EML4-ALK respectively. 
Patients’ clinical characteristics such as age, gender, histology, smoking status, metastatic 
sites and number were collected. Relationships of these oncogenic drivers and clinical 
characteristics were evaluted. Results: Among 286 patients with NSCLC tested for EGFR 
mutation, 112(39.1%) patients harboring EGFR mutation. Among 235 patients tested for 
EML4-ALK rearrangement, 21(8.9%) patients harboring EML4-ALK. EGFR mutation was 
more frequently in patients with female (50.4% vs 37.6%, P=0.031), non- squamous cell 
cancer(43.0% vs 12.9% P=0.0001), never or lighter smokers (47.4% vs 21.7%, P=0.0001) and 
exthoracic metastasis disease (45.2% vs 32.1%, P=0.024) than those of male, squamous cell 
cancer, current smoker and without exthoracic metastasis. Mean metastatic sites in patients 
with EGFR mutation is a slight more than the opposite patients (1.72 vs 1.53, P=0.056). 
EML4-ALK was more frequently in patients with younger (<70 years ) (11.9% and 7.3% 
P=0.234), non- squamous cell cancer(11.3% vs 1.8% P=0.027), never or lighter smokers 
(10.2%% vs 5.8%, P=0.277), and exthoracic metastasis disease (13.0% vs 4.3%, P=0.036) 
than those of elderly, squamous cell cancer, current smoker and without exthoracic 
metastasis. Compared with negative cohort, patients with advanced diseases harboring 
EML4-ALK had more metastasis sites (2.25 vs1.62, P=0.029) and more easily evaded to 
pleura (40.3% vs 21.1%, P=0.040), pericardium (20.8% vs 7.5%, P=0.016) and liver (15.4% vs 
6.1%, P=0.073). As to different oncogenic drivers status in metastatic diseases, patients with 
EML4-ALK had more metastasis sites than those harboring EGFR mutation (2.25 vs1.72, 
P=0.034). Conclusion: EGFR mutation was enriched in the patients with female, non-
squamous cancer cell, never or lighter smoker, extrathoracic metastasis. EML4-ALK was 
enriched in patients of younger, non-squamous cell cancer, and never or lighter smoker and 
extrathoracic metastasis in the Chinese Han ethnicity population. Patients with EML4-
ALK seem to be more aggressive than those harboring EGFR mutation.
Keywords: oncogenic driver, NSCLC, EGFR, EML4-ALK
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P1-044: EXPRESSION OF CAP1 IN TUMOR TISSUES AND ITS RELATIONSHIP 
TO THE METASTASIS AND PROGNOSIS OF LUNG CANCER 
Xiao Lian Song, Min Tan, Changhui Wang  
Respiratory, The Shanghai 10th People’S Hospital, Shanghai/CHINA
Background: Recent studies reported that the cytoskeleton may be associated with the 
metastasis of cancer. Adenylate cyclase-associated protein 1 (CAP1) is important in 
maintaining the stability of cytoskeleton. Whether CAP1 has a role in the migratory 
capacity of lung cancer? This study was conducted to explore the correlation between 
CAP1 and the metastasis and prognosis of lung cancer. Methods: 1) The fresh 
frozen specimens from 22 cases of NSCLC (11 of squamous cell carcinoma and 11 of 
adenocarcinoma, in which 13 cases were found metastases after surgery) and 10 cases 
of non-neoplastic patients were collected. The expression of CAP1 mRNA and protein 
were detected by real-time PCR and Western blot respectively. 2)We determined 
the expression of CAP1 in 82 paraffin-embedded specimens of lung cancer using 
immunohistochemical and stereological methods. Combining with clinical, pathological 
and follow-up data, we analyzed the relationship between CAP1 and the metastasis and 
prognosis of lung cancer. Results: 1) The result of PCR showed that the CAP1-mRNA 
was overexpressed in lung cancer tissues compared with normal lung tissues (P=0.028). 
The level of CAP1-mRNA was even higher in the patients with metastasis than that in 
the patients without metastasis (P=0.016). The expressions of CAP1-mRNA between 
squamous cell carcinoma and adenocarcinoma were no significant difference (P=0.227). 
The result of Western blot was similar, which showed a single high-density band at 
53-kDa (CAP1) in lung cancer tissues but only a weak band in the normal lung tissues 
(Figure1). 2) In immunohistochemistry, the ratio of CAP1-positive tumor cells in those 
clinical specimens was correlated with the presence of metastasis (especially lymph node 
metastasis) (Table 1). Logistic regression analysis implied that the overexpression of CAP1 
was the independent risk factor for lung cancer metastasis (OR=11.891, P=0.01). Kaplan–
Meier survival analysis demonstrated that the the high expression of CAP1 indicates a 
poor prognosis (Figure 1). Figure 1. The result of PCR(A), western blot(B) and Kaplan–
Meier survival analysis(C) Table 1. The result analysis of CAP1 expression
 
Conclusion: This is the first report demonstrating the involvement of CAP1 in the 
aggressive behavior of lung cancer. Higher expression of CAP1 may correlate with more 
metastasis and worse prognosis in lung cancer.
Keywords: Prognosis, metastasis, CAP1, LUNG CANCER
POSTER SESSION 1 - PROGNOSTIC AND PREDICTIVE BIOMARKERS 1 -  
November 27, 2012 14:05-14:55
P1-045: DISCORDANCE BETWEEN ANAPLASTIC LYMPHOMA 
KINASE STATUS IN PRIMARY NON-SMALL CELL LUNG CANCER 
AND THEIR CORRESPONDING METASTASES
Hyojin Kim1, Xianhua Xu2, Seol-bong Yoo1, Ping-li Sun3, Yan Jin2, Jin Ho Paik2, Gheeyoung 
Choe2, Sanghoon Jheon3, Choon-taek Lee4, Se Jin Jang5, Jin-haeng Chung2  
1Pathology, Seoul National University College Of Medicine, Department Of Patholgy, 
Seoul National University College Of Medicine, Seoul/KOREA, 2Pathology, Seoul National 
University Bundang Hospital, Department Of Pathology, Seoul National University 
Bundang Hospital, Seongnam/KOREA, 3Thoracic And Cardiovascular Surgery, Seoul 
National University Bundang Hospital, Department Of Thoracic And Cardiovascular 
Surgery, Seoul National University Bundang Hospital. Seongnam/KOREA, 4Internal 
Medicine, Seoul National University Bundang Hospital, Department Of Internal Medicine, 
Seoul National University Bundang Hospital, Seongnam/KOREA, 5Pathology, University 
Of Ulsan College Of Medicine, Asan Medical Center, Department Of Pathology, 
University Of Ulsan College Of Medicine, Asan Medical Center, Seoul/KOREA
Background: The anaplastic lymphoma kinase (ALK) gene has attracted considerable 
attention as a potential molecular target in non-small cell lung carcinoma (NSCLC). 
However, it is unclear whether ALK gene alterations are acquired during the metastatic 
progression of NSCLC.  Methods: ALK gene status and protein expression were evaluated 
in a series of 67 primary NSCLC and the corresponding metastatic lesions using 
fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Results: ALK 
gene rearrangement was detected in 7.5% (5/67) of the primary tumours and in 9.0% (6/67) 
of the metastatic sites (p < 0.001). There was a case of discordance between the primary 
tumour and the metastatic site. ALK gene copy number gain (CNG) was detected in 1.5% 
(1/67) of the primary tumours and in 35.8% (24/67) of the metastatic sites. While ALK 
gene rearrangement was detected only in adenocarcinomas, CNG was identified in various 
histologic subtypes of NSCLC. ALK protein expression was detected in 11.9% (8/67) of the 
primary tumours and in 25.4% (17/67) of the metastatic lesions. Conclusion: ALK gene 
alteration and protein expression can be acquired during metastatic progression in NSCLC 
and ALK CNG is associated with protein expression.
Keywords: metastases, non-small cell lung cancer, ALK, primary
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P1-046: CONCOMITANT EGFR MUTATION AND ALK FUSION DEFINED A 
SUBGROUP OF PULMONARY ADENOCARCINOMA: DIVERSE RESPONSE TO 
1ST LINE EGFR TKI AND PREDICTIVE ROLE OF PHOSPHORYLATION OF RTKS 
Jin-ji Yang1, Xu C. Zhang1, Jian Su1, Chong-rui Xu1, Qing Zhou1, Xue-ning Yang1, Wen-zhao 
Zhong1, Yi-long Wu2  
1Division Of Pulmonary Oncology, Guangdong General Hospital, Guangzhou/CHINA, 
21. Guangdong Lung Cancer Institute, Guangdong General Hospital And Guangdong 
Academy Of Medical Sciences, Guangzhou, Guangzhou/CHINA
Background: We investigated the incidence of concomitant epidermal growth factor 
receptor (EGFR) mutation and echinoderm microtubule-associated protein-like 4 
(EML4)- anaplastic lymphoma kinase (ALK) rearrangement in Chinese patients with lung 
cancer, and assessed response to first-line EGFR tyrosine kinase inhibitors (TKIs) in such 
tumors. Methods: Using rapid amplification of cDNA ends-coupled polymerase chain 
reaction sequencing and fluorescent in situ hybridization, we screened 1028 consecutive 
patients with lung cancer for the presence of concomitant EGFR mutation and EML4-
ALK rearrangement. Immunohistochemistry (IHC) and western blotting were used to 
correlate the activation of EGFR, ALK and downstream proteins with response to EGFR 
TKIs or crizotinib in such tumors. Results: The frequency of concomitant EGFR mutation 
and EML4-ALK fusion was 1.2% (12/1028) overally, and 3.6% (12/336) in EGFR mutant 
and 17.1% (12/70) in ALK positive patients with non-small-cell lung cancer (NSCLC) 
respectively. Co-expression of mutant EGFR protein and ALK protein by IHC on serial 
cut sections were detected in the same tumor cell populations in specimens from 5 
patients. Ten metastatic patients with such tumors were treated with first-line EGFR TKIs; 
response rate was 80% (8/10), and the two patients with higher phospho-ALK and lower 
phospho-EGFR achieved stable disease and progressive disease respectively. Median 
progression-free survival was 11.2 months. Two patients received third-line crizotinib, 
one of which with higher phospho-ALK but with lower phospho-EGFR achieved partial 
response with the downstream protein phospho-ERK inhibited. The other one with lower 
phospho-ALK underwent disease progression, in contrast to having higher phospho-EGFR 
and responding to first-line EGFR TKIs. Conclusion: EML4-ALK rearrangement and 
EGFR mutation could coexist and define a subset of primary NSCLC. Patients with such 
co-alterations showed diverse, though mostly favorable, response to first-line EGFR TKIs, 
probably due to higher phospho-EGFR level. Further evaluation of the guiding role of 
phosphor-EGFR and phosphor-ALK for selection of individual or combinational TKIs in 
this subgroup patients is warranted.
Keywords: EGFR, EML4-ALK, non-small cell lung cancer, EGFR tyrosine kinase inhibitor
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P1-047: TUMOR ISLANDS IN RESECTED EARLY STAGE LUNG AD-
ENOCARCINOMAS ARE ASSOCIATED WITH UNIQUE  
CLINICOPATHOLOGICAL AND MOLECULAR CHARACTERISTICS 
AND WORSE PROGNOSIS
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Maristela L. Onozato, Vicente Morales-Oyarvide, Alexandra E. Kovach, Beow Y. Yeap, 
Veronica E. Klepeis, Swathi Tammireddy, Rebecca S. Heist, Eugene J. Mark, Dora Dias-
Santagata, A John Iafrate, Yukako Yagi, Mari Mino-Kenudson  
Pathology, Massachusetts General Hospital, Boston/MA/UNITED STATES OF 
AMERICA
Background: Tumor islands - large collections of tumor cells isolated within alveolar 
spaces away from the main tumor - can be seen in lung adenocarcinomas. However, the 
details of their spatial distribution and structural interaction with the main tumor, and the 
clinicopathological and prognostic significance of tumor islands remain unknown. Tumor 
islands - large collections of tumor cells isolated within alveolar spaces away from the 
main tumor - can be seen in lung adenocarcinomas. However, the details of their spatial 
distribution and structural interaction with the main tumor, and the clinicopathological 
and prognostic significance of tumor islands remain unknown. Methods: 1. Paraffin 
embedded tissues of lung adenocarcinomas exhibiting tumor islands were sectioned with 
Kurabo-Automated tissue sectioning machine and serial sections were automatically 
stained and scanned with a Whole Slide Imaging device. The resulting stacks of images 
were 3D reconstructed by Mirax Panoramic View software. 2. Clinicopathological 
and molecular characteristics and prognosis were compared between Stage I-II lung 
adenocarcinomas with tumor islands (n=58) and those without (n=203). Results: 1. By 3D 
reconstruction, tumor islands were connected with each other and with the main tumor in 
different tissue planes, raising the possibility of tumor islands being a means of extension/
invasion. 2. Lung adenocarcinomas with tumor islands were more likely to occur in 
smokers, exhibit higher nuclear grade and a solid or micropapillary pattern of growth, 
and harbor KRAS mutations. In contrast, lung adenocarcinomas without tumor islands 
were more likely to present as minimally invasive adenocarcinoma, show a lepidic pattern 
of growth, and harbor EGFR mutations. Although there was no difference in stage, the 
prognosis of lung adenocarcinomas with tumor islands was significantly worse than those 
without. The five-year recurrence-free survival for patients with tumor islands and those 
without was 44.6% and 74.4%, respectively (log-rank p = 0.010). The survival difference 
remained significant (p < 0.020) by multivariate analysis, and the presence of tumor islands 
was associated with almost two-fold increase in the risk of recurrence. Even in the Stage IA 
cohort, more than half of the patients with tumor islands experienced recurrence within 
5 years. Conclusion: Tumor islands, likely representing a means of extension/invasion, 
were associated with unfavorable outcomes. Thus, aggressive surveillance and/or further 
intervention may be indicated for patients whose tumors exhibit tumor islands.
Keywords: lung adenocarcinoma, 3D reconstruction, tumor island, Prognosis
POSTER SESSION 1 - PROGNOSTIC AND PREDICTIVE BIOMARKERS 2 -  
November 27, 2012 14:05-14:55
P1-048: CRIZOTINIB IN ALK-POSITVE LUNG CANCER WITH 
NON-EML4 FUSION PARTNERS
Jin-ji Yang, Xu-chao Zhang, Qing Zhou, Jian Su, Chong-rui Xu, Hong-xia Tian, Xue-ning 
Yang, Wen-zhao Zhong, Yi-long Wu  
Division Of Pulmonary Oncology, Guangdong General Hospital, Guangzhou/CHINA
Background: In anaplastic lymphoma kinase (ALK) translocated lung cancer, echinoderm 
microtubule-associated protein-like 4 (EML4) is not the exclusive fusion partner with 
ALK. However, the incidence of non- EML4 fusion partners has not been investigated, and 
the efficacy of crizotinib in ALK-positive lung cancer with non- EML4 fusion partners has 
not been reported. Methods: Using RACE-coupled PCR, we screened tumor samples from 
1131 consecutive Chinese patients with lung cancer for the presence of ALK fusion. ALK-
positive patients with advanced non-small cell lung cancer (NSCLC) harboring non-EML4 
fusion partners were recommended to received crizotinib therapy. Results: The frequency 
of ALK-positive was 6.5% (74/1131) in Chinese patients with lung cancer, and the incidence 
of non-EML4 fusion partners was 4.1% (3/74) in ALK-positive lung cancer. These 3 tumors 
with non-EML4 fusion partners were found to include 2 with KIF5B- ALK fusion and 1 
with DCNT1 (dynactin1)-ALK fusion　confirmed by both immunohistochemistry and 
fluorescence in situ hybridization. The DCNT1 (dynactin1)-ALK fusion positive patient 
was diagnosed with pT3N1M0 stage 　A squamous carcinoma harboring wild type EGFR 
and KRAS mutation. One of the 2 KIF5B-ALK fusion positive patients had pT2aN1M0 
stage　A adenocarcinoma with wild type EGFR and KRAS mutation, and the other was a 
female with advanced adenocarcinoma harboring wild type EGFR and KRAS mutation. 
She received second-line crizotinib and achieved partial response (with a reduction by 
40%). Last follow up was done on July 10, 2012, and her progression-free survival was 11 
months+. Conclusion: DCNT1-ALK is the first novel oncogenic fusion. The incidence of 
non-EML4 fusion partners was 4.1% in ALK-positive lung cancer. The KIF5B-ALK fusion 
positive patients had a good response to crizotinib.
Keywords: EGFR, EML4-ALK, non-small cell lung cancer, EGFR tyrosine kinase inhibitor
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P1-049: PATHWAY-BASED SIGNATURES AND CLINICAL  
OUTCOME IN LUNG ADENOCARCINOMA
Ya Hsuan Chang1, Shun Chun Yu2, Yu Ju Chen3, Chien Yu Lin3, Chung Ming Chen1, 
Hsuan Yu Chen3  
1Biomedical Engineering, National Taiwan University, Taipei/TAIWAN, 2Epidemiology 
And Preventive Medicine, College Of Public Health, National Taiwan University, Taipei/
TAIWAN, 3Statistical Science, Academia Sinica, Taipei/TAIWAN
Background: Lung cancer is the leader cancer caused death worldwide. Because of poor 
treatment outcome and prognosis of lung cancer, exploring gene signatures for prediction 
of treatment response and prognosis is a very important issue. Microarray technologies 
can be used to measure many genes expressions at once and it is a useful tool for exploring 
genes which involve in cancer associated pathways. Up to date, there are many published 
microarray dataset and clinical information of lung adenocarcinoma. Above useful 
information can help researchers to discovery gene signature for prognosis prediction or 
drug response across different studies. In this study, by using published gene expression 
data, we use meta-analysis methods to identify prognosis associated genes and further 
develop the gene signature based on significant genes. Methods: Meta-analysis method 
was applied into 4 published microarray datasets to identify prognosis associated genes of 
lung adenocarcinoma. The significant genes were separated into different pathways. The 
pathway-based risk scores and survival analysis were further used to explore pathway-based 
signature of lung adenocarcinoma. Results: There were 2418 genes that were statistical 
significantly associated with lung adenocarcinoma. Among these genes, we observed that 
19-gene signature in the WNT signalling pathway, 12-gene signature in the degradation of 
beta-catenin without WNT signal in the WNT signaling pathway, and 13-gene signatures 
in the interleukin-6 signaling pathway were all associated with clinical outcome of lung 
adenocarcinoma (p-value of log-rank tests were all less than 0.05) across 4 datasets. High-
risk group with higher pathway-related risk scores had lower median survival rate than 
low-risk group with lower pathway-related risk scores. Conclusion: Taken together, based 
on gene expression profiling, pathway-based signatures were significantly associated with 
clinical outcome of lung adenocarcinoma. Our findings may give the insight of pathogenesis 
of lung cancer and improve accuracy of clinical outcome prediction.
Keywords: signalling pathway, lung adenocarcinoma, gene signatures, meta-analysis
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P1-050: HIGH EXPRESSION OF C-MET WITH WIDE TYPE EGFR 
MUTATION IDENTIFY A DISTINCT SUBSETS INDICATIVE POOR 
PROGNOSIS IN PATIENTS WITH NSCLC
Ling Huang, She J. An, Zhi H. Chen, Jian Su, Zhi Xie, Hong H. Yan, Xu C. Zhang, Ying 
Huang, Shi L. Chen, Wei B. Guo, Yi-long Wu  
Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital, 
Ggh, Guangdong Academy Of Medical Sciences, Guangzhou/CHINA
Background: Epidermal growths factor receptor (EGFR) and c-MET have been significant 
molecular targets for lung cancer treatment, and they have recently gained considerable 
attention. However, the relationships between EGFR mutations and c-MET protein 
expression and prognostic significance in Asian patients with non-small cell lung cancer 
are currently unclear. Methods: We investigated 102 frozen tumors from surgically 
resected NSCLC patients. No patient received EGFR tyrosine kinase inhibitors (TKIs) 
treatment. Mutation analyses of exon18-21 of the EGFR-TK domain were performed by 
using a polymerase chain reaction-based direct sequencing. MET protein expression was 
evaluated by immunohistochemistry (IHC) and analyzed by H-score and MetMAb scoring 
criteria respectively. Results: EGFR mutations were observed in 30 of 102 (29.4%) NSCLC 
patients. The median IHC score was 60, and the frequency of c-MET high expression 
was 52% (H-score), compared with 29.4% according to MetMAb scoring criteria. High 
expression levels of c-MET (H-score: χ2=7.390, P=0.007; MetMAb trial: χ2=4.977, P=0.026; 
respectively) were correlated with shorter OS in patients with wild type EGFR, however, this 
was not found in EGFR mutant patients. In multivariate analyses, c-MET high expression 
was significantly associated with shorter survival in patients with wild type EGFR, as 
analyzed using the H-score method (HR=2.787, 95% CI: 1.060-7.327, P=0.038). There 
were no association of c-MET expression with EGFR mutation status regardless of taking 
either method to evaluate c-MET (χ2=0.550, P=0.458; χ2=1.077, P=0.299; respectively).  
Conclusion: High expression of c-MET is an independent poor prognostic factor in TKI-
naïve NSCLC patients with wild type EGFR mutation. The patients with this subtype may 
need earlier treatment target MET. The study also suggested that H-score criteria maybe 
more rational than MetMAb scoring criteria in the evaluation of MET expression.
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P1-051: LUNG CANCER GENE EXPRESSION DATABASE FOR  
SURVIVAL ANALYSIS
Chun-ling Chen, Yi-chiung Hsu, Hsuan Yu Chen, Shinsheng Yuan, Ker-chau Li  
Academia Sinica, Taipei/TAIWAN
Background: Microarray-based gene expression profiling has been used to aid our 
understanding of the histological heterogeneity of non-small cell lung cancer and has 
defined novel potential biomarkers and gene signatures for grouping subjects with 
significantly different survival outcome. In this paper, we employ four large microarray 
datasets of NSCLC samples that provided from Kerby Shedden et al. [2008] and can be used 
to predict overall survival in lung cancer subject based on microarray measurements of 
gene expression either alone or combined with basic clinical covariates (stage, age, gender). 
In order to analyzing these datasets effectively, we present SALC (Survival Analysis in 
Lung Cancer), a web-based application that allows researchers to compare genes in survival 
related whole genome datasets in lung cancer. Methods: The overall framework about 
SALC is shown in Fig. 1. SALC integrates into the creation of the final product, the website 
containing the data and analysis tools. We performed a survival analysis (including cox-
regression analysis and Kaplan-Meier survival curves) in each cohort.
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Results: In Fig.2, we show the SALC interface and the query results about genes, e.g., 
EGFR, METTL1. Moreover, SALC offers an easy-to-use and integrated environment (Fig. 
2) to discover genes associated with clinical survival, which in turn may lead to the 
discovery of new markers for lung cancer progression prediction.
 
Conclusion: SALC aims to assist users to query the genes of interests from the set of 
public available survival related whole genome datasets. The overall survival analysis 
results are pre-computed and stored in our database. Besides the standard overall 
survival analysis, we also provide the advanced options for users to perform various 
analysis on subgroups for plotting the KM curves.
Keywords: database, microarray, survival
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P1-052: EXPRESSION OF TRKB AND BDNF IS ASSOCIATED WITH 
POOR PROGNOSIS IN NON-SMALL CELL LUNG CANCER
Kyoko Okamura1, Taishi Harada1, Shuo Wang1, Kazuto Furuyama1, Kayo Ijichi2, Takaomi 
Koga2, Tatsuro Okamoto3, Koichi Takayama1, Tokujiro Yano4, Yoichi Nakanishi1 
1Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, 
Kyushu University/Fukuoka/JAPAN, 2Division of Pathophysiological and Experimental 
Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu 
University/Fukuoka/JAPAN, 3Department of Surgery and Science, Graduate School of 
Medical Sciences, Kyushu University/Fukuoka/JAPAN, 4Clinical Research Institute, 
National Beppu Medical Center/Beppu/JAPAN
Background: High expression levels of TrkB and BDNF are associated with aggressive 
malignant behavior in tumor cells and a poor prognosis in patients with various types 
of cancer. In this study, we aimed to identify the relationship between TrkB and BDNF 
expression and clinicopathological variables and prognosis in non-small cell lung cancer 
(NSCLC). Methods: We evaluated TrkB and BDNF expression in the tumor cells of 
102 NSCLC patients by immunohistochemistry. Results: Out of all clinicopathological 
factors examined, only vascular invasion was significantly correlated with TrkB 
(P=0.010) and BDNF (P=0.015) expression. TrkB-positive tumors had significantly worse 
disease-free survival (P=0.0094) and overall survival (P=0.0019) than TrkB-negative 
tumors, and TrkB expression was an independent prognostic factor for disease-free 
survival (HR 3.735, 95%C.I. 1.560–11.068, P=0.002) and overall survival (HR 4.335, 
95%C.I. 1.534–15.963, P=0.004) in multivariate analysis. Finally, our analysis revealed 
that co-expression of TrkB and BDNF conferred poorer prognosis compared with 
overexpression of either protein alone. Conclusion: Our results indicate that expression 
of TrkB and BDNF is associated with poor prognosis in NSCLC patients. 
Keywords: LUNG CANCER, TrkB, BDNF, Prognosis
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P1-053: MILK FAT GLOBULE EPITHELIAL GROWTH FACTOR VIII 
(MFG-E8): NEXT CANCER MARKER? 
Gaili Liu, Youxin Ji  
Medical Oncology, Qingdao Central Hospital, Qingdao City/CHINA
Background: Cancer pathways research and targets therapeutic studies are imperative 
and promising new hope in cancer management. Milk fat globule-EGF factor VIII 
(MFG-E8), which is mainly produced by macrophages and dendritic cells, is an opsonin 
for apoptotic cells and acts as a bridging protein between apoptotic cells and phagocytes. 
It has effects close to VEGF and over expression in triple negative breast cancer and 
colorectal cancer. Study MFG-E8 may develop novel cancer marker or anti-cancer target 
agents. Methods: 120 metastasized axillary lymph nodes frozen samples from breast 
cancer patients and 30 normal lymph nodes from non-cancer patients were selected. 
Breast cancer lymph node samples were immune-histopathological confirmed basal-
like, luminal A (lumA), luminal B (lumB) and human epidermal growth factor receptor 
2 (HER2)-enriched breast cancer; each subtype 30 samples. MFG-E8 protein was 
tested with Western Blot and MFG-E8 gene expression was tested by RT-PCR. Results: 
MFG-E8 protein level was highest in HER2 subtype, basal-like, lumB, lumA and non-
cancer lymph node group thereafter (1.86, 1.77, 1.22, 1.17 fold change compared to non-
cancer group). MFG-E8 mRNA level was also highest in HER2, and basal-like subtype, 
lumB, lumA and non-cancer lymph node group thereafter (1.65, 1.48, 1.19, 1.12 fold 
change compared to non-cancer group). There were significant higher both in MFG-E8 
protein and mRNA levels in HER2 and basal-like subtypes compared to other subtypes 
(P<0.05, by one way ANOVA). They also higher in lumA, lumB subtypes than in non-
cancer lymph nodes, but there were no significant difference. Conclusion: MFG-E8 
protein and mRNA levels varieties in different molecular type of breast cancer. It may 
be used to be a marker of tumor prognosis or prediction of cancer progression, cancer 
burden in metastatic breast and the role in other types of cancer will be revealed in the 
future. MFG-E8 is presents wildly in human tissues and easily be targeted by its special 
multi-domain structures.
Keywords: target, molecular marker, Milk fat globule epithelial growth factor VIII 
(MFG-E8), cancer
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P1-054: A NOVEL OMICS STRATEGY TO IDENTIFY BIOMARK-
ERS FOR EARLY DIAGNOSIS AND CLASSIFICATION OF LUNG 
CANCER
Debmalya Barh, Neha Jain  
Centre For Genomics And Applied Gene Technology, Institute Of Integrative Omics 
And Applied Biotechnology (Iioab), West Bengal/INDIA
Background: Lung cancer (LC) contributes to 23% of the total deaths from all cancers 
and perhaps accounts for highest cancer-related deaths worldwide. Although, early 
diagnosis helps treatment efficacy and disease-free survival, no gold standard molecular 
marker is currently available that can predict at-risk or asymptotic patients prone to 
LC or even can classify the LC histologically. Methods: We developed and applied a 
novel in silico integrated omics strategy to identify early events and markers and in 
LC. miRNome, trancriptome, proteome, and transfactome (sum total of transcription 
factors) of type and stage specific LC were used to generate interactomes that were 
further analyzed for key nodes, centrality, and probability to identify markers 
specific to small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and 
markers common to both these LC subtypes. The markers were checked for their 
expression pattern and early diagnostic efficacy. Results: Using our strategy, ninety 
eight differentially expressed proteins are identified to be potential markers among 
which nineteen are not reported previously. Twenty six proteins are found be useful in 
classifying SCLC, NSCLC, and other type of LC. We also identified eleven key proteins 
that have high probability for their involvement in the very early events or initiation 
stages of LC irrespective of the histological class.  Conclusion: We have developed 
an integrated in silico omics strategy for biomarker discovery and applied to LC. The 
strategy is powerful enough in identifying early biomarkers and also classifying LC. 
Furthermore, the strategy can be useful to identify biomarkers in any cancer or disease 
provided omics data for the respective disease are available.
Keywords: Lung cancer bionarker, Early diagnosiss, Integrative Omics, In silico
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P1-055: USEFULNESS OF SERIAL MEASUREMENT OF SERUM 
N-TELOPEPTIDES OF TYPE I COLLOGEN (NTX) IN PATIENTS 
WITH LUNG CANCER WHO DEVELOPED BONE METASTASIS: A 
PROSPECTIVE STUDY.
Tomoyuki Otsuka1, Motohiro Tamiya1, Hideaki Okada2, Kanako Kitai1, Takayuki 
Shiroyama1, Tadahiro Yamadori1, Hidekazu Suzuki1, Norio Okamoto1, Naoko Morishita1, 
Haruko Daga2, Shinya Tokunaga2, Koichi Taira2, Michiyo Hattori2, Natsuko Miyamoto2, 
Koji Takeda2, Tomonori Hirashima1  
1Department Of Thoracic Malignancy, Osaka Prefectural Medical Center For 
Respiratory And Allergic Diseases, Habikino City Osaka/JAPAN, 2Department Of 
Clinical Oncology, Osaka City General Hospital, Osaka City Osaka/JAPAN
Background: The bone resorption biomarkers urinary NTx (uNTx) and serum NTx 
(sNTx) have been shown to aid in the diagnosis of bone metastasis in patients with lung 
cancer. Patients with metastatic bone disease from lung cancer (MBDLC) are often 
treated with zoledronic acid. Zoledronic acid reduces the levels of bone resorption 
biomarkers and also the risk of skeletal adverse events in patients with MBDLC. We 
studied the effects of treatments including zoledronic acid on levels of sNTx during 
disease progression. Methods: Patients with MBDLC at the initial diagnosis were entered 
to this study. sNTx was measured once a month using the sNTx assay OSTEOMARKTM 
serum NTx (Alere Medical). MBDLC was characterized by monthly physical 
examination and by bone scintigraphy every 3 months for 12 months. All patients were 
required to provide written informed consent. Results: Twenty patients were enrolled 
between June and December 2010. The mean +/- 1 SD of the sNTx concentrations was 
19.8 +/- 5.8 nM BCE/L at baseline. In the 16 patients receiving zoledronic acid, the levels 
of sNTx showed a significant decrease in the first month of treatment (baseline: 21.3 
+/- 5.5 nM BCE/L; one month later: 13.6 +/- 2.7 nM BCE/L; p<0.01). During follow-up 
period, 12 of the patients treated with zoledronic acid experienced worsening MBDLC or 
had died from lung cancer, and there were statistically significant differences in the levels 
of sNTx at baseline (19.7 +/- 4.47 nM BCE/L), at the lowest levels after the administration 
of zoledronic acid (11.5 +/- 2.73 nM BCE/L) and at the point of measurable disease 
progression or death (13.0 +/- 2.07 nM BCE/L). Conclusion: Serial measurements 
of sNTx in patients with MBDLC treated with zoledronic acid might predict disease 
progression of bone metastasis. Administration of zoledronic acid significantly 
decreased the level of sNTx from baseline within one month and maintained the level of 
sNTx lower than baseline during study periods.
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P1-056: PERIODIC MEASUREMENT OF N-TELOPEPTIDES OF 
TYPE I COLLAGEN IN SERUM (SNTX) FOR EARLY DIAGNOSIS OF 
BONE METASTASIS IN PATIENTS WITH LUNG CANCER
Koji Takeda1, Shinya Tokunaga2, Haruko Daga2, Hideaki Okada1, Koichi Taira1, Michiyo 
Hattori1, Motohiro Tamiya3, Norio Okamoto3, Hidekazu Suzuki3, Naoko Morishita3, 
Tomonori Hirashima3  
1Department Of Clinical Oncology, Osaka City General Hospital, Osaka/JAPAN, 
2Department Of Clinical Oncology, Osaka City General Hospital, Osaka City Osaka/
JAPAN, 3Thoracic Malignancy, Osaka Osaka Prefectural Medical Center For Respiratory 
And Allergic Diseases, /JAPAN
Background: The bone resorption biomarker sNTx has been previously shown to add 
value as an aid in the diagnosis of bone metastasis in patients with lung cancer. The 
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objective of this prospective study was to determine if periodic sNTx measurements 
could lead to early diagnosis of bone metastasis in patients with lung cancer. Methods: 
Patients with newly diagnosed organ-confined lung cancer were enrolled. sNTx values 
were determined once each month using the OSTEOMARKTM serum NTx assay (Alere 
Medical). The presence or absence of bone metastasis was determined by monthly 
physical examination and by bone scintigraphy every 3 months for 12 months. All 
patients were required to provide written informed consent. Results: Forty patients were 
enrolled between June and December 2010. One patient withdrew early and was excluded 
from analysis. The mean +/- 1 SD baseline level of sNTx was 17.5 +/- 4.4 nM BCE/L. Five 
patients developed bone metastasis (as characterized by bone scintigraphy) during the 
study period. The level of sNTx in subjects with bone metastasis was slightly increased 
(21.6 +/- 3.2 nM BCE/L), however, in these patients, there was no statistically significant 
difference between sNTx values at baseline (18.2 +/- 4.2 nM BCE/L) and when metastasis 
was diagnosed. (p=0.176). When a cut-off value of sNTx was set to 22.0 nM BCE/L, the 
sensitivity and the specificity of detection of bone metastasis were 80.0% and 41.2%, 
respectively. Using this cut-off, the elevation of sNTx could predict bone metastasis at 
least one month before diagnosis by bone scintigraphy in all 5 patients, however, the 
specificity was relatively low for clinical implementation. Additionally, the sensitivity 
and the specificity of early detection of systematic spread of disease (including bone 
metastasis) were 70.6% and 45.5%, respectively. Conclusion: Periodic determination 
of sNTx in patients with organ confined lung cancer did not provide sufficient 
specificity for it to be used for the early diagnosis of bone metastasis. However, periodic 
measurement of sNTx may provide a helpful marker for disease progression in patients 
with systematic spread of lung cancer.
Keywords: N-telopeptides of type I collagen, bone metastasis, LUNG CANCER
POSTER SESSION 1 - PROGNOSTIC AND PREDICTIVE BIOMARKERS 3 -  
November 27, 2012 14:05-14:55
P1-057: DEFORMABILITY-BASED ISOLATION OF CIRCULATING 
TUMOR CELLS IN LUNG CANCER PATIENTS WITH MICROCAV-
ITY ARRAY SYSTEM
Hirotsugu Kenmotsu1, Masahito Hosokawa2, Yasuhiro Koh3, Tomoko Yoshino2, Tateaki 
Naito1, Tetsuhiko Taira1, Toshiaki Takahshi1, Haruyasu Muarakami1, Takehito Shukuya1, 
Akira Ono1, Hiroaki Akamatsu1, Reiko Watanabe4, Sachiyo Ono4, Masahiro Endo5, 
Yoshihito Kikuhara6, Hisashige Kanbara6, Tadashi Matsunaga2, Nobuyuki Yamamoto1  
1Division Of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka/JAPAN, 2Institute 
Of Engineering, Tokyo University Of Agriculture And Technology, Koganei/JAPAN, 
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Institute, Shizuoka/JAPAN, 4Division Of Diagnostic Pathology, Shizuoka Cancer 
Center, Shizuoka/JAPAN, 5Division Of Diagnostic Radiology, Shizuoka Cancer Center, 
Shizuoka/JAPAN, 6Hitachi Chemical Co., Ltd, Chikusei/JAPAN
Background: Circulating tumor cells (CTCs) has prognostic value in solid tumors such 
as advanced breast, colon and prostate cancers. However, poor sensitivity has been 
reported in non-small cell lung cancer (NSCLC). We have developed a microcavity 
array (MCA) system integrated with a microfluidic device for recovery and enumeration 
of CTCs. This system can isolate tumor cells on the basis of differences in size and 
deformability between tumor and hematologic cells. Methods: Paired peripheral blood 
samples were collected from metastatic lung cancer patients for detection of CTCs 
by MCA system and CellSearch system. CTCs were enumerated by EpCAM-based 
immunomagnetic capture (CellSearch, Veridex) and by the MCA system in parallel. 
With MCA system, peripheral blood was introduced into the MCA and trapped cells 
were stained with Hoechst 33342, FITC-labeled anti-pan cytokeratin antibodies and 
PE-labeled anti-CD45 antibodies for subsequent imaging analysis. CTCs were defined 
as cells with round to oval morphology, a visible nucleus, positive staining for pan-
cytokeratin and negative staining for CD45. We evaluated the sensitivity of the MCA 
system for detecting CTCs in lung cancer patients compared with CellSearch system 
in a head-to-head manner. Statistical analyses were carried out to assess the advantage 
of detecting CTCs by MCA system over CellSearch system. In addition, we performed 
exploratory analysis of the prognostic value of CTCs. Results: Twenty-two metastatic 
NSCLC patients and 21 small-cell lung cancer (SCLC) patients were enrolled into this 
study between April 2011 and February 2012. CTCs were detected in 17 of 22 NSCLC 
patients (count ≥1 per 7.5 ml) using MCA system versus 9 of 22 patients using CellSearch 
system. On the other hand, CTCs were detected in 20 of 21 SCLC patients (count ≥1 per 
7.5 ml) using MCA system versus 14 of 21 patients using CellSearch system. Significantly 
more CTCs in NSCLC patients were detected by MCA system (median 13, ranging from 
0-291 cells/7.5ml) than by CellSearch system (median 0, ranging from 0-37 cells/7.5ml) 
demonstrating statistical superiority (p=0.0082, Wilcoxon test). Statistical significance 
was not reached in SCLC though the trend favoring MCA system over CellSearch system 
was observed (p=0.110, Wilcoxon test). By CellSearch system, patients with <8 CTCs 
showed not significantly better survival than those with ≥8 CTCs (p=0.7353, log-rank 
test). On the other hand, MCA system showed that patients with <8 CTCs tended to 
be better survival than those with ≥8 CTCs (p=0.0694, log-rank test). Conclusion: 
Our results suggest that MCA system is potentially superior to CellSearch system for 
detecting CTCs in both non-small cell and small cell lung cancer patients and further 
clinical development including genotyping of CTCs should be considered.
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P1-058: DEVELOPED METHOD FOR MULTIPLE QUALITATIVE 
MOLECULAR ANALYSIS USING BRONCHOSCOPIC ULTRA-
MICRO SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG 
CANCER (NSCLC)
Yuichi Sakairi1, Sakae Itoga2, Kenichi Sato2, Kazuyuki Matsushita2, Shigetoshi Yoshida1, 
Yuichi Takiguchi3, Fumio Nomura2, Ichiro Yoshino1  
1General Thoracic Surgery, Chiba University Graduate School Of Medicine, Chiba/
JAPAN, 2Laboratory Medicine And Clinical Genetics, Chiba University Hospital, Chiba/
JAPAN, 3Department Of Medical Oncology, Chiba University Graduate School Of 
Medicine, Chiba/JAPAN
Background: Genetic information is essential for molecular targeted therapy for 
personalized medicine, although tissue sampling for genetic analysis still remains 
challenging. In this study, we investigated the utility of bronchoscopic ultra-micro 
samples compared with conventional bronchoscopic histological materials for multiple 
gene analyses for NSCLC. Methods: Patients with NSCLC proven by on-site cytological 
examinations during bronchoscopic survey were eligible. Following conventional needle 
aspiration biopsy by flexible bronchofiberscope (from primary lesion) or convex probe 
endobronchial ultrasound (from metastatic lymph nodes), the used needle was rinsed 
with 20 ml of saline and collected remnant malignant cells. This ultra-micro sample 
(uMS) was used for both cytological diagnosis and genetic analysis. DNA and RNA 
were extracted from each sample and subjected to molecular analyses. Gene mutations 
were examined by direct sequencing of PCR products for EGFR (4 primer sets for exon 
18 – 21), K-ras (2 primer sets for codon 12-13) and BRAF (2 primer sets). Fusion genes 
were examined by RT-PCR for ALK (2 primer sets for EML4 and KIF5B) and RET (2 
primer sets). Each genetic abnormality of the PCR product was screened or diagnosed by 
a high resolution melting method. The results of cytological diagnoses and gene profiles 
using MS were compared to conventional histological diagnoses. Results: A total of 93 
lesions (32 primary and 61 metastatic nodes) from 99 patients (101 lesions) were eligible. 
Adenocarcinoma (N = 54), squamous cell carcinoma (N = 33), and NSCLC (N = 6) were 
pathologically confirmed in histological cores; however, only 45 malignant cells (48%) 
were detected with uMS. DNA and RNA could be extracted from all histological samples 
and uMS. In 38 cases, genetic disorders were identified from either sample, including 
EGFR mutations (N = 13), K-ras mutations (N = 6), BRAF mutation (N = 1), ALK fusion 
genes (N = 5), RET fusion gene (N=1), and silent mutations (N = 20); the detection 
concordance rate between histological core and uMS was 99.7% (1113/1116). All of the 
discrepancy in the results between histological core and uMS was due to inadequate 
quality of histological core sample. Only 4 mutations (4/45=8.9%) in uMS could not be 
identified by direct sequencing though could detect the existence of mutation by high 
resolution melting analysis. Conclusion: Bronchoscopic uMS are as useful for multiple 
genetic examinations as histological core.
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P1-059: ENZASTAURIN HAS ANTI-TUMOR EFFECTS IN LUNG 
CANCERS WITH OVEREXPRESSED JAK PATHWAY MOLECULES
Masahiro Seike, Tsuneo Shimokawa, Chie Soeno, Akihiko Miyanaga, Yuji Minegishi, 
Rintaro Noro, Kaoru Kubota, Akihiko Gemma  
Department Of Internal Medicine, Division Of Pulmonary Medicine, Infectious 
Diseases And Oncology, Nippon Medical School, Tokyo/JAPAN
Background: Enzastaurin, an oral serine-threonine kinase inhibitor, was initially 
developed as an ATP-competitive selective inhibitor against protein kinase C (PKC) β. 
However, the mechanism by which enzastaurin contributes to tumorigenesis remains 
unclear. Methods: We analyzed the antitumor effects of enzastaurin in 22 lung cancer 
cell lines to ascertain the potential for enzastaurin-based treatment of lung cancer. To 
identify molecules or signaling pathways associated with this sensitivity, we conducted a 
gene, receptor tyrosine kinases phosphorylation and miRNA expression profiling study 
on the same set of cell lines. Results: We identified eight genes by pathway analysis of 
molecules having gene-drug sensitivity correlation, and used them to build a support 
vector machine algorithm model by which sensitive cell lines were distinguished from 
resistant cell lines. Pathway analysis revealed that the JAK/STAT signaling pathway was 
one of the main ones involved in sensitivity to enzastaurin. Overexpression of JAK1 
was observed in the sensitive-cells by Western blotting. Simultaneous administration 
of enzastaurin and JAK inhibitor inhibited enzastaurin-induced cell growth-inhibitory 
effect. Furthermore, lentiviral mediated JAK1 overexpressing cells were more sensitive to 
enzastaurin than control cells. Conclusion: Our results suggested that the JAK1 pathway 
may be used as a single predictive biomarker for enzastaurin treatment. The anti-tumor 
effect of enzastaurin should be evaluated in lung cancer with overexpressed JAK pathway 
molecules. 
Keywords: LUNG CANCER, Enzautaurin, Drug sensitivity, Gene expression
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P1-060: GALIUM-68 NEOMANNOSYL HUMAN SERUM ALBUMIN-
BASED PET/CT LYMPHOSCINTIGRAPHY FOR SENTINEL LYMPH 
NODE IDENTIFICATION IN NON-SMALL CELL LUNG CANCER 
Hyun Koo Kim1, Jae Seon Eo2, Ho Kyung Sung1, Sungeon Kim2, Jae Min Jeong3, Young 
Ho Choi1  
1Thoracic And Cardiovascular Surgery, College Of Medicine, Korea University Guro 
Hospital, Seoul/KOREA, 2Nuclear Medicine, College Of Medicine, Korea University 
Guro Hospital, Seoul/KOREA, 3Nuclear Medicine, Seoul National University Hospital/
KOREA
Background: In the previous report, we developed a novel mannose receptor-binding 
agent, Technetium-99m human serum albumin (99mTc-MSA), for sentinel lymph node 
detection. To overcome the limited resolution of current lymphoscintigraphic imaging 
using Technetium-99m, we developed Galium-68 for PET/CT imaging. This study is the 
first clinical trial designed to test the reliability and feasibility of sentinel node detection 
using this new tracer in non-small cell lung cancer. Methods: Twenty-three patients 
(14 men, 9 women; mean age 62.6±10.3 years) that were candidates for lobectomy with 
mediastinal lymph node dissection for stage I non-small cell lung cancer were enrolled. 
A total dose of 0.2mCi of 68Ga-MSA in 0.1 mL was administered in one shot at the peri-
tumoral region, and then lymphoscintigram was taken by PET/CT just before surgery. 
All harvested lymph nodes were cut into 2 mm slices and ultimately diagnosed by using 
formalin-fixed and paraffin-embedded sections with hematoxylin and eosin staining. 
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 Results: 
The number of dissected lymph nodes per patient was 20.3±10.4 (7-49). In 22 of 23 
patients (95.7%), the sentinel lymph nodes could be identified on PET/CT (Fig.1). The 
number of sentinel lymph nodes identified was 1.4±0.6 (range 1-3) per patient. Six out 
of 22 patients (27.3%) had metastases in 10 sentinel lymph nodes. No false-negative 
sentinel lymph nodes were detected in any of the 6 patients with N1 or N2 disease 
(0%). Conclusion: 68Ga-MSA appears to be a promising tracer for sentinel lymph node 
identification by PET/CT in non-small cell lung cancer.
Keywords: LUNG CANCER, Sentinel lymph node
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P1-061: EARLY T1B LUNG CANCER BASED ON THIN-SECTION 
COMPUTED TOMOGRAPHIC SCAN.
Keiju Aokage, Yuki Matsumura, Tomohiro Haruki, Tomoyuki Hishida, Junji Yoshida, 
Kanji Nagai  
Division Of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa/JAPAN
Background: The advances in preoperative radiologic examination have been making it 
possible to predict cancer malignant potential more precisely. The Aim of this study is to 
identify radiologic early lung adenocarcinoma in clinical T1bN0M0 lung cancer from a 
perspective of pathological findings and long-term prognosis. Methods: A retrospective 
study was conducted on 173 consecutive lung cancer patients underwent pulmonary 
resection for clinical T1bN0M0 lung cancer between January 2003 and December 2007. 
We reviewed lung nodules on preoperative thin-section computed tomographic scan 
(TSCT) findings. The patients with multiple primary lung cancers, extensive cavity 
formation, and massive occlusive pneumonia were excluded from this analysis. The 
ratio of the size of solid attenuation to the maximum tumor dimension (Consolidation/
Tumor ratio; C/T ratio) was calculated in one dimension on TSCT. We set cut-off levels 
of C/T ratio at 0.00, 0.25, 0.50, 0.75, and 1.00. We compared the rate of pathological 
non-invasive lung adenocarcinoma (defined as a lung adenocarcinoma without nodal 
involvement, vascular invasion, lymphatic permeation, and pleural invasion), overall 
survival, and recurrence rate in two groups divided by each cut-off level of C/T ratio 
and decided optimal cut-off level. Additionally, various clinical factors available at the 
time of operation (optimal C/T ratio, sex, age, smoking history, preoperative serum CEA 
value, laterality, lung lobe, and maximum tumor diameter) were analyzed by univariate 
and multivariate analyses (logistic regression analysis) for predicting pathological 
lymph node involvement. Results: Median follow up period was 62 months. The median 
preoperative maximum tumor diameter was 25mm on TSCT. There were no correlation 
between tumor diameter and the C/T ratio (r=0.16; Spearman Rank Correlation 
Coefficient). All the patients with the C/T ratio less than 0.5 were diagnosed with 
pathological non-invasive cancers. When I set cut-off levels of the C/T ratio at 0.50, 0.75, 
and 1.00, there was significant difference for overall survival among each two groups. 
However, the patients with the C/T ratio less than 0.5 did not develop a recurrence and 
only one patient died of the other cancer. On the other hand, as for the patients that the 
C/T ratio was 0.5 or more and less than 0.75, a recurrence rate amounted to 18%. Five 
years survival rate of patients with the C/T ratio less than 0.5 was 97.4% and those with 
the C/T ratio more than 0.5 was 76.2%, respectively. The C/T ratio was independent 
predictors for pathological lymph node metastasis. Conclusion: Clinical T1b lung 
adenocarcinoma dominant with ground glass opacity on TSCT revealed rare lymph node 
involvement and an excellent prognosis. These findings would warrant a feasibility study 
of limited surgery for this population. 
Keyword: Radiologic early lung cancer
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P1-062: ANATOMICAL SUBLOBAR RESECTION OF THE LUNG, 
WITH SPECIAL REFERENCE TO IDENTIFYING THE INTERSEG-
MENTAL PLANE
Mitsuhiro Kamiyoshihara1, Hitoshi Igai1, Takashi Ibe1, Seshiru Nakazawa2, Kai 
Obayashi2, Yoichi Ohtaki2, Jun Atsumi2, Toshiteru Nagahima2, Seiichi Kakegawa2, 
Masayuki Sugano2, Osamu Kawashima2, Kimihiro Shimizu2, Izumi Takeyoshi2  
1Department Of General Thoracic Surgery, Maebashi Red Cross Hospital, Maebashi/
JAPAN, 2Gunma University Graduate School Of Medicine/JAPAN 
Background: A pulmonary segmentectomy requires identification of the segmental 
planes, making it technically more difficult than a lobectomy. Therefore, we present a 
selective segmental-inflation technique using a butterfly needle. This paper discusses 
anatomical sublobar resection with special reference to identifying the intersegmental 
plane. Methods: First, the lung is deflated and the pulmonary vessels to the involved 
segment are divided. The segmental bronchus is divided using a stapling device or 
ligation. Then, using a butterfly needle, oxygen/air (0.5–1.5 L) is instilled into the 
targeted bronchus to inflate the involved segment, and the involved segment is severed 
and removed using electrocautery or a stapling device. The raw surface is covered with 
an absorbable sealing material to prevent air leaks. Results: Fifty-three (M:F = 27:26) 
patients underwent anatomical segmentectomy with the selective segmental-inflation 
technique using a butterfly needle. Their median age was 67.6 years. The diseases were 
malignant lung disease in 44 patients and benign lung disease in nine. The surgical 
procedure was segmentectomy only in 47 and segmentectomy combined with lobectomy 
in six. The median operating time was 170 min; the blood loss was 100 (slight) to 950 
g; and the postoperative stay was 4 days. The duration of chest tube drainage was 3 
days. One patient had a minor air leak for 9 days and required treatment with OKT-432 
for pleural adhesions. No in-hospital mortality occurred. Conclusion: In summary, 
anatomical sublobar resection was performed successfully with the selective segmental-
inflation technique using a butterfly needle. Advantages: Surgeons can control every 
manipulation. No special device is needed; a butterfly needle is sufficient. It is useful 
regardless of the situation of proximal bronchus. Ultra-selective air instillation into the 
subsegmental bronchus depends on the needle direction. Disadvantages: The proximal 
site of the targeted bronchus must be identified. Care is needed to avoid systemic air 
embolism.
Keywords: anatomical segmentectomy, LUNG CANCER
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P1-063: PREOPERATIVE LIPIODOL MARKING FOR SMALL-SIZED 
LUNG CANCERS
Junichi Shimada1, Kunihiko Terauchi2, Masanori Shimomura1, Daishiro Katoh1  
1Chest Surgery, Kyoto Prefectural University Of Medicine, Kyoto/JAPAN, 2Nara 
Municipal Hospital/JAPAN
Background: Recently, the therapeutic strategy for small-sized lung tumor has been 
dramatically changing because the development of imaging device enables us to 
find out tumor at earlier stage. On the other hand, we cannot always diagnose them 
pathologically before surgery. So we sometimes need to do VATS for therapeutic 
resection as well as diagnostic excisional biopsies. The small-sized lung tumors, such 
as a bronchioloalveolar carcinoma, are difficult to localize during surgery by seeing 
or palpating from the surface of lung because lung is a soft and deformable organ and 
contains much air in it. It is very important for surgeons to know exactly where the 
tumor is located during the operation. We usually perform preoperative lipiodol-
marking for small-sized tumor, especially when they are located deep in lung, in order 
to make invisible and impalpable tumor to “visible target”. With this visualization 
technique with lipiodol marking, we can resect marked lesions under X-ray fluoroscopy. 
Methods: We analyzed 86 lesions in 67 cases, in which the unconfirmed but lung cancer 
suspected lesions are less 10 mm in diameter, or deep inside from the visceral pleura, 
or ground glass opacity. One to three markings with lipiodol were done in each case. 
The tumor was 9.8±5.6 mm in diameter, existed 8.8±8.1 mm away from the surface of 
the visceral pleura. Before operation, we injected 0.1-0.5mL lipiodol at the vicinity of 
the tumor with a CT fluoroscopy. In VATS operations, we checked and resected the 
lipiodol-marked lesion under a X-ray fluoroscopy. Results: This marking procedure took 
19.5 minutes per lesion. Pneumothoraces occurred as complications in 7 cases (13.4%). 
No air embolization was occurred. All lipiodol-marked lesions were detectable and 
safely resected. Pathological examinations revealed lung cancers in 36 cases, atypical 
adenomatous hyperplasias in 8 cases, and organized pneumoniae in 38 cases. There were 
no histological modifications in and around lipiodol markings. Conclusion: The lipiodol 
marking with CT fluoroscopy before VATS operations is an useful technique for early 
and small and impalpable lung tumors. 
Keywords: lipiodol marking, LUNG CANCER, CT guided marking
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P1-064: CLINICAL IMPLICATIONS OF THE MARGIN CYTOLOGY 
FINDINGS AND MARGIN/TUMOR SIZE RATIO IN PATIENTS 
WHO UNDERWENT PULMONARY WEDGE RESECTION FOR PE-
RIPHERAL NON-SMALL CELL LUNG CANCER
Noriyoshi Sawabata, Soichiro Funaki, Tomoyuki Nakagiri, Yasushi Shintani, Masayoshi 
Inoue, Masato Minami, Meinoshin Okumura  
General Thoracic Surgery, Osaka University Graduate School Of Medicine, Osaka/
JAPAN
Background: A pulmonary wedge resection is a strategy for the treatment of peripheral 
non-small cell lung cancer (NSCLC). The margin/tumor size ratio (M/T) is a predictor of 
positive margin cytology results in these procedures, although the clinical implications 
of peripheral small (less than 2cm) NSCLC remain unclear. This relationship was 
investigated in this study. Methods: The survivals of 58 patients with a high surgical 
risk who underwent pulmonary wedge resection for peripheral small NSCLC without 
additional pulmonary resection were analyzed according to the status of M/T and 
surgical margin cytology results. Results: Margin cytology finding was an indicator of 
survival but M/T is not. Five cases of surgical margin recurrence had a cytology-positive 
surgical margin in 4 cases (80%) and M/T less than 1 in 5 cases (100%). The 5-year 
survival rate was 82% (n = 35) for M/T less than 1 and 89% for M/T more than 1 (n = 
23, P = 0.1), while it was 50% for positive margin (n = 9) and 94% for negative margin 
(n = 49) cases (P = 0.002). In addition, the rate of malignant positive surgical margin 
was 9/35(26%) in cases of M/T less than 1 and 0/23(0%) in cases of M/T more than 1. 
Conclusion: A pulmonary wedge resection for peripheral small NSCLC should result in 
a negative malignant margin, which might be obtained from a sufficient tumor margin 
ratio of M/T more than 1.
Keywords: Wedge resection, margin cytology, clinical implication, non-small cell lung 
cancer
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P1-065: THORACOSCOPIC LOBECTOMY WITH MEDIASTINAL 
LYMPH NODE DISSECTION IS STANDARD  TO TREAT EARLY-
STAGE NON-SMALL CELL LUNG CANCER.
Mikhail I. Davydov, Arif K. Allakhverdiev, Konstantin Laktionov, Mikhail Davydov  
Thoracic Surgery, Russian Cancer Research Center, Moscow/RUSSIAN FEDERATION
Background: Many thoracic surgeons are now advocating the use of minimally invasive 
thoracoscopic surgery to perform lobectomies for early-stage primary NSCLC, with the 
objective of lessening postoperative morbidity while still providing a good oncologic 
outcome. This series is reviewed to assess these issues. Methods: Between 2008 and 2011, 
we performed 76 thoracoscopic lobectomies in 25 women (33%) and 51 men (67%), with 
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a mean age of 52.3 years. All operated patients had clinical stage I or II of lung cancer. 
Right upper lobectomy met 15(19,7%), midell – 12(15,8%) and lower – 27(35,5%) from 
the total number of operated patients. Left completed 15(19,7%) lower and 7(9,3%) upper 
lobectomy. Of the primary lung cancers, 55 (72,3%) were adenocarcinoma. All patients 
with primary lung cancer performed hilar and mediastinal lymph node dissection. Four 
incisions were made four 10-mm instrument ports. 4-5cm incision were carried out 
exclusively in the end of operation for the purpose of removal resected lung.  Results: 
Thoracoscopic lobectomy and mediastinal lymph dissection was successfully performed 
in 70 patients (92,1%); 6(7,9%) patients required conversion to thoracotomy to control 
bleeding in the setting of dense hilar adenopathy. There were no intraoperative and 
perioperative deaths. Сomplications included pneumonia - 5 patients and prolonged 
air leak - 3 patients. Median time to chest tube removal was 3 days, and median length 
of stay was 6 days. Conclusion: Thoracoscopic lobectomy has been proven to be an 
adequate surgical approach to lung cancer and should be considered as a viable approach 
to treating selected patients with early-stage NSCLC.
Keyword: lung cancer, thoracoscopic lobectomy, erly-stage lung cancer, VATS lobectomy
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P1-066: A NEW TECHNIQUE FOR DISSECTION OF THE PULMO-
NARY VESSELS IN LUNG CANCER
Sadanori Takeo  
Division Of General Thoracic Surgery, Respiratory Center And Clinical Institute,, 
National Hospital Organization Kyushu Medical Center, Fukuoka/JAPAN
Background: The conventional method for dissecting of the pulmonary artery and vein 
is the dissection of the sheaths of vessels by exfoliation of these vessels.Dissection of the 
pulmonary artery and vein is difficult to perform during hybrid and complete Video-
Assisted Thoracic Surgery. This report describes a new technique (Ann Thorac Surg 2011) 
for the safe and rapid dissection of these vessels. Methods: This method employs Mayo-
type scissors for sharp dissection of the pulmonary artery and vein. First, the sheaths 
on the surface of the central part of the pulmonary vessels are dissected using scissors 
approximately 5 mm in length and the vessel is single ligated by 2-0 silk at the same site. 
The surgeon directly grasps the point on the blood vessel just distal to the first ligation 
and retracts it to the central side with vascular forceps. The distal side of the blood vessel 
is exposed aggressively with Mayo-type scissors by dissecting the sheaths surrounding 
the vessel with the associated connective tissue including the perivascular lymph nodes. 
It is important that the entire side of the blood vessel contained with lymph nodes is 
clearly exposed with the scissors. Results: This procedure can easily expose about 2 
cm of a small vessel and over 3 cm of a slightly larger vessel by dissecting the sheaths 
with Mayo-type scissors. This method is very useful in most circumstances, such as for 
tumor invasion to the area surrounding a blood vessel or with a perivascular enlarged 
lymph node without direct invasion. This method has been applied in over 1000 cases 
of lobectomy and segmentectomy since 2001, and none of these cases have shown blood 
vessel injury.  Conclusion: The length of surgery can be dramatically shortened by this 
method. I will show this technique by video. I will show this technique by video.
Keywords: new technique, pulmonary vessels, VATS
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P1-067: SURGICAL TREATMENT OF IPSILATERAL MULTI-FOCAL 
NON-SMALL CELL LUNG CANCER
Tang Yong, Qiao Guibin  
Thoracic Surgery, General Hospital Of Guangzhou Military Command Of Pla, 
Guangzhou/CHINA
Background: The staging and treatmant of multi-focal non-small cell lung cancer 
(NSCLC) are controversial. This study evaluated the current staging of multi-focal 
NSCLC and the therapeutic effectiveness of resection. Methods: Data of 729 complete 
surgically treated patients with non-small cell lung cancer from December 1999 to 
December 2006 were retrospectively reviewed. Clinico-pathological and overall survival 
data of patients with ipsilateral multi-focal NSCLC were obtained. Prognostic impact of 
ipsilateral multi-focal NSCLC on overall survival was calculated by the Kaplan-Meier 
method and compared by the log rank test.  Results: Among 68 patients with multi-focal 
NSCLC, 54 patients had multiple nodules in primary lobe (T4) and 13 had additional 
nodules in non-primary lobe (M1), and a patient was proved to have synchronous 
primary NSCLC lesions. The study included 44 male and 24 female patients. Median 
age of this series was 60.3 years old. The majority of patients had adenocarcinoma, 
including pure bronchioloalveolar carcinoma and bronchioloalveolar carcinoma 
components. The median overall survival time of this series was 24.2 months. Prognostic 
study demonstrated that mediastinal lymph node metastasis and bronchioloalveolar 
carcinoma histology had significant impact on overall survival. The median survival 
times were 39 months for patients with N0 and N1, and 14 months for patients with 
N2, respectively, and there was significant difference between the groups (p<0.0001). 
The difference in survival was significant between patients with bronchioloalveolar 
carcinoma components and other NSCLC histologic types (p<0.0001), and the median 
survival times were 58.8 months and 27.0 months, respectively. Conclusion: Surgery 
could provide choice for multi-focal NSCLC patients (T4 and M1), especially for patients 
with bronchioloalveolar carcinoma components and without mediastinal lymph node 
metastasis. The results suggest that the current TNM classification system may be 
inappropriate in designation of ipsilateral multi-focal NSCLC and needs modification. 
Keywords: TNM Staging system, Lung neoplasms, Surgery, Prognosis
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P1-068: THE PRESENT SITUATION IN SURGICAL TREATMENT 
FOR OCTOGENARIAN LUNG CANCER IN OUR HOSPITAL
Masashi Yanada1, Junichi Shimada2, Kazuhiro Ito2, Masanori Shimomura2, Hiroaki 
Tsuneduka2  
1Ayabe City Hospital, Kyoto/JAPAN, 2Chest Surgery, Kyoto Prefectural University Of 
Medicine, Kyoto/JAPAN
Background: In 2010 World Health Organization (WHO) reported that the average 
life expectancy of the Japanese male was 79.59 years and that of the female was 86.44. 
Our ayabe city has a higher proportion of elderly people. Therefore, in our hospital, 
octogenarians with lung cancer are increasing year by year in step with the increase of 
the average life expectancy. So we discussed surgical treatment for octogenarian lung 
cancer in our hospital. Methods: The patients of lung cancer more than 80 year old who 
underwent surgical treatment between January 2006 and December 2011 were enrolled. 
The postoperative survival rate was analyzed by the Kaplan-Meier method, and the 
differences in survival rates were assessed by the log-rank test. Continuous data between 
two groups were compared using Mann-Whitney U test. A probability value of <0.05 was 
considered significant. Results: Surgical resection was performed in 41 octogenarians, 
which represented 31.3% of the 131 resections for lung cancer performed during the 
study period. There were 26 men and 15 women with a mean age of 81.6 years old (80-
85 years old). In one patient, the operation was aborted due to unexpected metastatic 
disease discovered at the time of thoracotomy. The remaining 40 patients underwent 21 
lobectomies, 1 segmentectomy and 18 wedge resections. All patients recovered and were 
discharged home. There was no operative mortality, and no hospital death. But 1 died of 
acute myocardial infarction within 30 days of surgery. Complications occurred in 6 of 
41 patients (14.6%). Complications included pneumonia (2), empyema (2), prolonged air 
leak (2) and acute myocardial infarction (1). The average postoperative hospital stay was 
11.6 days (3-109 days). Overall 5-year survival was 64.9%. Disease specific 5-year survival 
was 85.4%. Postoperative complications were not related to survival rate (p=0.52). In 
addition, no significant difference of survival was observed between the types of surgery 
(p=0.18). Conclusion: Age itself isn’t a risk factor for lung cancer operation. If there is 
no problem with patient’s physical capacity, even octogenarian patients of lung cancer 
should be treated surgically.
Keyword: octogenarian lung cancer
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P1-069: VALIDITY AND FEASIBILITY OF RE-RESECTION FOR 
THE SOLITARY LUNG RECURRENCE AFTER COMPLETE RESEC-
TION IN NON-SMALL CELL LUNG CANCER
Soichiro Funaki, Tomoyuki Nakagiri, Yasushi Shintani, Masayoshi Inoue, Noriyoshi 
Sawabata, Masato Minami, Meinoshin Okumura  
Department Of General Thoracic Surgery, Osaka University Graduate School Of 
Medicine, Osaka/JAPAN
Background: Most of recurrence after initial resection of primary non-small cell 
lung cancer (NSCLC) usually occurs in multiple other organs, therefore, systemic 
chemotherapy can be the choice of treatment for those cases. However, in some 
instances, a solitary recurrent lesion can be found in the lung. In those cases, it is 
also difficult to determine whether the new lesion is recurrence or primary cancer. In 
addition, there are several options of treatment modality. Although re-resection of those 
lesions can be one of the promising options, it remains controversial. We examined the 
validity of surgical treatment for new lung lesion after complete resection for initial 
NSCLC based on our experiences. Methods: There were 30 recurrent NSCLC cases 
in which complete re-resection was performed. The clinical outcome was reviewed 
retrospectively to elucidate the clinical factors determining the treatment failure. We 
analyzed the difference of clinical background between the re-recurrent cases and 
non-re-recurrent cases- the average age, sex, operation (first and second operation), 
p-stage, disease free interval (the duration from the first operation to second operation), 
the complication after second operation, and the surgical results. Results: Among 30 
cases, post-operative complication (empyema) was found in only one case (3%). The 
re-recurrences were found in 13 cases (43%). The re-recurrent group had significantly 
shorter disease free interval from the initial operation than the re-recurrence free group 
(p<0.005; 63 months vs 27 months) and higher age (61 years vs 69 years, t-test). On the 
other hand, there was no difference in gender, p-stage of the primary lung cancer, and 
the surgical procedure between the re-recurrence group and the re-recurrence free 
group. Conclusion: Re-resection of pulmonary lesions is challenging, but may be a 
feasible treatment of choice for the selected cases with solitary recurrence after the initial 
operation.
Keywords: Non small cell lung cancer, recurrence, re-resection
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P1-070: SURGICAL PREVENTION OF DEVELOPMENT OF BRON-
CHOPLEURAL FISTULA AFTER PNEUMONECTOMY IN LUNG 
CANCER PATIENTS 
Otabek Eshonkhodjaev1, Shukhrat Khudaybergenov2, Ortikali Irisov2  
1Department Of Lungs And Mediasinum Surgery, Republican Specialized Centre Of 
Surgery Named After Academician V.Vakhidov, Tashkent/UZBEKISTAN, 2Department 
Of Lungs And Mediasinum Surgery, Republican Specialized Centre Of Surgery Named 
After Academician V.Vakhidov/UZBEKISTAN
Background: Development of BSF after pneumonectomy (PE) was always related to 
bronchial suture failure and unfavorable conditions of its healing. Nowadays a necessity 
of stratification of patients with local distributed and disseminated cancer forms of any 
localization is scientifically proved. It allows to determine heterogeneity of patients’ 
group in relation to the nearest and remote prognosis as well as to work out and to 
implement optimal volumes of surgical treatment into practice. Methods: Stratification 
data of risk factors of bronchial stump failure (BSF) development in 575 patients, who 
underwent primary pneumonectomy in this article were presented. Control group (CG) 
consisted of 477 patients, 390 patients of them had different tumors of the lungs and 
87 patients had purulent diseases of the lungs. The main group (MG) consisted from 
98 patients, 72 patients of them had pulmonary tumors and 26 patients had purulent 
pulmonary diseases. They underwent the worked out treatment tactics based on 
determination of risk groups development of bronchial failure after pneumonectomy. 
An analysis of surgical treatment of patients on a base of the elaborated multi-factoral 
evaluation and determination of risk groups of bronchial stump fistula development after 
pneumonectomy has been conducted that allowed to reduce an incidence of mortality. 
Results: In accordance with factor estimation of risk degree of development of BSF 
worked out an accomplishment of PE was conjugated with minimal risk in 47,1% (271) 
patients, mean risk - in 38,3% (220) and maximal risk – in only 14,6% (84), at the same 
time depending upon a side of operation a 3-fold real increase of risk after PE to the right 
was registered. An incidence of BSF after PE in patients of CG accounted for minimal 
risk 1,3%, at an average – 16,0%, and maximal – 32,3%, in its turn, an implementation of 
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factor estimation of risk degree of development of BSF after PE in MG allowed to reduce 
an incidence of this complication until 0,0%, 2,6% and 9,1% respectively. The right-sided 
PE in patients in a group of mean risk as well as PE to the left in patients with maximum 
risk cause a necessity to suture bronchus stump by manual method as the most hermetic 
as well as consolidation of suture line with pericardial flap. Sternotomic approach is 
necessary for patients in a group of maximum risk for an adequate accomplishment 
of surgical intervention, and consolidation by a proposed method with omentum flap 
after suturing stump by manual method. Conclusion: 1. Peculiarities of a tactics of 
surgical intervention in PE must be determined strong in accordance with risk degree 
of development of BSF and, depending on the latter, include various in their efficacy of 
hermetization as well as work volume of accomplishment methods of suturing bronchus 
stump and consolidation of suture line. 2. An introduction of tactics of surgical 
intervention based on the worked out factor estimation of risk degree of development of 
BSF after PE permitted to decrease an incidence of lethality from 7,1% up to 3,1%.
Keyword: Pneumonectomy, Bronchial stump fistula, Lung cancer surgery
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P1-071: SURVEILLANCE PROGRAM FOR THE DETECTION OF 
BRAIN METASTASES AFTER CURATIVE SURGERY FOR NON-
SMALL CELL LUNG CANCER: SINGLE INSTITUTIONAL  
EXPERIENCE
Yoshihisa Kadota, Mitsunori Ohta, Eiji Okura, Naoto Kitahara, Eriko Fukui, Akio Hara  
Thoracic Surgery, Osaka Prefectural Medical Center For Respiratory And Allergic 
Disease, Habikino, Osaka/JAPAN
Background: Brain metastasis of non-small cell lung cancer (NSCLC) requires special 
considerations, for which can induce neurologic deterioration quickly. Selected patients 
with metastatic disease in the brain seem to benefit substantially from local treatment. 
To develop an adequate surveillance of patients to detect brain metastasis after curative 
surgery for non-small cell lung cancer. We have retrospectively evaluated our 
surveillance program to detect recurrence in brain. Methods: From our institute, 639 
patients after curative surgery for NSCLC between 2000 and December 2006 were 
reviewed. The surveillance program for the detection of brain metastases was performed 
for 5 years after surgery, which included periodic visit and CEA measurement in every 3 
month, and annual scanning of brain with CT or MRI. Results: Among 639 patients with 
curative surgery for NSCLC, 29 patients, which composed of 9 stage 1 disease, 2 stage 2 
and 18 stage3, developed brain metastasis as the first site of recurrence. 75% of these 
patients have the recurrence in 2 year after surgery. 18 patients was neurologically 
symptomatic and detected brain metastasis with following imaging survey. 11 were 
neurologically asymptomatic at the time of diagnosis, and their brain metastases were 
detected by annual imaging study [23%] or brain scan following CEA elevation [77%]. 
All patients could undergo cyber-knife for brain tumors, apart from 4 cases which could 
not because of their multiple tumors. The median survivals after recurrence were 12 
month form detection of brain metastasis which was better in those asymptomatic 
patients [18 months] than those symptomatic [9 months] [p<0.01](Figure 1). 
 
 
The overall survivals from surgery of these two groups were 22m and 36 m respectively 
and were not significantly different.Among 639 patients with curative surgery for 
NSCLC, 29 patients, which composed of 9 stage 1 disease, 2 stage 2 and 18 stage3, 
developed brain metastasis as the first site of recurrence. 75% of these patients have the 
recurrence in 2 year after surgery. 18 patients was neurologically symptomatic and 
detected brain metastasis with following imaging survey. 11 were neurologically 
asymptomatic at the time of diagnosis, and their brain metastases were detected by 
annual imaging study [23%] or brain scan following CEA elevation [77%]. All patients 
could undergo cyber-knife for brain tumors, apart from 4 cases which could not because 
of their multiple tumors. 
The median survivals after recurrence were 12 month form detection of brain metastasis 
which was better in those asymptomatic patients [18 months] than those symptomatic [9 
months] [p<0.01](Figure 1). The overall survivals from surgery of these two groups were 
22m and 36 m respectively and were not significantly different. Conclusion: Our results 
suggested that a surveillance program with imaging study of more frequent intervals was 
required for early detection of brain metastasis especially in the first 2 years, which may 
allow radiation therapy for more number of patients. Prospective randomized studies are 
needed on large number of patients to define appropriate regimen and to evaluate 
patients quality of life and cost-effectiveness of the strategy.
Keywords: surveillance, brain metastasis, currative surgery
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P1-072: PHASE II TRIAL OF ADJUVANT CHEMOTHERAPY WITH 
TRI-WEEKLY CARBOPLATIN PLUS DOCETAXEL IN PATIENTS 
WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CAN-
CER: INTERIM ANALYSIS
Hidetaka Uramoto1, Ryoichi Nakanishi2, Masakazu Sugaya3, Akihiko Uchiyama4, 
Masaaki Inoue5, Teruo Iwata6, Noriyuki Ebi7, Takeshi Hanagiri8, Fumihiro Tanaka8  
1Department Of Surgery, Uoeh, Kitakyushu/JAPAN, 2Shin-Kokura Hospital/JAPAN, 3, 
Chubu Rosai Hospital/JAPAN, 4, Kyushu Kouseinenkin Hospital/JAPAN, 5Shimonoseki 
City Hospital/JAPAN, 6Niigata Rousai Hospital/JAPAN, 7Aso Iizuka Hospital/JAPAN, 
8Department Of Surgery, Uoeh/JAPAN
Background: The benefits of adjuvant chemotherapy have been demonstrated for the 
patients with NSCLC after a complete resection. However, some problems still remain. 
For example, an inpatient setting is required over a long duration to achieve safe 
treatment of patients without good drug compliance. Furthermore, treatment-related 
deaths sometimes occur with CDDP chemotherapy.  Methods: A total of 67 patients 
were enrolled in a multi-institutional study. The patients received chemotherapy 
with carboplatin (CBDCA) area under the curve of 5 and docetaxel (DTX) 60 mg/
m2 every tri-weekly for three cycles after surgery. The primary endpoint of this 
study was compliance to this regimen in the adjuvant setting, while the secondary 
endpoints were adverse events (AE) and recurrence-free survival (RFS). Patients were 
eligible for the main trial if they fulfilled the following local criteria for pathologic 
diagnosis of stage IB, II, or IIIA NSCLC after a curative lobectomy and a systematic 
mediastinal lymphadenectomy: at age 80 years or younger; Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) of 0 or 1; a leukocyte count of 
4000 mm-3 and a neutrophil count of 2000 mm-3 or greater; hemoglobin level 9.5 g/
dl or greater; a platelet 100, 000 ul or greater; serum bilirubin level less than 1.5 mg/
dl; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels 
equal to or less than 2 times the institutional normal; and creatinine less than 1.5 mg/
dl. The patients were ineligible if they had concurrent malignancy, uncontrollable 
complications, severe postoperative morbidity, previous treatment other than surgery, 
hypersensitivity to agents, the possibility of being pregnant, and other conditions such 
as hepatic inflammation as judged by the attending physician. The maximum grade on 
the NCI Common Toxicity Criteria for Adverse Events was reported for hematological 
and non-hematological toxic effects. Results: Sixty patients were evaluated at interim 
analysis. Fifty patients (83.3%) completed all cycles of therapy. They included 44 
adenocarcinomas, 13 squamous cell carcinomas, and 3 others. Nineteen patients were in 
stage IB, 10 in IIA, 9 in IIB, and 22 in IIIA. None of the patients received either induction 
or postoperative radiotherapy. The presence of Grade 3 and 4 toxicities of neutropenia 
were 6.7, and 71.6%, respectively. The non-hematological adverse effects were less 
frequent and no treatment-related death was registered. Conclusion: A tri-weekly 
schedule of CBDCA and DTX as adjuvant chemotherapy showed an acceptable toxicity 
and favorable feasibility in Japanese NSCLC patients after complete tumor resection. 
Consequently, it is desirable to validate this regimen in a mature data.
Keyword: NSCLC, adjuvant chemotherapy, carboplatin, docetaxel, treatment 
compliance, surgical resection
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P1-073: RISK FACTORS OF MARGIN RECURRENCE IN SUBLOBAR 
RESECTION OF NON-SMALL CELL LUNG CANCER
Masashi Nagata1, Yasuhisa Ohde1, Naoko Miyata1, Hideaki Kojima1, Yoshiki Kozu1, 
Chihiro Yamatani1, Yoshikane Yamauchi1, Tomohiro Maniwa1, Shoji Takahashi1, 
Mitsuhiro Isaka1, Takashi Nakajima2  
1Division Of Thoracic Surgery, Shizuoka Cancer Center, Nagaizumi, Shizuoka/JAPAN, 
2Division Of Pathology, Shizuoka Cancer Center, Nagaizumi, Shizuoka/JAPAN
Background: The surgical margin(SM) is one of the important risk factors of margin 
recurrence (MR) in sublobar resection of non-small cell lung cancer (NSCLC). The 
purpose of this study was to analyze risk factors of MR and adequate SM in sublobar 
resection of NSCLC. Methods: We retrospectively reviewed 132 lesions treated with 
sublobar resection in our institute from 2003 to 2010. All resected tumors were 
confirmed histologically that surgical margin was free for malignancy. We analyzed the 
association of SM distance, margin distance / tumor size ratio (M / T ratio) and the other 
clinico-pathological findings with MR. 67 lesions of Adenocarcinoma in situ (AIS) were 
excluded from this study, because there was no MR, which suggested AIS was good risk 
for MR. There were 82 males and 50 females in the cases. Median age was 73 (range 47-
91). Median follow up period was 41 months (1-110). Median tumor diameter was 18mm 
(2-60). Results: Of 132 lesions, there were 21 (15.6%) MR. SM distance was significantly 
shorter (12 mm vs 15 mm in median, p=0.042) for MR cases than no-MR cases. M / T 
ratio was also lower (0.65 vs 0.95 in median, p=0.025) for MR cases than no-MR cases. 
There was no MR in 29 cases with SM over 24mm or M / T ratio over 1.6. In univariate 
analyses, wedge resection, maximum standardized uptake value (SUV max) in positron 
emission tomography (PET), poor differentiation, pleural invasion and SM highly 
affected MR. In multivariate analyses, SM (p=0.020, OR 0.89) and poor differentiation 
(p =0.041, OR 3.59) were significantly associated with MR. Conclusion: SM and poor 
differentiation are independent risk factors of MR. In sublobar resection, for safety 
margin, SM should be needed over 24 mm and / or M / T ratio should be over 1.6.
Keywords: cancer diffrentiation, margin distance, sublober resection, local recurrence
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P1-074: THE INFLUENCE OF SMOKING INTENSITY ON THE 
CLINICOPATHOLOGIC FEATURES AND SURVIVAL OF PATIENTS 
WITH SURGICALLY TREATED NON-SMALL CELL LUNG CANCER
Seong Yong Park1, Jin Gu Lee1, Changyoung Lee2, Mi Kyung Bae1, Lee Seokkee1, Dae Joon 
Kim1, Kyung Young Chung1  
1Department Of Thoracic And Cardiovascular Surgery, Yonsei University, College Of 
Medicine, Seoul/KOREA, 2Department Of Thoracic & Cardiovascular Surgery, Yonsei 
University College Of Medicine/KOREA
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Background: Smoking is a well-known risk carcinogen of lung cancer and cigarette 
smoking has also been reported to be a negative prognostic factor for lung cancer patients. 
However, whether cigarette smoking affects the biological behavior of lung cancer remains 
uncertain. This study aimed to investigate the influences of smoking intensity on 
clinicopathologic characteristics and survival of non-small cell lung cancer (NSCLC). 
Methods: We retrospectively reviewed the medical records of 2,238 consecutive patients 
who underwent surgical resection for NSCLC between 1990 and 2010. Smoking intensity 
was defined as pack-years (PY). The patients were divided into 3 groups, by median value of 
smoking: nonsmokers, light smokers (less than 40 PY) and heavy smokers (more than 40 
PY). Results: There were 1,629 (72.8%) male patients and mean age was 61.71 ± 13.17 years. 
Adenocarcinoma was reported in 1,058 (47.3%) patients. The median follow-up period was 
30.7 months (range: 0.0 - 261.7 months). The 5-year overall survival for nonsmokers, light 
smokers and heavy smokers was 60.1%, 51.6% and 43.2%, respectively (p<0.001). In subset 
analysis by histology, the 5-year overall survival differed according to smoking intensity in 
adenocarcinoma patients (64.2% in nonsmokers, 51.9% in light smokers and 39.4% in 
heavy smokers, p<0.001), but there was no difference in the non-adenocarcinoma patients. 
In adenocarcinoma patients, the 5-year overall survival also differed according to smoking 
intensity at each stage. The incidences of vascular invasion (p=0.028), pleural invasion 
(p=0.013) and poor differentiation (p<0.001) were higher in heavy smokers than in light 
smokers or nonsmokers. Tumor size was also larger in heavy smokers compared to the 
other groups (p<0.001). After adjusting the sex, stage, lung function, type of operation, 
neoadjuvant therapy and adjuvant therapy, smoking intensity was an adverse risk factor in 
surgically treated adenocarcinoma patients in terms of overall survival (hazard 
ratio=1.008, p=0.028) and disease-free survival (hazard ratio=1.005, p=0.019). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion: Smoking intensity was an adverse prognostic factor after surgical 
resection of adenocarcinoma and heavy smoking was correlated with poor pathologic 
characteristics of adenocarcinoma. The relationship between heavy smoking and poor 
pathologic characteristics may explain the poor survival of heavy smokers.
Keywords: lung cancer surgery, smoking, survival
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P1-075: ANALYSIS OF RESECTED LOCALLY ADVANCED LUNG 
CANCER -A SINGLE INSTITUTE OVER 20 YEARS EXPERIENCE-
Takuro Miyazaki, Naoya Yamasaki, Tomoshi Tsuchiya, Keitaro Matsumoto, Takeshi 
Nagayasu  
Surgical Oncology, Nagasaki University Hospital, Nagasaki/JAPAN
Background: The prognosis of most patients with locally advanced non-small cell 
lung cancer (NSCLC) is poor. However, there have been some reports that T4 NSCLC 
can be safely resected with better long-term survival. We retrospectively analyzed the 
survival of patients with resected T4 NSCLC according to the subgroups of T4 category. 
Methods: We investigated a cohort of pathological T4 39 cases, 35 men and 4 women, 
who underwent pulmonary resection from 1990 to 2011 in our department. Malignant 
nodule in ipsilateral lobe was excluded in this study. Patients were categorized based 
on involved sites: tumors invading carina (CA group), left atrium (LA group), superior 
vena cava and aorta (GV group), and other organs (OT group). Results: The median 
age was 66 years, ranging from 38 to 83 years. 23 (60.0%) patients were squamous cell 
carcinoma. The number of each group was CA group (n=11), LA group (n=11), GV group 
(n=9), OT group (n=8). OT group was consisted of tumor invading esophagus (n=3), 
vertebrae (n=3), pulmonary artery (n=1), and mediastinum (n=1). Neo-adjuvant therapy 
was given in 6 (15.4%) cases, and adjuvant therapy was given in 10 (27.8%) cases. The 
surgical procedures were follows, pneumonectomy (30.8%, n=12), bilobectomy (n=3), 
and lobectomy (n=18). The overall survival rate of the 39 patients was 58.0% at 3 years, 
and 28.0% at 5 years. In involved organs, the 3 year survival of patients with CA group 
and LA group was 59.3% and 57.7%. Conversely, there were no patients who survived 
more than 3 years in GV group. In nodal status, the 3 year survival of patients with n0/1 
disease was significantly better than that with n2/3 disease, 66.8% and 20.8% (p=0.005), 
respectively. We had mortality (within 30days) rate of 7.7% in this study. From these 
results, there could be long-term survivors with n0-1 patients invaded to the carina and 
left atrium. Conclusion: The surgery for T4 NSCLC patients had high mortality, and 
for highly selected patients with carina or left atrium invasion is recommended only if 
lymph node status is n0 or n1 and complete resection is possible.
Keyword: lung cancer, advanced, surgery
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P1-076: THE SIZE OF A SOLID COMPONENT IS A PROGNOSTIC 
FACTOR IN PATHOLOGICAL STAGE I LUNG ADENOCARCINOMA 
WITH GGO.
Michiyo Miyawaki, Hiroomi Takayama, Yohei Kono, Mirei Kamei, Shuji Suehiro, Kenji 
Sugio  
Department Of Surgery Ii, Oita University, Faculty Of Medicine, Yufu/JAPAN
Background: The patients with pure lepidic growth or predominant lepidic growth 
with <=5mm invasion, showed 100% or near 100% disease-free survival after complete 
resection. Pure ground glass opacity (GGO) presented by high resolution CT (HRCT) is 
considered to predict pathological non-invasiveness, whereas solid appearance suggests 
invasiveness. In this study, we evaluated the tumor diameter to predict prognosis in stage 
I lung adenocarcinoma.  Methods: Between 2002 and 2012, we retrospectively reviewed 
224 patients with pathological stage I adenocarcinoma, in which 160 had IA and 64 had 
IB. The age ranged from 37 to 89 with a mean of 69 years-old. The maximum tumor 
diameter was evaluated in total size including GGO and in size only solid component, 
in each case. Disease-free survival (DFS) and overall survival (OS) were examined in 
relation to the tumor diameter. Results: The mean maximum tumor diameter including 
GGO was 20.4mm (6-69mm), and the mean maximum tumor diameter in only solid 
component was 16.2mm (0-69mm). In maximum tumor diameter including GGO 
(criteria of total size), there were 6 patients in 10mm or less than 10mm, 104 in 10-20mm, 
61 in 20-30mm, 53 in >30mm. In maximum tumor diameter of only solid component 
(criteria of solid size), there were 52 patients in 10mm or less than 10mm, 99 in 10-20mm, 
37 in stage in 20-30mm, 36 in >10mm. Fifteen of 224 patients (6.7%) showed recurrent 
disease. In criteria of total size, recurrent disease was observed in 0 of 6 patients who had 
a tumor in 10mm or less than 10mm, 8 of 104 with 10-20mm tumor, 4 of 61 with 20-
30mm tumor, 3 of 53 with >30mm tumor. In patient with 10-20mm tumor in criteria of 
total size, 7 of 64 patients with more than 10 mm of solid component showed recurrence, 
whereas one of 40 patients with 10mm or less than 10mm of solid component showed 
recurrence. In patients with >20mm tumor in criteria of total size, 7 of 108 patients with 
more than 10 mm of solid component showed recurrence, whereas 6 patients with 10mm 
or less than 10mm of solid component did not show recurrence. In criteria of solid size, 
only one of 52 patients with 10mm or less than 10mm showed recurrence. The results of 
DFS and OS in relation to the tumor diameter will be presented at the APLCC meeting. 
Conclusion: In adenocarcinoma with GGO component presented by HRCT, the tumor 
diameter of only solid component is a better prognostic T factor than the tumor diameter 
including GGO.
Keywords: adenocarcinoma, ground glass opacity (GGO), solid component, stage I
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P1-077: PATHOLOGICAL VASCULAR INVASION AND THE HISTO-
LOGICAL GRADE OF DIFFERENTIATION PREDICT RECURRENCE 
IN RESECTED STAGE IA NON-SMALL CELL LUNG CANCER
Yoshihisa Shimada, Hisashi Saji, Koichi Yoshida, Masatoshi Kakihana, Hidetoshi 
Honda, Masaharu Nomura, Jitsuo Usuda, Naohiro Kajiwara, Tatsuo Ohira, Norihiko 
Ikeda  
Surgery I, Tokyo Medical Universtiy, Tokyo/JAPAN
Background: The TNM staging system for non-small cell lung cancer (NSCLC) is 
currently the best confirmed predictor of survival and guide for treatment. NSCLC 
patients with pathologic stage IA disease have the best chance of survival, and resection 
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is standard in such cases. However, even after curative resection, the 5-year survival rate 
was 73% in pathologic stage IA patients as shown in the large-scale data from the 
International Association for the Study of Lung Cancer lung cancer staging project. 
There is the prognostic heterogeneity of this population, including the risk of recurrence. 
Therefore, the appropriate therapeutic strategy and postoperative management for 
patients with stage IA NSCLC still remain a matter of debate. The objective of this study 
is to identify the clinicopathological factors that affect recurrence of stage IA NSCLC. 
Methods: We reviewed the data of 532 patients in whom complete resection of stage IA 
NSCLC had been performed. Overall survival (OS) and recurrence-free proportion 
(RFP) were estimated using the Kaplan-Meier method. RFP was estimated from the date 
of the primary tumor resection to the date of the ﬁrst recurrence or last follow-up. We 
performed univariate and multivariate analyses to determine the independent 
prognostic factors. Results: The median follow-up for survivors was 5.1 years. For the 
T1aN0M0 NSCLC patients and T1bN0M0 NSCLC patients, the 5-year OS rates were 
87.1% and 77.2% (p = 0.013), whereas the 5-year RFPs were 88.6% and 78.6% (p = 0.056), 
respectively. On multivariate analyses, 3 variables were shown to be independently 
signiﬁcant recurrence risk factors: histologic differentiation (hazard ratio [HR], 1.925), 
blood vessel invasion (HR, 1.712), and lymph vessel invasion (HR, 1.751). On subgroup 
analyses combining these risk factors, the 5-year RFP was 91.3% for patients with no risk 
factors, 79.5% for those with either poorly differentiated carcinoma or vascular invasion, 
(p < 0.001 for both), and 62.9% for those with both poorly differentiated carcinoma and 
vascular invasion (p = 0.068). Conclusion: These results indicated that vascular invasion 
and tumor differentiation have a signiﬁcant impact on the prediction of cancer 
recurrence in patients with stage IA NSCLC. Patients with these predictive factors of 
recurrence may be good candidates for adjuvant chemotherapy. 
Keywords: Prognostic factor, Stage IA, Vascular invasion, Historogical grade
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P1-078: THE EXPRESSION OF MATRIX METALLOPROTEINASES 
9 WAS ASSOCIATED WITH POOR PROGNOSIS IN SURGICALLY 
RESECTED NON SMALL CELL LUNG CANCER.
Changyoung Lee1, Hyo Sup Shim2, Sung Young Park3, Dae Joon Kim4, Mi Kyung Bae3, Jin 
Gu Lee3, Kyung Young Chung3  
1Department Of Thoracic And Cardiovascular Surgery, Yonsei University, Seoul/
KOREA, 2Department Of Pathology, Yonsei University College Of Medicine, Seoul/
KOREA, 3Department Of Thoracic & Cardiovascular Surgery, Yonsei University College 
Of Medicine/KOREA, 4Department Of Thoracic And Cardiovascular Surgery, Yonsei 
University, College Of Medicine, Seoul/KOREA
Background: The role of matrix metalloproteinase 9 (MMP-9) expression in non-
small cell lung cancer (NSCLC) remains controversial. In this study, we investigated 
the prognostic value of MMP-9 expression and other clinico-pathologic factors in 
completely resected NSCLC. Methods: The specimens and data of 430 patients who 
underwent surgical resection for NSCLC were reviewed. Tumor samples were stained 
immunohistochemically, and the expression of MMP-9 and vascular endothelial growth 
factor (VEGF) was evaluated in tumor cells. Results: There were 288 men and 142 
women; median age was 64 years (range 30 to 81 years). There were 234 pateints (54.4%) 
in stage I, 124patients (28.8%) in stage II, and 72 (16.7%) in stage III. The univariate 
analysis showed that preoperative serum carcinoembryogenic antigen (CEA) level (≥5ng/
ml vs <5ng/ml, p= 0.047), tumor size (≤3cm vs 3-5cm vs >5cm, p<0.001), pathologic 
stage (I vs II vs III, p<0.001), vascular invasion (yes vs no, p<0.001), expression of 
MMP-9 (positive vs negative, p< 0.001), and expression of VEGF (positive vs negative, 
p=0.01) were prognostic factors for recurrence. Multivariate analysis demonstrated that 
pathologic stage (p = 0.003) and expression of MMP-9 (p=0.029) emerged as independent 
prognostic factors of recurrence. Conclusion: In this study, pathologic stage and 
expression of MMP-9 were identified as independent predictors of disease free survival 
for completely resected NSCLC.
Keywords: MMP-9, Prognosis, Non small cell lung cancer
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P1-079: LYMPHOVASCULAR INVASION AS A PROGNOSTIC 
FACTOR IN NON-SMALL CELL LUNG CANCER PATIENTS WITH 
PATHOLOGIC T4 SEPARATE TUMOR NODULE IN A DIFFERENT 
IPSILATERAL LOBE.
Jae Hyun Jeon, Chang H. Kang, Hye S. Kim, Yong W. Seong, In K. Park, Young T. Kim  
Thoracic And Cardiovascular Surgery, Seul National University Hospital, Seoul/KOREA
Background: The 7th AJCC non-small cell lung cancer(NSCLC) staging revisions 
assigned a T4 descriptor to separate tumor nodule in a different ipsilateral lobe. We 
reviewed our experience of T4 NSCLC following these revisions and evaluated 
prognostic factors for this group. Methods: A retrospective review was made for 70 
patients with surgically resected T4 NSCLC between 2000 and 2011 in our institution. 
They were divided into two subgroups: 39 patients with mediastinal structures 
involvement, 31 patients with separate tumor nodule. There were 52 men and 18 women 
with a mean age of 61.1 years. Resection was complete in 64 (91%) patients. The 
pathologic N status was N0/N1 in 55 and N2/N3 in 15 patients. Results: Operative 
mortality and morbidity rates were 4.3% and 30%, respectively. Overall 5-year survival 
rate was 52.1% (mediastinal group 55.6%, separate nodule 47.9%). Lymphovascular 
invasion was identified in 30 patients (mediastinal group: 20 patients, separate nodule 
group: 10 patients) and found to be significantly correlated with tumor size and 
mediastinal lymph node metastasis. In separate tumor nodule group, univariate analysis 
revelead lymphovascular invasion (p=0.005), main tumor size (p=0.015), nodal status 
(p=0.012) to be prognostic factors for overall survival. But, multivariate analysis revealed 
that only lymphovascular invasion influenced overall survival (invasion(-) versus 
invasion(+); 66.5% versus 15.0% at 5 years;p=0.002). 
 
Figure 1. Overall survival curves of separate nodule group (n=31) according to 
lymphovascular invasion  
Variable
Univariate Multivariate (Cox’s proportional hazard model) 
p value p value Hazard Ratio [95% CI] 
Age 0.343 
Sex(male/female) 0.145 ns 
Induction therapy 0.912 
Operation type (lobectomy+wedge 
resection versus bilobectomy/
pneumonectomy) 
0.072 ns
Histology (squamous 
cell carcinoma versus 
adenocarcinoma) 
0.647 
Tumor size 0.015 ns
N status (N0/N1 versus N2/N3) 0.012 ns
Lymphovascular invasion 0.005 0.007 5.053 [1.563-16.340] 
Complete resection (R0 versus R1) 0.219 
Adjuvant therapy 0.215 
 
Table 1. Factors Affecting Survival in T4 non-small cell lung cancer patients with 
separate tumor nodule. (Univariate variables with P value less than 0.20 were candidate 
for inclusion in the Cox’s proportional hazard model with forward stepwise) 
 
Conclusion: In surgically resected T4 non-small cell lung cancer patients with separate 
tumor nodule, lymphovascular invasion was the only independent factor affecting 
overall survival.
Keywords: non-small cell lung cancer, T4, lymovascular invasion, separate nodule
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P1-080: THE PROGNOSIS AND PROGNOSTIC FACTORS OF POST-
OPERATIVE BRAIN METASTASES AS THE FIRST RECURRENCE IN 
NON-SMALL CELL LUNG CANCER (NSCLC)
Naoko Miyata1, Yasuhisa Ohde1, Hideaki Kojima1, Yoshiki Kozu1, Chihiro Yamatani1, 
Masashi Nagata1, Yoshikane Yamauchi1, Tomohiro Maniwa1, Shoji Takahashi1, Mitsuhiro 
Isaka1, Hideyuki Harada2, Yoko Nakasu3, Nobuyuki Yamamoto4  
1Division Of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka/JAPAN, 2Radiation 
Oncology, Shizuoka Cancer Center, Shizuoka/JAPAN, 3Neurosurgery, Shizuoka Cancer 
Center, Shizuoka/JAPAN, 4Division Of Thoracic Oncology, Shizuoka Cancer Center, 
Shizuoka/JAPAN
Background: Brain metastasis frequently occurs in lung cancer patients. Although brain 
metastasis is a systemic disease resulting from hematogenous metastases, some patients 
nevertheless have a long-term survival with local treatment. Methods: We reviewed 
retrospectively 40 patients of non-small cell lung cancer (NSCLC) with postoperative 
brain metastases as the first recurrence, and analyzed the prognosis and prognostic 
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factors for these patients. Results: There were 26 males and 14 females. There were 13 
in pathological stage I, 11 in stage II, 12 in stage III, and 4 in stage IV, respectively. 
There were 31 adenocarcinomas, 5 squamous carcinomas, and 4 large cell carcinomas. 
Twenty-seven patients had brain metastasis only (16 single, 11 multiple) and 13 patients 
had concomitant extracranial disease at first recurrence. Seventeen patients received 
local treatment only, 17 patients received local treatment and systemic therapy, 5 
patients received systemic therapy only, and 1 patient received best supportive care. 
Local treatments included surgery, stereotactic radiation therapy, gamma knife, and 
whole-brain radiation. The median disease free interval (DFI) was 12 months (range: 
1.3 - 63.4 months). The median survival time from the time of brain metastasis was 
14.8 months (range: 2.0 - 107.2 months). The 5-year survival rate after brain metastasis 
was 38%. A univariate analysis showed adenocarcinoma and single brain metastasis 
without extracranial disease are to be associated with favor survival significantly 
(p<0.05). Female tended to have a favorable prognosis (p=0.06). Age, extracranial 
disease, pathological N status, pathological staging, and DFI were not significant. Of 
27 patients with brain metastasis without extracranial disease were treated by local 
treatment only, 17 patients have no extracranial disease to the last follow-up (median: 
54 months). The median survival time from brain metastasis was 12.6 months (range: 
2.0 - 75.3 months) in these patients, and 4 patients had a long-term survival of more 
than 5 years. Conclusion: The 5-year survival rate after postoperative brain metastasis as 
the first recurrence was 38%. This was a good result in comparison to previous reports. 
Adenocarcinoma and single brain metastasis without extracranial disease were favorable 
prognostic factors.
Keywords: postoperative brain metastases, Prognostic factor
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P1-081: CT-GUIDED INTERSTITIAL HIGH-DOSE-RATE BRACHY-
THERAPY IN THE LOCAL TREATMENT OF INTRATHORACIC 
MALIGNANCIES
Nikolaos Tselis1, Konstantinos Ferentinos1, Christos Kolotas2, Joachim Schirren3, Dimos 
Baltas4, Hanns Ackermann5, Nikolaos Zamboglou1  
1Radiation Oncology, Klinikum Offenbach, Offenbach/GERMANY, 2Institute For 
Radiotherapy, Hirslanden Medical Center-Aarau/GERMANY, 3Thoracic Surgery, 
Horst Schmidt Kliniken/GERMANY, 4Medical Physics And Engineering, Klinikum 
Offenbach/GERMANY, 5Institute Of Biostatistics, University Of Frankfurt/GERMANY
Background: Image-guided interstitial (IRT) brachytherapy (BRT) is an effective 
therapeutic option as part of a multimodal approach to the treatment of intrathoracic 
tumors. In this study we report our results of computed tomography (CT)-guided IRT 
high-dose-rate (HDR) BRT in the local treatment of inoperable primary and secondary 
intrathoracic malignancies. Methods: Between January 1997 and December 2010, 65 
consecutive patients underwent a total of 102 interventional procedures for a total of 77 
lesions. All patients were not surgical candidates and BRT was performed for progressive 
or locally recurrent disease after failure of previous anti-tumor therapies. Forty-five 
patients received BRT for primary intrathoracic tumors and 20 for metastatic disease. 
Forty-five patients were male and 20 female with a median age of 66 years (range, 23-93 
years). The median tumor volume was 160 cm3 (range, 24-633 cm3). The IRT-HDR-BRT 
delivered a median dose of 25.0 Gy (range, 10.0-35.0 Gy) in twice-daily fractions of 4.0-
15.0 Gy in 30 patients, and a median dose of 10.0 Gy (range, 7.0-32.0 Gy) in once-daily 
fractions of 4.0-20.0 Gy in 35 patients. Results: The median follow-up was 13 months 
(range, 1-49 months). The overall survival rate was 61 % at one year, 24 % at two years 
and 6 % at three years. The overall local control (LC) rate was 87 % at one year, 83 % 
at two years and 78 % at three years. The LC rate for metastatic tumors was 95 %, 88 % 
and 88 %, and for primary intrathoracic cancers 84 %, 77 % and 73 % at one, two and 
three years, respectively. Pneumothoraces occurred in 8 % of interventional procedures, 
necessitating post-procedural drainage in one patient. Conclusion: Our results confirm 
CT-guided IRT-HDR-BRT to be an effective modality for the palliative treatment of 
inoperable intrathoracic malignancies.
Keywords: CT-guided interstitial brachytherapy, Intrathoracic malignancies, Local 
ablation
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P1-082: TREATMENT RESULTS OF CYBERKNIFE RADIOSURGERY 
FOR PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER
Woo Chul Kim1, Hyun Do Huh2, Sang Hyun Choi2  
1Radiation Oncology, Inha University Hospital, Incheon/KOREA, 2Inha University 
Hospital/KOREA
Background: Recently, the use of stereotactic body radiosurgery (SBRT) as a local therapy 
in patients with early stage non-small cell lung cancer(NSCLC) was increasing instead 
of surgical resection. To evaluate the efficacy of SBRT, we analyze the treatment results 
in patients with stage I NSCLC. Methods: From July 2008 to May 2012, medical records 
were reviewed retrospectively of total 28 patients with NSCLC who received SBRT at Inha 
University Hospital. Among 28 patients 13 patients have T1a and T1b lesion and rest of 
patients have T2a lesion. Six MV X-ray was used for SBRT and the prescribed dose was 42-
60 Gy (median : 54 Gy) for PTV1 in 3-5 fractions. Median follow up was 205 days. Results: 
The median volume of GTV was 16.3cc(3.3-86.5cc) and median volume of PTV1 was 
24.9cc(8.9 – 116.6cc). Two-year overall survival rate was 62.7% and disease free survival 
was 72.9%. The response at last follow up on SBRT area was relatively good (CR : 13, PR : 
10, SD : 2, PD : 3). The local failure was identified in three patients and distant metastasis 
in 3 patients. Among 7 patients who were dead after SBRT, 3 patients due to cancer and rest 
of patients were dead because of pneumonia. The CR was recorded in 2 out of 11 patients 
(18.2%) received below BED(biologically equivalent dose) 150 Gy10 and among 17 patients 
received above 150 Gy10, 11patients experienced CR (64.7%)(P=0.018). Only three patient 
experience grade 2 pulmonary toxicity and grade 1 in 6, grade 0 in 19. Conclusion: Even 
though the local control rate was low in our results compared with other report, the SBRT 
using CyberKnife was effective treatment modality for stage I NSCLC because high local 
control rate without severe complication was achieved. The patients who received radiation 
dose above total 150 Gy10 for stage I NSCLC had good tumor response. Prospective studies 
are needed to validate these results.
Keywords: non-small cell lung cancer, Radiosurgery, CyberKnife
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P1-083: HYPO-FRACTIONATED RADIATION THERAPY ALONE 
FOR CENTRALLY LOCATED CT1-3N0 NON-SMALL CELL LUNG 
CANCER
Dongryul Oh, Yong Chan Ahn, Bo Kyong Kim, Hongryull Pyo  
Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School Of 
Medicine, Seoul/KOREA
Background: We retrospectively analyzed the treatment outcomes and toxicities by 
hypo-fractionated radiation therapy (RT) alone in the patients with centrally-located 
cT1-3N0 non-small cell lung cancer (NSCLC). Methods: Sixty patients with centrally-
located cT1-3N0 NSCLC received definitive RT alone using 3 Gy per fraction for either 
medical co-morbidity or refusal of surgery between January 2001 and December 2010. 
The central tumor was defined as being within 2 cm around the proximal bronchial tree. 
The median total dose was 60 (39~60) Gy. Results: The overall survival and cancer-
specific survival rates at 2- and 5-years were 59.6% and 61.7%, and 33.5% and 40.5%, 
respectively. The median OS and CSS were 33 months and 33 months. The actuarial LC 
rates at 2- and 5-years were 57.9% and 50.1% (Figure 1). Multivariate analyses showed 
that high cT stage (87.5% for T1, 63.2% for T2, and 30.8% for T3, p=0.014) and histology 
with NSCLC-NOS (63.3% for squamous cell carcinoma, 60.0% for adenocarcinoma, and 
33.3% for NSCLC-NOS, p=0.010) were the significantly unfavorable prognostic factors 
for OS, and that high cT stage (100% for T1, 56.5% for T2, and 28.6% for T3, p=0.031) and 
poor performance state (72.9% for ECOG 0-1 and 32.1% for ECOG 2, p=0.007) were for 
local control. No patients experienced grade 3 or higher esophagitis, and three 
experienced Grade 3 or higher pneumonitis.  
Figure 1. The overalll survival (OS), cancer-specific survival (CSS) and local control (LC) 
rates in all patients 
 
 
Conclusion: Authors could achieve favorable clinical outcomes with minimal toxicity 
profiles by definitive hypo-fractionated RT alone in the patients with centrally-located 
cT1-3N0 NSCLC. Further dose escalation might be necessary to improve local control in 
cT2-3 tumors.
Keywords: Non small cell lung cancer, Radiotherapy, Central tumors
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P1-084: 4D-CT PULMONARY VENTILATION IMAGING IN FUNC-
TIONAL TREATMENT PLANNING FOR THORACIC CANCER 
RADIOTHERAPY
Tzung-chi Huang1, Chien-Yi Hsiao2, Chun-Ru Chien3, Ji-An Liang3, Tzu-Ching Shih1, 
Kwan-Hwa Chi2, Geoffrey Zhang4  
1Biomedical Imaging And Radiological Science, China Medical University, Taichung/
TAIWAN, 2Radiation Oncology, Shih Kong Wu Ho Su Memorial Hospital, Taipei/
TAIWAN, 3Radiation Oncology, China Medical University Hospital/TAIWAN, 
4Radiation Oncology, Moffitt Cancer Center, Tampa/FL/UNITED STATES OF 
AMERICA
Background: In current practice of thoracic cancer radiotherapy, the variation in 
pulmonary function was not considered when generating treatment plans. Lung volumes 
are deemed equally in pulmonary function when placing radiation beams in planning. 
The primary purpose of this study was to evaluate the radiation dose of IMRT treatment 
plans on highly functional lung volumes by incorporation of functional lung imaging 
using 4D CT for thoracic cancer patients. Methods: Eleven patients who had non-trivial 
but stable respiration motion and were available for 4D simulation schedule received 4D 
radiotherapy simulation and were included in this retrospective study. With deformation 
calculated by deformable image registration among 4D CT image sets, pulmonary 
ventilation can be defined as the fractional volume change in respiration. The 3-D dose 
distributions of IMRT plans were overlapped with the 3-D ventilation distributions and 
analyzed. Highly-functional regions were avoided to be irradiated in the functional 
treatment planning. Results: The ventilation difference of the left and right lungs can 
be seen on the corresponding ventilation image. Lower ventilation around lung tumor 
region was also observed. For the cases of small target volumes (planned target volume < 
400 cc, 6 cases in total), all V5, V20 and the mean lung dose (MLD) values for the highly 
functional regions, top 20%, 30% and 40% ventilation, were lower than the values for 
the total lung. For the cases of large target volumes, two out of five cases had higher V5 
and V20 values for the highly functional regions compared with total lung. Conclusion: 
The present study has demonstrated the evaluation of radiation dose of IMRT treatment 
plans with incorporation of functional lung imaging from 4D CT for thoracic cancer 
patients. Radiation treatments affect functional lung volumes more seriously on larger 
tumors than small tumors. Thus it is more critical to arrange radiation beams for 
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functional lung sparing for patients with large tumors.
Keyword: 4D-CT, deformable image registration, functional lung, IMRT treatment plan
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P1-085: GAMMA KNIFE SURGERY (GKS) ALONE VERSUS 
GKS FOLLOWED BY WHOLE BRAIN RADIOTHERAPY (WBRT) AS 
THE INITIAL TREATMENT OF BRAIN METASTASIS
Yoon Ji Choi1, Dae Ho Lee1, Chang Min Choi1, Jae Cheol Lee1, Heung-moon Chang1, Jin 
Hee Ahn1, Jung Shin Lee1, Eun Kyung Choi2, Seung Do Ahn2, Do Hoon Kwon3, Sang-we 
Kim1  
1Oncology, Asan Medical Center, University Of Ulsan College Of Medicine, Seoul/
KOREA, 2Radiation Oncology, Asan Medical Center, University Of Ulsan College Of 
Medicine, Seoul/KOREA, 3Neurological Surgery, Asan Medical Center, University Of 
Ulsan College Of Medicine, Seoul/KOREA
Background: The purpose of this study is to determine if additional whole brain 
radiotherapy(WBRT) resulted in improved control of brain metastasis and increased 
survival in patients with metastatic brain tumor, by comparing the effectiveness 
and safety of gamma knife surgery(GKS) followed by WBRT with that of GKS alone. 
Methods: Major eligibility criteria: histologically or radiologically proven metastatic 
brain tumor; single or multiple (≤ 4); max. diameter ≤ 3 cm. Between March 2004 
and January 2007, the findings of 42 patients were analyzed in this prospective trial at 
Asan Medical Center, Korea. The patients were randomly assigned to GKS followed by 
WBRT(arm A) or GKS alone(arm B) after stratification by extent of disease, number of 
metastatic brain tumor, age and performance status. Brain CT or MRI scan was repeated 
every 3 months for first year and every 6 months thereafter. The primary endpoint is 
time to recurrence of brain metastasis and secondary endpoint is overall survival(OS). 
Results: Total 42 patients were enrolled and randomized; 21 to GKS followed by 
WBRT and 21 to GKS alone. Most of them (40) had lung cancer as primary. There were 
no differences in baseline characteristics between GKS followed by WBRT and GKS 
alone. Median age was 60, primary diseases were controlled in 31 patients (73.8%). 31 
patients had a single metastatic brain tumor and mean number of brain tumor was 1.4. 
The median follow up duration was 65.7 months. Recurrence of brain metastasis was 
confirmed in 24 patients (57.1%). And more often recurrence of brain metastasis was 
observed in GKS alone group (GKS followed by WBRT 42.9% vs GKS alone 71.4%). 
GKS followed by WBRT group showed longer time to recurrence of brain metastasis, 
comparing to GKS alone group in obvious statistical significance. (18.27 vs 5.23 months, 
p<0.001) The pattern of recurrence was different between two arms; distant recurrence in 
the brain(defined as the appearance of a new brain metastasis at a site different from that 
of the original metastasis) was observed in 1/9 patients of GKS followed by WBRT group 
(11.1%) but 10/14 patients of GKS alone group (71.4%). (p=0.014) However, there was no 
difference of overall survival between two arms. (GKS followed by WBRT 13.97 vs GKS 
alone 10.53 months, p=0.358) Conclusion: GKS followed by WBRT showed less distant 
recurrence in brain metastasis and favorable time to recurrence of brain metastasis 
comparing to GKS alone in patients with metastatic brain tumor. However, there was no 
difference of overall survival between two arms. Therefore, when determining follow up 
treatment after GKS, disease status, toxicity and compliance should be considered.
Keywords: brain metastasis, gamma knife surgery, whole brain radiotherapy
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P1-086: PHASE I STUDY OF VELIPARIB IN COMBINATION WITH 
WHOLE BRAIN RADIATION THERAPY IN PATIENTS WITH 
BRAIN METASTASES
Minesh Mehta1, Walter Curran2, Ding Wang3, Fen Wang4, Lawrence Kleinberg5, Anthony 
Brade6, Nael Mostafa7, Jiang Qian7, Terri Leahy7, Bhardwaj Desai7, Vincent Giranda7  
1Feinberg School Of Medicine, Northwestern University, Chicago/UNITED STATES OF 
AMERICA, 2Winship Cancer Institute Of Emory University, Georgia/UNITED STATES 
OF AMERICA, 3Henry Ford Hospital, Detroit/UNITED STATES OF AMERICA, 
4Kansas University Medical Center, Kansas City/UNITED STATES OF AMERICA, 
5Johns Hopkins University, Baltimore/UNITED STATES OF AMERICA, 6Princess 
Margaret Hospital, Toronto/CANADA, 7Abbott, Abbott Park/UNITED STATES OF 
AMERICA
Background: Poly (ADP-ribose) polymerase (PARP)-1 and PARP-2 are nuclear enzymes 
that recognize DNA damage and facilitate its repair. Elevated PARP levels can result in 
resistance to cytotoxic chemotherapy and radiation. Veliparib is an oral PARP-1 and -2 
inhibitor that enhances the antitumor activity of DNA damaging agents and increases 
efficacy of radiation therapy in several preclinical models. Veliparib has been shown to 
cross the blood brain barrier and achieve CSF level with doses known to inhibit PARP 
in human clinical studies.  Methods: This is an ongoing phase 1 dose-escalation study 
evaluating the safety, pharmacokinetics and preliminary antitumor activity of veliparib 
in combination with whole brain radiation therapy (WBRT) in patients with brain 
metastases (NCT00649207). Patients with brain metastases (including leptomeningeal) 
from primary non-CNS metastatic solid tumors (except germ cell cancer), adequate 
organ function, and RPA Class 2 and Karnofsky performance status (KPS) ≥70 were 
treated with WBRT (37.5 Gy in 15 fractions or 30 Gy in 10 daily fractions excluding 
holidays and week-ends) and veliparib (escalating doses of 10-200 mg administered 
orally twice a day continuous without interruption); the final WBRT fraction was 
followed by 1 extra day of veliparib. Safety, pharmacokinetics (PK), and tumor response 
by RECIST were assessed. Results: Currently, 66 patients (M/F, 23/43; median age 58 
years [31-81]) have been dosed. Baseline KPS was 70, 80, 90, and 100 in 8, 32, 38, and 23% 
patients, respectively; primary tumor types were non-small cell lung cancer (NSCLC; 
n=23), breast, (n=21) , melanoma (n=10), colorectal (n=3), and others (n=9); 74% of 
patients had multiple lesions, and 17% had prior brain stereotactic radiosurgery. The 
most common treatment-emergent veliparib-related adverse event (TEAEs; ≥10%) were 
fatigue (33%), nausea (20%), vomiting (12%), and decreased appetite (12%). Fatigue (5%) 
and hypokalaemia (3%) were the only Grade 3/4 veliparib-related TEAEs observed in ≥ 
2 patients. PK of veliparib was approximately dose-proportional, with oral clearance of 
22 ± 14 L/h (mean ± SD, n=45), minimal drug accumulation at day 15, and no significant 
effect of food on bioavailability. Of the 66 patients dosed, 54 had measurable disease at 
baseline. Best brain metastases tumor response rate (CR or PR) and median survival 
time (95% CI) were 37% and 6.6 (3.3-13.0) months for NSCLC, and 50% and 8.3 (2.8 
-16.9) months for breast cancer primary. 6-month survival rates (95% CI) were 55% 
(30-73%) for NSCLC, 69% (44-85%) for breast cancer, and 39% (18-60) for patients with 
other cancers. Currently, 56 patients have completed ≥80% of the assigned veliparib dose 
regimen, 58 patients completed the entire course of WBRT. Conclusion: Veliparib up to 
200 mg BID was well tolerated with standard WBRT; dose escalation is ongoing. The PK 
of veliparib was dose proportional with no food effect. Preliminary antitumor activity is 
encouraging and informative for the design of more definitive trials.
Keywords: non-small cell lung cancer, Veliparib, Phase 1, whole brain radiation therapy
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P1-087: A FEASIBILITY OF CONCURRENT WHOLE BRAIN RADIA-
TION PLUS EPIDERMAL GROWTH FACTOR RECEPTOR-TYRO-
SINE KINASE INHIBITOR FOR NON-SMALL CELL LUNG CANCER
Eiko Inamasu1, Gouji Toyokawa1, Yoshimasa Shiraishi1, Yosuke Morodomi1, Tomohiro 
Takenaka1, Yoshimitsu Hirai2, Masahumi Yamaguchi1, Takashi Seto1, Mitsuhiro 
Takenoyama1, Yukito Ichinose1
1Department Of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka/JAPAN, 
2Department Of Thoracic And Cardiovascular Surgery, Wakayama Medical University, 
Wakayama/JAPAN
Background: Approximately thirty percent of non-small cell lung cancer (NSCLC) 
patients present with brain metastases. Most of those patients are treated with whole 
brain radiation (WBRT). NSCLC patients often experience disease progression with 
only brain metastases, although other sites are well controlled, during treatment with 
an epidermal growth factor receptor-tyrosine kinase inhibitor ( EGFR-TKI ). Systemic 
chemotherapy is usually avoided during WBRT due to concers regarding the toxicity. 
However, the concurrent administration of EGFR-TKI, such as Gefitinib (GEF) or 
Erlotinib(TAR), during WBRT might be feasible without causing any severe toxicity. This 
report presents the institutional date on the adverse events associate with concurrent 
WBRT plus EGFR-TKI. Methods: The medical records of patients with NSCLC, whose 
disease were well controlled except for brain metastases; receiving concurrent WBRT 
plus EGFR-TKI (GEF or TAR) treatment were retrospectively reviewed. Results: 
Eighteen NSCLC patients with brain metastases received concurrent WBRT plus EGFR-
TKI at Kyushu Cancer Center between March 2005 and June 2011. The median age was 
59 years (range 37-82). Ten patients were male and 8 patients were female. The ECOG 
performance status was 0 in 9 patients, 1 in 7 patients and 2 in 2 patients. All patients had 
multiple brain metastases. Eleven patients received GEF and 7 received TAR with WBRT. 
All patients were evaluable for the feasibility and had intracranial disease control. 
There were no severe incidences of hematological toxicity. There was grade 2 skin rash 
in one patient and grade2 fatigue in one patient. However, there was no severe non-
hematological toxicity including of interstitial lung disease. No treatment-related death 
was observed. Conclusion:  No unexpected severe adverse events were observed during 
concurrent treatment with WBRT plus EGFR-TKI. Concurrent treatment with WBRT 
plus EGFR-TKI might therefore be a feasible treatment modality. However, further data 
from prospective trials are needed to clearely determine the benefits and toxicity of 
EGFR-TKI during WBRT.
Keyword: WBRT NSCLC EGFR-TKI
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P1-088: INCREASING THE DIAGNOSTIC ACCURACY BY USING A 
RAPID CYTOLOGICAL ON-SITE EXAMINATION FOR DIAGNOS-
ING LUNG CANCER
Ryota Tanaka1, Kyoko Komatsu2, Yoshimasa Nakazato3, Keisei Tachibana4, Haruhiko 
Kondo4, Tomoyuki Goya4  
1Department Of Thoracic Surgery, Gunma Prefectural Cancer Center, Gunma/JAPAN, 
2Department Of Pathology, Kyorin University School Of Medicine/JAPAN, 3Department 
Of Anatomic And Diagnostic Pathology, Dokkyo Medical University School Of 
Medicine/JAPAN, 4Department Of Surgery, Kyorin University School Of Medicine, 
Mitaka-shi, Tokyo/JAPAN
Background: Examinations used to diagnose pulmonary malignant lesions should 
be safe, accurate, and easy to use for obtaining adequate information. Rapid on-site 
cytopathological examinations (ROSE) have previously been reported to be good 
methods for several cytopathological procedures. At our university hospital and 
corporate institution (Gunma Prefectural Cancer Center), ROSE has recently been 
performed with various procedures and practices, especially via trans-bronchial lung 
biopsy (TBLB) and computed tomography-guided needle biopsy (CTNB), etc.  Methods: 
We retrospectively compared group A (without ROSE; from April 2004 to April 2005) 
with group B (with ROSE; from May to December 2005) regarding the diagnostic rates 
of the bronchoscopic examinations of cytological materials or lung biopsy specimens, 
and also analyzed the number of specimens collected, such as those obtained from 
brushing, curetting, washing and biopsy, respectively. We also retrospectively reviewed 
a consecutive series of 270 patients (group A; 98 patients without ROSE, group B; 172 
patients with ROSE) who underwent CTNB between 2002 and 2009. Diff-Quik and 
ultrafast Papanicolaou staining have been used for the ROSE, because they are fast 
and easy to perform. The adequacy of the specimen for diagnosis was assessed by a 
cytotechnologist and a cytopathologist in the two approaches (TBLB and CTNB) for 
diagnosing lung cancer. The final cytopathological diagnoses were determined using 
conventional Papanicolaou stained preparations and histopathological specimens.  
Results: The diagnostic rates for malignant lesions in group A and group B by 
bronchoscopic biopsies were 61.9% (39 of 63 patients) and 88.5% (23 of 26 patients), 
respectively. The diagnostic rate was significantly higher in group B than in group A. 
The number of specimens collected was significantly lower in group B than in group A. 
The diagnostic accuracy and the complication rates were compared between the two 
groups. The diagnostic accuracy by CTNB was 79.6% and 94.8%, respectively; and the 
rates of major complications were 14.3% and 2.9%, for groups A and B. Group B had a 
significantly higher diagnostic accuracy and a lower complication rate in comparison 
with group A.  Conclusion: The application of ROSE in the bronchoscpoic approaches 
and CTNB positively contributed to an increased diagnostic accuracy, and as a 
result, might reduce the burden for patients. However, for ROSE using Diff-Quik, it is 
necessary to obtain sufficient experience to ensure that the specimens will be diagnosed 
immediately and accurately. For the performance of rapid cytological examinations, 
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clinicians should therefore closely cooperate and exchange information with clinical 
pathologists and cytotechnologists. 
Keywords: Cytology, Bronchoscopy, CTNB, Rapid on-site examination
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P1-089: USEFULNESS OF RAPID ON SITE MICROSCOPIC 
EVALUATION(ROME) OF CORE BIOSY-SPECIMEN TO IMPROVE 
DIAGNOSTIC EFFICASY OF EBUS-TBNA
Chulho Oak, Taewon Jang, Mannhong Jung, Bongkwon Chun  
Department Of Internal Medicine, Kosin University College Of Medicine, Busan/
KOREA
Background: Endobronchial ultrasound guided transbronchial needle aspiration 
(EBUS TBNA) is performed by using special bronchoscope which has an ultrasound 
probe at its tip that could demonstrate lymph node outside the airway and allow 
for harvest of cytologic and core-biopsy specimen. Although feedback from rapid 
cytology tests are expected to improve diagnostic rates, the value of the routine use of 
rapid cytology tests has not been established. We developed Rapid on site microscopic 
evaluation(ROME) of core-biopsy specimens using USB microscope to improve the 
clinical relevancy. Methods: All lymph node stations were examined by EBUS and their 
sizes were recorded. Selected puncture of a lymph node was done and tissue was sent for 
cytological examination. Before cytologic and pathologic examination. We performed 
rapid on site microscopic evaluation(ROME) of core-biopsy specimen. Total 20 EBUS-
Core biopsy specimens were evaluated. All the specimen, we couldn’t classify them 
in gross appearance. The core-biopsy specimens were classified to five groups under 
microscopic view. The first group have no visual evidence of whitish tumor islet(-). The 
second group have one or several tiny suspicious tumor islet(-/+). The third group have 
less than 5 visible tumor islets(+). The fourth group have 5-10 ten tumor islets(++), The 
fifth group have more than 10 tumor islets(+++). The ROME was compared with final 
pathologic examination. Clinical relevancy was approved by pathologist. The impact on 
ROME was assessed by diagnostic value from final pathologic report. Results: Among 
20 specimens, 3(15%) specimens were classified as first group(-), 2(10%) as second 
group(-/+), 5(25%) as third group(+), 7(35%) as fourth group(++), 3(15%) as fifth group, 
respectively. 100%(10/10) clinical relevancy was confirmed in the fourth, the fifth group 
with 90%(9/10) diagnostic rate. 70%(5/7) clinical relevancy was confirmed in third group 
with 57% diagnostic rate(4/7). There was no clinical relevancy(5/5) in the first group and 
second group with no diagnostic value(5/5).  Conclusion: ROME have usefullness for 
predicting the diagnostic value and clinical relevancy in EBUS-core biopsy specimens. 
The further study would be warranted to supporting the use of ROME in routine EBUS-
TBNA.
Keywords: LUNG CANCER, EBUS-TBNA, Core biospy, Microscopy
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P1-090: EVALUATION OF CT GUIDED TRANSTHORACIC  FINE 
NEEDLE ASPIRATION CYTOLOGY (TTFNAC) OF LUNG: A FIVE 
YEAR STUDY
Neha Lanke1, Nirmala A. Jambhekar1, C S. Pramesh1, George Karimundackal2, Saral 
Desai3  
1Pathology, Tata Memorial Hospital, Mumbai,/INDIA, 2Surgical Oncology, Tata 
Memorial Hospital, Mumbai/INDIA, 3Department Of Pathology, Tata Memorial 
Hospital, Mumbai/INDIA
Background: Radiology guided TTFNAC for cytologic evaluation of intrathoracic 
mass lesions is widely accepted as an accurate and safe modality with a high sensitivity 
and specificity.The aim of this study was to evaluate the cytomorphological features 
of TTFNAC and to compare the TTFNAC findings with histology diagnosis wherever 
available. The objective was to evaluate the efficacy of TTFNAC to distinguish SCLC 
from NSCLC, to subtype NSCLC and analyse the sensitivity, specificity and accuracy 
for common lung cancers. Methods: The 937 TT FNACwere grouped into five groups 
Category A: Non-diagnostic aspirate: Category B: Primary Lung tumour: Category C: 
Metastatic tumour to lung (from a known primaryelsewhere): Category D: Inflammatory 
lesion: Category E: Indeterminate: Surgical specimens were available for comparing 
TTFNAC diagnosis with histology diagnosis in 390 out of 937 TTFNAC cases (41.62%). 
The final diagnosis was determined by histology and clinical course. Results: The 937 
cases reviewed comprised 222 in-house cases (23.7%) and 715 consult cases (76.3%) 
from other hospitals. The 937 TTFNACs comprised : Category A: 120 aspirates i.e. 
12.81% : Category B: 726 i.e. 77.49% Category C: 38 i.e. 4.05% Category D: 38 i.e. 
4.05% : Category E: Indeterminate: 15 i.e. 1.6% Histology was available in 60 of 120 
non-diagnostic aspirates, 265 of 726 primary malignant tumours, 27 of 38 metastatic 
tumours, 25 of 38 inflammatory lesions and 13 of the 15 ‘indeterminate’ aspirates. Of 
the non-diagnostic category (A), 29 of the 38 cases (76.32%) wherein the subsequent 
histology revealed a confirmatory diagnosis, were proved to be malignant.Of the 726 
TTFNAC of the primary malignant tumour category (B), 58 i.e. 8% were SCLC and 626 
i.e. 86% were NSCLC. Amongst the 626 NSCLC, 53% were adenocarcinomas and 14.21% 
were squamous carcinomas and 32.79% were not otherwise specified (NOS). The overall 
performance indicators, namely, the Sensitivity, Specificity and Accuracy of TTFNAC 
was 96%, 93.3% and 96%, respectively. The positive and negative predictive value of 
TTFNAC was 99.5% and 58.33%, respectively. The false positive rate and the false 
negative rate was 0.3% and 3.7%, respectively. The single false positive result was given 
in a case of tuberculosis where metaplastic squamous cells on a background of necrosis 
were interpreted as malignant. The 10 false negative results were due to sampling errors, 
and not interpretative or observational errors.  Conclusion: SCLC and NSCLC were 
precisely and discriminatively recognised on TTFNAC with 100% accuracy. But within 
the NSCLC category, 2% of adenocarcinomas were mistaken for squamous carcinoma 
whereas 11.4% of squamous carcinomas were mistaken for adenocarcinoma.The 0.3% 
false positivity was due to over interpretation of metaplastic squamous cells in a necrotic 
background of tuberculosis. The 3.7% false negative rate (inclusive of malignant and 
inflammatory categories) was due to sampling error and not interpretative error. 
Finally, non-diagnostic, non-specific inflammatory and indeterminate TTFNAC results 
harbored malignancy in 76.32%, 47.62% and 61.53% cases, respectively. This emphasises 
that a negative TTFNAC result is unreliable, undependable with a low negative predictive 
value and requires further evaluation.
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P1-091: EVALUATION OF EGFR MUTATION STATUS ACCORD-
ING TO CYTOLOGIC DIAGNOSIS IN NON-SMALL CELL LUNG 
CANCER -A STUDY OF SINGLE INSTITUTIONAL EXPERIENCE IN 
KOREA
Jae-soo Koh1, Hee-jong Baek2, Jong-myeon Hong3  
1Pathology, Korea Cancer Center Hospital, Seoul/KOREA, 2Thoracic Surgery, Korea 
Cancer Center Hospital, Seoul/KOREA, 3Thoracic Surgery, Chungbuk National 
University Hospital, Cheongju/KOREA
Background: The aim of this study was to evaluate EGFR mutation status according to 
customary performed cytologic diagnosis categories in lung cancer patients. Methods: 
From March 2009 to June 2012, the authors collected 264 cytology specimens from 
patients with lung cancer at the Korea Cancer Center Department of Pathology. The 
specimens included 241 cases of fine-needle aspiration (FNA) of lung or metastatic sites, 
15 cases of pleural fluid, 6 cases of bronchial washing, and 2 cases of sputum specimens. 
Cytologic diagnosis was categorized as definite adenocarcinoma, favor adenocarcinoma, 
non-small cell lung carcinoma (not otherwise specified), favor squamous cell carcinoma, 
and definite squamous cell carcinoma. Mutation analysis using pyrosequencing method 
was performed for EGFR exons 18, 19, 20, and 21. Results: EGFR mutations were 
detected in 39.4% (104 of 264) of non-small cell lung carcinoma (NSCLC) with a higher 
frequency in adenocarcinoma and favor adenocarcinoma categories (48%, 81 of 168) 
than in squamous cell carcinoma and favor squamous cell carcinoma categories (4%, 1 
of 24). Mutation rate of non-specified category was 31% (22 of 72). Higher frequencies 
of EGFR mutations in exons 19 (45%) and 21 (35%) than in exons 18 (8%) and 20 (0%) 
were detected. Combined mutations were detected in 13%. Conclusion: Our findings 
support clinical utilization of routinely prepared cytology specimens as a reliable source 
for molecular testing to detect EGFR mutations in patients with NSCLC. Mutation rates 
according to cytologic categories were compatible with those of histologic classification 
of NSCLC. Higher mutation rates in non-categorized NSCLC suggested that most of 
them were essentially adenocarcinomas.
Keywords: LUNG CANCER, Cytology, EGFR mutation
POSTER SESSION 1 - PATHOLOGY 1 - November 27, 2012 14:05-14:55
P1-092: HIGH CONCORDANCE OF EGFR STATUS BETWEEN HIS-
TOLOGICAL SPECIMENS AND CORRESPONDING CYTOLOGICAL 
SPECIMENS IN LUNG ADENOCARCINOMA
Pingli Sun1, Yan Jin2, An Na Seo2, Sanghoon Jheon1, Hyojin Kim2, Hyun Chang3, Jong-
suk Lee3, Jin-haeng Chung2  
1Department Of Thoracic And Cardiovascular Surgery, Seoul National University 
Bundang Hospital, Department Of Thoracic And Cardiovascular Surgery, Seoul 
National University Bundang Hospital, Seongnam/KOREA, 2Pathology, Seoul National 
University Bundang Hospital, Department Of Pathology, Seoul National University 
Bundang Hospital, Seongnam/KOREA, 3Internal Medicine, Seoul National University 
Bundang Hospital, Department Of Internal Medicine, Seoul National University 
Bundang Hospital, Seongnam/KOREA
Background: The feasibility of EGFR mutational analysis on cytological samples 
had been demonstrated in some previous studies, however few studies performed 
comparison between histological and cytological samples from the same patient. 
The aim of this study was to compare the EGFR mutation between histological and 
cytological specimens in lung adenocarcinomas, to investigate the yield and applicability 
of molecular testing for EGFR in cytologic specimens.  Methods: DNA was extracted 
from 60 paired histological and cytological specimens of lung adenocarcinoma, the 60 
histological specimens consisting of either biopsy (33 cases) or resection materials (27 
cases). The 60 cytological specimens included 36 cases of primary lung carcinoma and 
24 cases of metastatic lesions. A comparison of the EGFR mutation status between the 
smears and cell blocks was done in 43 cytologic specimens. DNA was extracted from all 
the specimens, exons 18-21 of EGFR gene were amplified by PCR and mutational status 
was analyzed by pyrosequencing. Results: Based on a minimum DNA concentration 
of 25ng/ul, 88.3 % of the smear slides and 58.1% of the cell blocks were considered 
suitable for EGFR mutation analysis. Ninty percent of the smear slides and 58.1% of the 
cell blocks have more than 50% tumor cellularity. The DNA concentration and tumor 
percentage in smear slides are significantly higher than in cell blocks (p < 0.01). The 
lowest DNA concentration and tumor percentage with which a mutation was detectable 
was 3.8 ng/ul and 15%, respectively. The overall concordance rate of EGFR mutation 
between histological specimens and corresponding cytological specimens was 91.7% 
(55 of 60). In the 43 cases which have both smear slides and cell blocks, the concordance 
rate was significantly higher in corresponding smear slides (95.3%, 41 of 43) than cell 
blocks (81.4%, 35 of 43)(p = 0.04). The concordance rate was 94.4% (34 of 36) between 
histological specimens and corresponding cytological specimens of primary lesions 
and was 87.5% (21 of 24) between histological specimens and corresponding cytological 
specimens of metastatic lesions. There was no significant difference of the concordance 
rate between corresponding cytological specimens from primary lesions and specimens 
from metastatic lesions. (p = 0.63). Conclusion: Although the quantity and quality 
of the DNA are important factors, routinely prepared cytology specimens, including 
aspirations and fluid specimens are reliable sources for EGFR mutation test. Cytological 
specimens obtained from smear slides seem to be more reliable than cytology specimens 
obtained from cell blocks for molecular analysis.
Keyword: EGFR mutation, lung adenocarcinoma, cytology
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P1-093: INTRA-ACINAR MICROPAPILLARY COMPONENTS IN 
LUNG ADENOCARCINOMAS: SHOULD BE CLASSIFIED INTO 
ACINAR OR MICROPAPILLARY PATTERN?
Vicente Morales-Oyarvide, Mari Mino-Kenudson  
Pathology, Massachusetts General Hospital, Boston/UNITED STATES OF AMERICA
Background: The recently proposed IASLC/ATS/ERS classification of lung 
adenocarcinoma that recognizes 5 major patterns (lepidic, papillary, acinar, 
micropapillary and solid) and 4 variants is expected to facilitate diagnostic 
standardization and improve risk stratification of patients with lung adenocarcinomas. 
However, interobserver concordance in assigning patterns remains suboptimal, 
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particularly when multiple patterns are present in one tumor. A micropapillary pattern 
(MPAP) consists of small clusters of tumor cells without fibrovascular cores present 
within alveolar spaces often in association with a papillary pattern. Adenocarcinomas 
with MPAP are likely to have lymphatic invasion and are associated with poorer 
outcomes. We have observed tumors containing micropapillary clusters of tumor cells 
within well-formed acinar structures (acinar-MPAP) (Figure 1) that may be subject to 
interobserver discordance. In this study, we sought to evaluate the clinicopathological 
features and survival of lung adenocarcinomas with acinar-MPAP in order to gain 
insight as to whether the unique structure should be classified as an acinar or 
micorpapillary pattern. 
 
Figure 1. Methods: We evaluated 226 stage I lung adenocarcinomas resected at the 
Massachusetts General Hospital. Of those, tumors with an acinar predominant pattern 
were extracted and classified into 2 groups: those with acinar-MPAP that comprise at 
least 5% of the tumor cells (group AM) and those without significant acinar-MPAP 
(group A). Demographics, clinicopathological features, mutation status and survival 
data were compared between the 2 groups. Results: Of 226 tumors, 34 (15%) were 
classified into group AM and 60 (27%) into group A. There was no difference between 
group AM and group A in terms of gender (female: 53% vs. 53%, p=1.0), age (median: 69 
years vs. 69 years, p=0.67), tumor size (mean: 2.34 cm vs. 2.35 cm, p=0.96), pleural 
invasion (21% vs. 20%, p=1.0), vascular invasion (26% vs. 17%, p=0.29), and highest 
nuclear grade (grade 3: 56% vs. 45%, p=0.39). However, group AM revealed a 
significantly higher rate of lymphatic invasion compared to group A (59% vs. 23%, p = 
0.0008, OR 4.69). Mutation status was assessed in 14 group AM tumors and 16 group A 
tumors, and no significant difference was found between the two groups. As for the 
outcomes, 5-year recurrence-free survival was similar between group AM and group A 
(68% vs. 77%, p=0.92). Conclusion: Stage I lung adenocarcinomas with an acinar 
predominant pattern containing acinar-MPAP are associated with a higher rate of 
lymphatic invasion (suggesting a higher metastatic capacity), but not with adverse 
outcomes compared to those without acinar-MPAP in our cohort. Larger cohort studies 
are warranted to determine whether the unique structure indicates more aggressive 
biology and should be classified into a micropapillary pattern.
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P1-094: CLINICOPATHOLOGIC FEATURES OF MET GENE COPY 
NUMBER GAIN IN NON-SMALL CELL LUNG CANCER
Yan Jin1, An Na Seo1, Pingli Sun2, Hyojin Kim1, Hyun Chang3, Jin-haeng Chung1, Jong-
suk Lee3  
1Pathology, Seoul National University Bundang Hospital, Department Of Pathology, 
Seoul National University Bundang Hospital, Seongnam/KOREA, 2Department Of 
Thoracic And Cardiovascular Surgery, Seoul National University Bundang Hospital, 
Department Of Thoracic And Cardiovascular Surgery,seoul National University 
Bundang Hospital,seoul National University Bundang Hospital/KOREA, 3Internal 
Medicine, Seoul National University Bundang Hospital, Internal Medicine,internal 
Medicine,seongnam/KOREA
Background: MET gene copy number (GCN) gain is associated with advanced tumor 
stage and poor clinical outcome in non-small cell lung cancer (NSCLC). The rate of 
MET amplification in NSCLC remains controversial, and ranges from 3% to up to 
10% depending on the detection technique and cut-off criteria. The aim of this study 
was to evaluate the clinicopathologic implication of increased GCN of MET in korean 
NSCLC. Methods: Tumor tissues were obtained from 298 patients with NSCLC who 
underwent surgical resection. MET GCN was assessed by silver in situ hybridization 
(SISH), and estimated according to the University of Colorado Cancer Center (UCCC) 
criteria and correlated with clinicopathologic variables. Results: SISH–positive MET 
was observed in 50 (19.0%) patients using the UCCC criteria; specifically amplification 
was seen in 7 (2.7%) patients and high polysomy in 43 (16.3%). Median MET GCN was 
3.08 (range: 1.19-10.20; n=263). High MET GCN (mean 　5 copies per cell) was found 
in 14 (5.3%) patients. MET GCN gain was not associated with gender, smoking, stage, 
but was associated adenocarcinoma histology. There were no associations of MET GCN 
with disease-free survival, or overall survival both with UCCC criteria. Using cut-off 
value of median GCN (3.08), MET GCN gain was significantly associated with shorter 
overall survival, but not disease-free survival. While using cut-off value of mean GCN 
(3.26), MET GCN gain was associated with shorter disease-free survival and overall 
survival. Conclusion: Our study demonstrated that MET GCN gain is more common 
in adenocacinoma, and MET GCN gain more than or equal to 3.26 was associated with 
shorter disease-free survival and overall survival.
Keywords: Met, non-small cell lung cancer, SISH, clinicopathology
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P1-095: CLINICO-PATHOLOGIC FEATURE OF FGFR1 
AMPLIFICATION IN KOREAN NON SMALL CELL CARCINOMA
An Na Seo1, Yan Jin1, Ping-li Sun1, Hyojin Kim2, Jin-haeng Chung1  
1Pathology, Seoul National University Bundang Hospital, Department Of Pathology, 
Seoul National University Bundang Hospital, Seongnam/KOREA, 2Pathology, Seoul 
National University College Of Medicine, Department Of Patholgy, Seoul National 
University College Of Medicine, Seoul/KOREA
Background: Fibroblast growth factor receptor type 1 gene (FGFR1) is a receptor 
tyrosine kinase of which the ligands belong to specific members of the fibroblast 
growth factor family. Recently, FGFR1 amplification has been identified as a driver 
event in breast cancer and squamous cell carcinoma (SqCC) of lung. It was also found 
that FGFR1 amplification of SqCC was associated with tumor growth and survival, 
and suggested that FGFR inhibitors may be a targeted therapeutic option for selected 
SqCC patients. This study aimed to evaluate clinicopathologic and demographic 
characteristics of FGFR1 amplification in Korean lung cancer patients and further 
investigate the association between FGFR1 amplification and prognosis of patients. 
Methods: This retrospective study was conducted in a cohort of 392 lung cancer (144 
squamous cell carcinoma, 224 adenocarcinoma, 10 adenosquamous cell carcinoma, 
and 14 carcinoma of other differentiation type) patients that received a surgical 
resection of primary lung cancer at Seoul National University Bundang Hospital from 
2003 until 2007. Tissue microarrays were constructed and performed a dual color 
fluorescence in situ hybridization (FISH) (Abbott Molecular, IL) for evaluation of FGFR1 
amplification. Following the guidelines, suggested by Hans-Ulrich et al, at least 60 
malignant nonoverlapping nuclei were selected, and counted green FGFR1 and orange 
centromere 8 (CEN8) signals. Results: FGFR1 amplifications were observed 41 cases 
(28.5%) in squamous cell carcinomas, whereas these were amplified 11 cases (4.9%) in 
adenocarcinomas (ADCs), 3 cases (30 %) in adenosquamous cell carcinomas, and 2 
cases (14.3%) in tumor of other differentiation. High-level amplification was shown at a 
frequency of 23.6% and low-level amplification at a frequency of 4.9% in squamous cell 
carcinoma. The FGFR1 amplification were significantly association with SqCC compared 
to other histologic types (P=0.003), and smoking history (P<0.0001). In multivariate 
analysis, there was no significant difference with respect to disease-free survival 
(DFS) and overall survival (OS) between any results for FGFR1. Conclusion: FGFR1 
amplification is shown relatively common in Korean SqCC (28.5%) and is rarely detected 
in Korean adenocarcinoma (4.9%). Furthermore, FGFR1 was frequently amplified in 
patient who smoked, and not related to DFS or OS.
Keywords: FGFR1, FISH, Squamous Cell carcinoma
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P1-096: HETEROGENEITY OF ANAPLASTIC LYMPHOMA KINASE 
EXPRESSION IN NON-SMALL CELL LUNG CARCINOMA
Heae Surng Park1, Jeong Wook Seo2  
1Department Of Pathology, Gangnam Severance Hospital, Yonsei University College 
Of Medicine, Seoul/KOREA, 2Department Of Pathology, Seoul National University 
Hospital/KOREA
Background: Anaplastic lymphoma kinase (ALK) gene rearrangements had been 
discovered in a minor subset of non-small cell lung cancer (NSCLC), preferentially 
adenocarcinoma. Development of ALK and MET kinase inhibitor enables target therapy 
in ALK-positive NSCLC patients. Heterogeneity in ALK-positive lung cancer may cause 
problems in detecting ALK rearranged lung cancer. We evaluated the heterogeneity 
of ALK protein expression and gene rearrangement in surgically resected lung cancer. 
Methods: Tissue microarrays were constructed using formalin-fixed paraffin-embedded 
blocks from 401 consecutive NSCLC patients who underwent surgical resection at the 
Seoul National University Hospital, Korea between January 1997 and February 2002. 
ALK immunohistochemistry (IHC) using monoclonal antibody 5A4 (Novocastra) was 
performed on TMA to select ALK IHC positive tumors. Immunoreactivity was scored 
from 0 to 3. ALK IHC and ALK fluorescence in situ hybridization (FISH) on full section 
of tumor were examined in cases with ALK immunoreactivity scores with more than 1 
on TMA section. Each ALK FISH pattern was assessed in the area of different intensity 
in ALK IHC. FISH patterns were classified negative, positive with split signals, positive 
with isolated red signals. Results: Seventeen cases (4.2%) out of 401 NSCLC showed more 
than 1 immunoreactivity score of ALK on TMA section. In full tissue section study, 11 
out of 17 lung cancers showed heterogeneity in ALK immunointensity. All 11 NSCLCs 
with heterogenous ALK immunointensity were ALK FISH positive with homogenous 
pattern. Six out of 17 tumors stained homogenously with ALK IHC. They comprised 
of 3 ALK FISH positive cases and 3 ALK FISH negative cases. Conclusion: Although 
ALK immunointensity in NSCLC can be variable within the same tumor, ALK gene 
rearrangement is homogenous. Therefore, the result of ALK FISH in small tumor area 
may represent the state of ALK gene rearrangement in whole tumor regardless of ALK 
immunoreactivity.
Keywords: tumor heterogeneity, fluorescence in situ hybridization, Anaplastic 
lymphoma kinase, immunohistochemistry
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P1-097: ANGIOGENESIS AND MAST CELL DENSITY PREDICT 
POOR SURVIVAL IN PULMONARY ADENOCARCINOMA
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Background: Angiogenesis and mast cells affect the behavior of pulmonary 
adenocarcinoma. Measuring the angiogenesis and mast cell density and their effecton 
survival of the patients may be helpful to guide the use of cancer chemotherapeutic 
agents which target tumor angiogenesis and mast cells. Methods: It was a descriptive 
study, conducted at Gulab Devi Chest Hospital and University of Health Sciences Lahore. 
It included 23 newly diagnosed, adult patients of invasive pulmonary adenocarcinoma. 
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Clinical history was obtained and biopsy specimen was processed. Angiogenesis was 
determined byimmunohistochemical staining with CD34. Mast cells were counted in 
Tolouidine blue stained sections. Patients were followed till death. Results: Mean age of 
the patients was 54.83±2.799 years. Majority (60.9%) were males. Only 39.1% patients 
were smokers. Morphologically, large proportions of tumors (73.9%) were non-mucinous 
and moderately or poorly differentiated. Majority (69.6%) of patients presented at 
advanced stage (TNM III and IV). Mean microvascular density (MVD) was 13.04±1.12 
and mean mast cell density (MCD) was 3.26±0.36 per high power field (HPF). High 
MVD was associated with poor differentiation and advanced stage and correlated with 
poor survival (p=0.0001). High MCD was associated with high grade but not the advance 
stage of disease. However, high MCD correlated with poor survival (p=0.047). Moreover, 
MCD was positively correlated with angiogenesis (r=0.727, p=0.0001). Conclusion: High 
angiogenesis and mast cell density predict poor survival and are positively correlated 
with each other and with the histological grades in pulmonary adenocarcinoma. High 
angiogenesis is also associated with advance TNM stage of disease.
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P1-098: IMPACT OF VISCERAL PLEURAL INVASION ON THE SUR-
VIVAL OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
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Background: In this study, we investigated visceral pleural invasion (VPI) as a poor 
prognostic factor in patients with non-small cell lung cancer (NSCLC) according to the 
7th Edition of the TNM classification. Methods: Between January 2000 and December 
2007, 886 consecutive patients with pathological T1a-T2b NSCLC underwent complete 
resection with systematic lymph node dissection in Tokyo Medical University. We 
statistically analyzed the association between VPI and clinicopathologic factors, or 
clinical outcomes. Results: The 5-year overall survival (OS) rates of the pl0, pl1, and pl2 
patients were 80.8%, 63.7%, and 49.6%, respectively, with significant differences between 
pl0 and pl1 (p = 0.002), pl1 and pl2 (p = 0.03). Thus, the pl1 and pl2 patient groups were 
defined as patients with VPI. VPI was found to be a significant independent prognostic 
factor by multivariate survival analysis (p = 0.0002). In patients with tumors ≤ 3 cm, 
especially with tumors ≤ 2 cm, VPI was significantly associated with an increased 
rate of lymph node metastasis, compared with non-VPI (p = 0.0003 and p = 0.015, 
respectively). Analysis of the OS of patients stratified by tumor size (≤ 3 cm, 3.1-5 cm, 
5.1-7 cm) and VPI status showed that in any nodal status, patients with 3.1-5 cm/VPI 
tumors had significantly worse survival than patients with ≤ 3 cm/VPI tumors (p = 
0.019) and patients with 3.1-5 cm/non-VPI tumors (p = 0.001). On the other hand, there 
was no significant difference in the OS between patients with 3.1-5 cm/VPI tumors and 
patients with 5.1-7 cm tumors regardless of lymph node metastasis (T2b tumors). Similar 
relationships were observed among these groups with N0 disease. Conclusion: We 
identified the presence of VPI as an independent poor prognostic factor in patients with 
NSCLC of ≤ 7 cm. Tumors 3.1-5 cm with VPI should be upstaged to T2b tumors in the 
future in the TNM classification of the Union of International Cancer Control staging 
system. In addition, the surgical strategy as more extensive lymph node dissection for 
patients with ≤ 3 cm/VPI tumors, especially ≤ 2 cm/VPI, is warranted owing to more 
frequent lymph node metastasis.
Keywords: TNM classification, Visceral pleural invasion, non-small cell lung cancer, 
lymph node metastasis
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Background: According to the World Health Organization Classification of Tumors, the 
prognostic value of morphometric cytologic atypia has not been assessed in pulmonary 
adenocarcinoma. Nakazato et al. reported Nuclear Grading; the cases with its nuclear 
area and nuclear diameter being 5 ≤ and 3 ≤ larger than the corresponding values  for 
small lymphocytes showed poor prognosis. However, no study about relation between 
Nuclear Grading and clinical findings including diagnostic imaging has been reported 
yet. The purpose of this study is to compare Nuclear Grading and image findings. 
Methods: Patients with surgical resected adenocarcinoma of the lung with a maximal 
tumor diameter of less than 2 cm were selected. A contrast-enhanced CT scan was 
performed to evaluate the entire lung for preoperative staging. In addition, the main 
tumor was evaluated preoperatively to estimate the extent of ground-glass opacity with 
thin-section helical CT scan with 1 to 5 mm collimation. The lung was photographed 
as a lung window setting and as a mediastinal window setting. The evaluated factors 
on the lung window were the maximum diameters of the tumor and consolidation. The 
maximum tumor diameter was also evaluated from the mediastinal window. And also, 
Nuclear Grade was assessed in each case pathologically. The cases with its nuclear area 
and nuclear diameter were 5 ≤ and 3 ≤ larger than the corresponding values  for small 
lymphocytes were defined as Nuclear grade 1, and the others were defined as Nuclear 
grade 0. Consolidation / tumor ratio (C/T ratio) was calculated and compared with 
Nuclear Grading. Results: We retrospectively selected 105 cases that had been diagnosed 
as primary pulmonary adenocarcinoma, resected at Gunma Prefectural Cancer Center 
during the period from April 2005 to March 2012. Pathological stage was 93 cases of 
stage I, four cases of stage II, eight cases of stage III, one case of stage IV. Nuclear grade 0 
was 57 cases with mean C/T ratio 0.27. Nuclear grade 1 was 48 cases with mean C/T ratio 
0.68. Difference in C/T ratio between nuclear grade 0 and 1 was significant (p < 0.05). 
The ROC curve analysis for Nuclear Grade showed that a cutoff C/T ratio level of 0.52 
had a sensitivity and specificity of 79% and 77%, respectively (area under the curve: 0.85, 
95% confidence interval: 0.77-0.92). Kaplan-Meier curves comparing overall survival 
showed that the cases with Nuclear Grade 1 (5-year survival rate: 77%) were associated 
with significantly shorter survival than the cases with Nuclear Grade 0 (5-year survival 
rate: 94%), as determined by the log-rank test (p < 0.05). Conclusion: Nuclear Grading 
was well correlated to the C/T ratio. Nuclear Grading as a pathological prognostic factor 
of lung adenocarcinoma gives the impact on the diagnostic imaging in clinical diagnosis.
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CHUS AND LUNG. A CLINICOPATHOLOGICAL STUDY OF 30 
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Background: A common tumour of the salivary glands, adenoid cystic carcinoma 
rarely occurs in the bronchus or the lungs. It is thought to arise from the minor salivary 
glands present in the bronchus and the bronchioles. Methods: All cases of adenoid cystic 
carcinoma occurring over a period of 10 years (2002 – 2012), primarily of the bronchi 
and lungs were retrieved from the pathology records at the Tata Memorial Hospital. 
The clinical features were noted, histology evaluated and the treatment was reviewed.  
Results: A total of 30 cases of adenoid cystic carcinoma were identified. The female to 
male ratio was 1:1. The age range was 25 – 78 years. Most patients (where the history was 
available) presented with cough. They underwent routine radiological examinations 
where a hilar / lung mass was identified. All cases were biopsied and histologically 
examined. Most of the cases were of grade 2 on biopsy. Only a few cases were operated 
upon and we received the lobectomy specimens for examination. Others were treated 
with radiotherapy. Though the histology was typical, immunohistochemistry for 
pancytokeratins, myoepithelial markers and CD117 (c-KIT) was performed in some 
cases. Where available, the grade of the tumour was compared to the stage. Conclusion: 
Adenoid cystic carcinoma is a rare tumour of the bronchi and lungs. It can be mistaken 
for lung adenocarcinoma. The grade of the tumour does not correlate with the stage. 
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